Document:

Exhibit 10.9

 

Execution Copy

   

Pursuant
to Item 601(B)(10) of Regulation S-K, certain portions of this exhibit have been redacted and, where applicable, have been marked
“[***],” such redactions are immaterial and would be competitively harmful if publicly disclosed.

 

 

 

SHARE PURCHASE AGREEMENT

 

 

by and among

 

BiomX LTD.

 

RondinX LTD.,

 

The Shareholders and Warrant Holders
of RondinX LTD.

 

and

 

Guy Harmelin

 

as the Shareholders’ Representative

 

 

Dated November 19, 2017

 

 

 

 

 

     

     

    

 

Table of Contents

 

	1.	INTERPRETATION	3
	2.	PURCHASE AND SALE OF THE SHARES	11
	3.	CLOSING	17
	4.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY	21
	5.	REPRESENTATIONS AND WARRANTIES OF EACH CONSIDERATION RECIPIENT	38
	6.	REPRESENTATIONS AND WARRANTIES OF THE PURCHASER	41
	7.	COVENANTS	42
	8.	RELEASES	45
	9.	INDEMNIFICATION AND REMEDIES	46
	10.	TERMINATION	51
	11.	MISCELLANEOUS	52
	Exhibit 2.4.1 MILESTONES SCHEDULE	58
	Exhibit 2.4.5 REDEMPTION OF MILESTONES	65
	Exhibit 2.5 MILESTONE ROADMAP	66
	Schedule A-1 LIST OF COMPANY SHAREHOLDERS	68
	Schedule A-2 LIST OF COMPANY WARRANT HOLDERS	69

 

    2

     

    

  

THIS SHARE PURCHASE AGREEMENT (“Agreement”)
is entered into on the 19 day of November, 2017, by and among:

 

BIOMX LTD., a company existing under
the laws of the State of Israel (the “Purchaser”);

 

RONDINX LTD., a company duly and
validly organized under the laws of Israel (the “Company”);

 

THE SHAREHOLDERS OF THE COMPANY LISTED
IN SCHEDULE A-1 HERETO (the “Shareholders”);

 

HOLDERS OF COMPANY’S WARRANTS
LISTED IN SCHEDULE A-2 HERETO (the “Company Warrant Holders”, and collectively with the Shareholders,
the “Consideration Recipients”); and

 

Guy Harmelin, as the “Shareholders’
Representative”

 

(collectively, the “Parties”
and each of them, a “Party”).

 

WHEREAS: 

 

		(A)	The Purchaser desires, subject to the terms and conditions
set forth in this Agreement, to acquire 100% of the issued and outstanding share capital of the Company on a fully diluted basis
(the “Share Purchase”), all such outstanding securities being free and clear of any Security Interests, in
consideration for certain securities of the Company and other consideration set forth herein, all on the terms and subject to
the conditions hereinafter set forth; and

 

		(B)	The Shareholders are the owners on the date hereof of 100%
of the issued and outstanding share capital of the Company, as detailed in Schedule A-1 hereto, and have accepted
the offer extended by the Purchaser and agreed, subject to the terms and conditions set forth in this Agreement, to sell to the
Purchaser all of their outstanding securities in the Company, free and clear of any Security Interests, on the terms and subject
to the conditions hereinafter set forth; and

 

		(C)	Concurrently with the execution of this Agreement, and as
a condition and inducement to Purchaser’s willingness to enter into this Agreement, each key employee and consultant of
the Company listed in Schedule B hereto (each, a “Key Employee”) shall have executed an employment
agreement with Purchaser, in form acceptable to the Purchaser and the applicable Key Employee (the “Key Employee Agreements”);
and

 

		(D)	Concurrently with the execution of this Agreement, and as
a condition and inducement to the Company’s and Consideration Recipients’ willingness to enter into this Agreement,
(i) the Purchaser’s shareholders possessing voting authority necessary for the requisite Purchaser’s shareholders’
approval with respect to the execution and consummation of the Transaction and the Amended IRA (as defined below) will execute
and deliver an irrevocable voting proxy, in the form of Schedule C hereto, providing, among other things, for the
voting by such shareholders of their Purchaser’s shares in favor of the adoption of this Agreement and the execution and
consummation of the Transaction and the Amended IRA; and (ii) the Parties have obtained the Tax Ruling (as defined below) confirming,
among other things, that Purchaser and any Person acting on its behalf shall be exempt from Israeli withholding tax in relation
to any payments made under this Agreement.

 

    3

     

    

 

NOW THEREFORE, the Parties agree
as follows:

 

		1.	INTERPRETATION

 

		1.1.	Definitions.

 

The following
terms shall have the following meanings:

 

	 	
        102
Options
	Company Options subject to tax in accordance with Section 102(b)(2) of the ITO.
	 	 	 
	 	102 Shares	Ordinary Shares issued upon exercise of 102 Options, if any.
	 	 	 
	 	102 Trustee	ESOP Management & Trust Services Ltd., the trustee nominated by the Company as trustee for the Option Plan in accordance with Section 102.
	 	 	 
	 	Acquisition Transaction	
        Any transaction involving:

         

        (a)          the
        sale, license, disposition or acquisition of all or a material portion of the Company’s business or assets;

         

        (b)          the
        issuance, disposition or acquisition of (i) any capital stock or other equity security of the Company (other than Ordinary Shares
        issued to employees of the Company upon exercise of Company Options), (ii) any option, call, warrant or right (whether or
        not immediately exercisable) to acquire any capital stock or other equity security of the Company, or (iii) any other security,
        instrument or obligation that is or may become convertible into or exchangeable for any capital stock or other equity security
        of the Company; or

         

        (c)          any
        merger, consolidation, business combination, reorganization or similar transaction involving the Company.

	 	 	 
	 	
        Affiliate

         
	Any Person controlling, controlled by or under common control with any Person and if such Person as first stated above is a natural person, then the immediate family of such natural person. For the purpose of this definition of Affiliate, “control” shall mean the ability to direct the activities of the relevant entity and shall include the holding of more than 50% of the issued and outstanding share capital, voting rights or other ownership interests of such entity or the right to appoint more than 50% of the directors (or the equivalent thereof) in such entity.
	 	 	 
	 	Aggregate Consideration 	Means the Closing Shares, the Closing Warrants, Milestone Consideration Shares, Contingent Consideration, Cash Contingent Consideration, Equity Contingent Consideration, Cash Payment Amount and/or the Milestone Payment Amount.  
	 	 	 
	 	Board of Directors	The board of directors of the Company.
	 	 	 
	 	Books and Records 	Books and records of the Company.
	 	 	 
	 	
        Business Day

         
	Any day that is neither a Friday nor Saturday, a day on which banking institutions chartered by the State of Israel are required or authorized to be closed, nor any day which is recognized by the Bank of Israel as not being a business day. 

 

    4

     

    

 

	 	Claims	Claims, proceedings, investigations or demands, actions commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Authority or any arbitrator or arbitration panel.
	 	 	 
	 	Company Share Capital 	Means Company’s Ordinary Shares and Preferred Seed Shares and all options, warrants or other securities exercisable or exchangeable for, or convertible into such shares.
	 	 	 
	 	Company Intellectual Property Assets	Company-Controlled Intellectual Property Assets and any other Intellectual Property Assets in-licensed by Company.
	 	 	 
	 	Company- Controlled Intellectual Property Assets	All Intellectual Property Assets owned by or exclusively licensed to the Company.
	 	 	 
	 	Company Options	Options to purchase Ordinary Shares of the Company granted under the Option Plan.
	 	 	 
	 	Companies Law	The Israel Companies Law 5759-1999, as amended from time to time.
	 	 	 
	 	Company Material Adverse Effect	Any event, change, effect, condition or circumstance that has occurred which has, or could reasonably be expected to have a material adverse effect upon the business, operations, assets, condition (financial or otherwise), assets, liabilities, business, or operations of the Company; provided, however, that none of the following shall constitute a Company Material Adverse Effect: (a) changes in general economic conditions or financial credit or securities markets in general or changes or developments affecting generally the industry in which the Company operates, (b) national or international political or social conditions, and outbreak of acts of war, armed hostilities or terrorism or any escalation or worsening of any acts of war, armed hostilities or terrorism, or (c) changes in applicable Laws or applicable accounting regulations or principles or interpretations thereof. Notwithstanding the foregoing any material breach by the Company of any of the agreements with Pfizer and/or Estee Lauder shall be deemed to constitute a “Company Material Adverse Effect” hereunder. 
	 	 	 
	 	Contract	Any written or oral  agreement, contract, subcontract, lease understanding obligation, license, arrangement, permit, concession, franchise, purchase order, sales order contract, note, bond, warranty, mortgage, indenture, deed of trust, loan, credit agreement, insurance policy, benefit plan or legally binding commitment or undertaking of any nature.

 

    5

     

    

 

	 	Debt	(a) all indebtedness for borrowed money, whether current or funded, or secured or unsecured (including all obligations for principal, interest premiums, penalties, fees, expenses and prepayment or breakage costs), (b) all indebtedness for the deferred purchase price of property or services represented by a note or other security, (c) all indebtedness created or arising under any conditional sale or other title retention agreement with respect to property acquired (even though the rights and remedies of the seller or lender under such agreement in the event of default are limited to repossession or sale of such property), (d) all indebtedness secured by a purchase money mortgage or other Security Interest to secure all or part of the purchase price of property subject to such mortgage or Security Interest (other than any Security Interest with respect to the Company’s leases), (e) all obligations under leases which shall have been or must be, in accordance with GAAP, recorded as capital leases in respect of which such person is liable as lessee, (f) any Liability in respect of banker’s acceptances or letters of credit to the extent outstanding, and (g) any amount of unfunded or under-funded pension or severance contributions in accordance with applicable Laws or Contract, in accordance with applicable Laws, and(h) all indebtedness referred to in clauses (a), (b), (c), (d), (e), (f) or (g) above which is guaranteed by the Company.
	 	 	 
	 	Fundamental Representations	The representations and warranties contained in Section ‎4.1 (Constitution and Compliance), Section ‎4.2 (No Conflict) Section ‎4.4 (Capitalization), Section ‎4.22 (No Debt) (all of the forgoing, the “Company Fundamental Representations”) and Section 5 (Representations and Warranties of Each Shareholder) (the “Shareholders Fundamental Representations”).
	 	 	 
	 	GAAP	Generally accepted accounting principles in effect from time to time in the United States of America, applied on a consistent basis.
	 	 	 
	 	Governmental Authority 	Any foreign, federal, state, county, city, municipal, local or other government or any subdivision, authority, court, agency, commission board, bureau, administrative panel, or other instrumentality thereof, including any “competent authority,” “notified body” or non-governmental self-regulatory organization or other governmental authority and any entity owned or controlled by one of the foregoing.

 

    6

     

    

 

	 	Intellectual Property Assets	Any and all of the following, as they exist throughout the world: (i) patents and patent applications (which for the purposes of this Agreement will be deemed to include certificates of invention and applications for certificates of invention), including provisional applications, divisionals, continuations, continuations-in-part, reissues, reexaminations, renewals, extensions, supplementary protection certificates, and the like of any such patents and patent applications, and any foreign equivalents thereof (collectively, “Patents”); (ii) rights in registered and unregistered trademarks, service marks, trade names, trade dress, logos, packaging design, slogans and Internet domain names, and registrations and applications for registration of any of the foregoing (collectively, “Marks”); (iii) copyrights in both published and unpublished works, including without limitation all compilations, rights in databases and computer programs, rights in manuals and other documentation and all copyright registrations and applications, and all derivatives, translations, adaptations and combinations of the above (collectively, “Copyrights”); (iv) inventions, discoveries and invention disclosures (whether or not patented) and rights in know-how, trade secrets and confidential or proprietary information, including research in progress, algorithms, data, databases, methodologies, systems, frameworks, playbooks, data collections, designs, processes, formulae, schematics, blueprints, flow charts, models, strategies, prototypes, techniques, source code, source code documentation, and beta testing results and inventions, all of non-public nature (collectively, “Trade Secrets”); and (v) any and all other intellectual property rights and/or proprietary rights recognized by Law.
	 	 	 
	 	IRS	The United States Internal Revenue Service. 
	 	 	 
	 	ITA	The Israel Tax Authority.
	 	 	 
	 	ITO	The Israeli Income Tax Ordinance [New Version] 1961 and all the regulations, rules and orders promulgated therein.
	 	 	 
	 	Law	Any federal, state, county, city, municipal, foreign, or other governmental statute, law, rule, regulation, ordinance, order, code, or requirement (including pursuant to any settlement agreement or consent decree) and any permit or license granted under any of the foregoing, or any requirement under the common law.
	 	 	 
	 	Leakage Payments	Any expenses paid or incurred by the Company other than the expenses set forth in Schedule D attached hereto.
	 	 	 
	 	Legal Requirement	Any Law issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority and any orders, writs, injunctions, awards, judgments and decrees issued against or applicable to the Company or any of its respective assets, properties or businesses, as of the date hereof or the Closing Date, as applicable.
	 	 	 
	 	Liability	Any and all Debt, liabilities and obligations, whether accrued or fixed, known or unknown, absolute or contingent, matured or unmatured, determined or determinable, accrued or unaccrued, liquidated or unliquidated or due or to become due, and regardless of whether arising out of or based upon any Contract, Law, tort, strict liability or otherwise.

 

    7

     

    

 

	 	Open Source Software	Any software (in source or object code form) that is subject to (i) a license or other agreement commonly referred to as an open source, free software, copyleft or community source code license (including but not limited to any code or library licensed under the GNU General Public License, GNU Lesser General Public License, BSD License, Apache Software License, or any other public source code license arrangement) or (ii) any other license or other agreement that requires, as a condition of the use, modification or distribution of software subject to such license or agreement, that such software or other software linked with, called by, combined or distributed with such software be (1) disclosed, distributed, made available, offered, licensed or delivered in source code form, (2) licensed for the purpose of making derivative works, (3) licensed under terms that allow reverse engineering, reverse assembly, or disassembly of any kind, or (4) redistributable at no charge, including without limitation any license defined as an open source license by the Open Source Initiative as set forth on  www.opensource.org.
	 	 	 
	 	M&A Transaction	As defined in the Amended Articles. 
	 	 	 
	 	Option Plan	The RondinX Ltd. 2016 Share Option Plan.
	 	 	 
	 	Order	Any judgment, injunction, order, or decree that is issued by a Governmental Authority.
	 	 	 
	 	Ordinary Course of Business	The ordinary and usual course of business of the Company, consistent with past practices.
	 	 	 
	 	Ordinary Shares	Ordinary shares of the Company, without par value.
	 	 	 
	 	Organizational Documents	In respect of any entity, the memorandum of association (if any) and articles of association or similar corporate documents as per the applicable jurisdiction of incorporation.
	 	 	 
	 	Pro Rata Portion	With respect to each Consideration Recipient, the ratio between (a) such portion of the Aggregate Consideration actually paid to such Consideration Recipient at the relevant time of calculation; and (b) such portion of the Aggregate Consideration actually paid to all Consideration Recipients at such relevant time.
	 	 	 
	 	IIA	Israel Innovation Authority, formerly the Office of the Chief Scientist of the Israeli Ministry of Economy and Industry.
	 	 	 
	 	Optionholder	Holder of Company Options.
	 	 	 
	 	
        Person
	Includes any individual, sole proprietorship, partnership, firm, entity, limited partnership, limited liability company, unlimited liability company, corporation, Governmental Authority, association, trust, joint stock company, joint venture, unincorporated organization, governmental or national entity or other entity or organization.

 

    8

     

    

 

	 	Preferred A-1 Shares	Series A-1 Preferred Shares of the Purchaser with par value NIS 0.01 each. 
	 	 	 
	 	Preferred Seed Shares	Preferred Seed Shares of the Company without par value. 
	 	 	 
	 	R&D Law	The Encouragement of Research, Development and Technological Innovation Law, 5744-1984, as amended.  
	 	 	 
	 	Related Party	With respect to any specified Person, means: (a) any Affiliate of such specified Person, or any director, executive officer, general partner or managing member of such affiliate; (b) any Person who serves as a director, executive officer, partner, member or in a similar capacity of such specified Person; (c) any Immediate Family member of a Person described in clause (b); or (d) any other Person who holds, individually or together with any affiliate of such other Person and any member(s) of such Person’s Immediate Family, more than five percent (5%) of the outstanding equity or ownership interests of such specified Person.  For the purposes of this definition, “Immediate Family,” with respect to any specified Person, means such Person’s spouse, parents, children and siblings, including adoptive relationships and relationships through marriage, or any other relative of such Person that shares such Person’s home.
	 	 	 
	 	Representatives	Officers, directors, employees, agents, attorneys, accountants, advisors and representatives.
	 	 	 
	 	Registered Intellectual Property Assets	Intellectual Property Assets that are the subject of an application, certificate, filing, registration or other document issued, filed with, or recorded by any Governmental Authority, including any of the following: (i) issued Patents and Patent applications; (ii) Mark registrations, renewals and applications; and (iii) Copyright registrations and applications.
	 	 	 
	 	Security Interest	Any interest or equity of any Person (including any right to acquire, option, or right of pre-emption) or any mortgage, charge, pledge, lien (including ikavon), attachment, assignment, deed of trust, hypothecation, easement, security interest, right of first refusal, right of preemption, transfer or retention of title agreement, or restriction by way of security of any kind or nature, including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership or any other encumbrance or security interest over or in the relevant property.

 

    9

     

    

 

	 	Subsidiaries	With respect to any Person, (i) any corporation, of which a majority of the aggregate voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote generally in the election of directors thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof or (ii) any limited liability company, partnership, association, or other business entity, of which a majority of the partnership, membership or other similar ownership interests thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more Subsidiaries of that Person or a combination thereof.  For purposes of this definition, a Person or Persons will be deemed to have a majority ownership interest in a limited liability company, partnership, association, or other business entity if such Person or Persons will be allocated more than fifty percent (50%) of the limited liability company, partnership, association, or other business entity gains or losses, or is or controls the managing member or general partner of such limited liability company, partnership, association, or other business entity. 
	 	 	 
	 	Tax	And with the corresponding meaning “Taxable”:  (i) any net income, alternative or add-on minimum tax, gross income, gross receipts, sales, use, ad valorem, value added, margins, transfer, franchise, profits, license, payroll, employment (including amounts payable under the Israeli social security or national health insurance payments), excise, severance, stamp, occupation, premium, property, environmental, or windfall profit tax, deductions, charges, withholding required by any Taxing Authority on amounts paid to or by the Company or any of its Affiliates, custom, duty, or other tax, escheat of unclaimed funds or property, governmental fee, or other like assessment or charge of any kind whatsoever, together with any interest, inflation linkage differentials (hefreshei hatzmadah), penalty, addition to tax, or additional amount imposed by any Taxing Authority; and (ii) any liability of the Company or any of its Affiliates for the payment of any amounts as a result of being a party to any Tax Sharing Agreements or with respect to the payment of any amounts of any of the foregoing types as a result of any obligation to indemnify any other Person or as a result of being a transferee or successor, by Contract or otherwise.
	 	 	 
	 	Taxing Authority	The ITA, the IRS and any other national, regional, municipal or other governmental or regulatory authority or administrative body responsible for the administration of any Taxes.
	 	 	 
	 	Tax Return	Any return, declaration, report, claim for refund, or information return or statement relating to Taxes, filed or required to be filed, including any amendment thereof, and including, where permitted or required, combined, consolidated, affiliated or unitary returns for any group of entities that includes the Company or any of its Affiliates.
	 	 	 
	 	Tax Ruling	As defined in Section ‎2.9. 

 

    10

     

    

 

	 	Tax Sharing Agreements	All existing Tax allocation or Tax sharing agreements or arrangements (whether oral or written) binding the Company or any of its Affiliates.
	 	 	 
	 	Transaction	The transactions contemplated under the Transaction Documents.
	 	 	 
	 	Transaction Documents	This Agreement, its exhibits and schedules and any and all other Contracts, certificates and documents contemplated to be delivered or executed in connection with this Agreement and the transactions contemplated hereby, including, without limitation,  the Amended Articles.
	 	 	 
	 	Vested Options	Company Options that are vested upon Closing in accordance with their vesting schedule after giving effect to any acceleration duly approved by the Company.
	 	 	 
	 	Waterfall	The waterfall attached in Schedule E, which may be updated as of the Closing by the Shareholders’ Representative solely with regard to the issuance of additional Ordinary Shares deriving from exercise of Vested Options, included in Schedule ‎4.4.2 and/or reduction of the Closing Shares and shares under Closing Warrants as a result of Leakage Payments (per the provisions of Section ‎7.11).

  

		1.2.	Certain Rules of Interpretation.

 

		1.1.1	Number and Gender. Words and defined terms denoting the singular number include the plural
and vice versa and the use of any gender shall be applicable to all genders.

 

		1.1.2	Headings. The paragraph headings are for the sake of convenience only and shall not affect
the interpretation of this Agreement.

 

		1.1.3	Any agreement or instrument defined or referred to herein, or in any agreement or instrument that
is referred to herein, means such agreement or instrument as from time to time amended, modified or supplemented. Other terms may
be defined elsewhere in the text of this Agreement and shall have the meaning indicated throughout this Agreement.

 

		2.	PURCHASE AND SALE OF THE SHARES

 

		2.1.	Agreement to Purchase and Sell. Subject to and
in accordance with the terms and conditions of this Agreement, at the Closing each of the Shareholders shall sell to the Purchaser,
and the Purchaser shall purchase from each of the Shareholders, the Ordinary Shares and the Preferred Seed Shares, owned by each
Shareholder as of the Closing, as set forth in the Waterfall (the “Purchased Shares”), such that immediately
following the Closing, the Purchaser shall be the owner of 100% of the issued and outstanding share capital of the Company, free
and clear of Security Interests; and any and all outstanding stock options, warrants, convertible securities, convertible debt
and equity equivalents of the Company shall have been exercised, repaid, expired or cancelled prior to Closing as set forth in
this Agreement.

 

    11

     

    

 

		2.2.	Consideration.

 

		2.2.1.	In consideration of the transfer and sale of the Purchased Shares, at the Closing and subject thereof,
the Purchaser shall issue to (a) the Shareholders an aggregate of 250,023 Preferred A-1 Shares which shall be deemed as the “Closing
Shares” and (b) the Company Warrant Holders as listed in the Waterfall, Closing Warrants (as defined in Section 2.6 hereto),
all as set forth in Section 2.6 hereof.

 

		2.2.2.	In the event that the Tax Ruling is rejected (the “Trigger Event”) then (i)
the 6,426 Closing Shares issued to the Shareholders (according to the allocation between the Shareholders as set forth in the Waterfall)
shall be reconveyed to the Purchaser and shall be deemed deferred and not valid; (ii) the Closing Warrant shall be reduced by 1,402
Preferred A-1 Shares according to the allocation between the Company Warrant Holders as set forth in the Waterfall; and (iii) the
Purchaser shall transfer to the Consideration Recipients, within seven (7) Business Days following the occurrence of the Trigger
Event, an aggregate amount equal to [***], to be split among the Consideration Recipients
as provided for in the Waterfall (the “Cash Payment Amount”).

 

For purposes
of this Agreement, (i) the Tax Ruling shall be deemed to be obtained if the ITA grants a tax ruling containing the Qualified Terms
and does not impose any additional limitation, restriction or obligation on the Shareholders other than as set forth in the Qualified
Terms or such other terms acceptable to both the Purchaser and the Shareholders Representatives after discussion in good faith
by the Parties during a period of 30 days following the receipt of such Tax Ruling; and (ii) the Tax Ruling shall be deemed to
be rejected if (x) the Purchaser and the Company receive a rejection in writing from the ITA that cannot be reasonably appealed
or challenged, or (y) at least nine (9) months from the Closing have lapsed without obtaining the Tax Ruling and the tax advisors
of the Shareholders, the Purchaser and the Company believe that there is no reasonable likelihood of obtaining the Tax Ruling.

 

“Qualified
Terms” means the following terms and conditions: (a) the transfer of shares of the Company to the Purchaser pursuant
to this Agreement is treated as a “tax exempt” exchange of shares pursuant to Section 103T (כ103( of the ITO;
and (b) other than the restrictions set forth in Section 103T (כ103( of the ITO, there shall be no restrictions, limitations
or obligations, of any kind, applying to the Shareholders. In case that the Application was rejected as evidenced by a written
notice of the ITA, the issuance of the Closing Shares and the Cash Payment Amount shall be subject to withholding Taxes in accordance
with Section 2.10 hereto.

 

		2.3.	Reserved.

 

		2.4.	Additional Issuances and/or Earn-Out Payments.

 

		2.4.1.	Issuances of Milestone Shares. In the case of the attainment
of a milestone set forth in Section 2 of Exhibit 2.4.1 hereto (such Exhibit 2.4.1, the “Milestones Schedule”)
prior to the fourth anniversary of the Closing Date or of a milestone set forth in Section 3 of the Milestone Schedule prior to
the third anniversary of the Closing Date, then upon the first attainment of any such milestone, the Consideration Recipients
listed in the Waterfall will be entitled to receive a one-time payment of an additional aggregate amount of 234,834 ordinary shares
of the Purchaser (the “Milestone Consideration Shares”). The allocation of the Milestone Consideration Shares
shall be made per the allocation set forth in the Waterfall. The issuance of the Milestone Consideration Shares shall be subject
to withholding Taxes in accordance with Section 2.10 hereto. If at the time of such payment of Milestone Consideration Shares,
the Tax Ruling has not yet obtained or a Trigger Event has occurred (and only in such events), the Purchaser shall, in addition
to the issuance of the Milestone Consideration Shares, pay the Consideration Recipients an aggregate amount of US$300,000 to be
split among the Shareholders as provided for in the Waterfall (the “Milestone Payment Amount”). Issuance of
the Milestone Consideration Shares and the payment of the Milestone Payment Amount (if applicable) shall be made by the Purchaser
within 30 days from the date that the applicable milestone was met. Each of the milestones set forth in the Milestone Schedule
shall be referred hereto as a “Milestone”. The payment of the Milestone Payment Amount shall be subject to
the provisions of Section ‎2.10 hereto.

 

    12

     

    

 

		2.4.2.	Contingent Consideration.

 

		2.4.2.1.	In addition to the issuance of the Milestone Consideration
Shares (to the extent applicable), subject to and upon meeting of any Milestone during the period listed therein, the Purchaser
shall make the applicable and additional payment as listed in the Milestone Schedule in shares and/or in cash (as set forth below)
to the Consideration Recipients per the allocation set forth in the Waterfall (the “Contingent Consideration”).

 

		2.4.2.2.	Any payment of the Contingent Consideration, calculated
as set forth in the Milestone Schedule, may be paid at the discretion of the Purchaser in one of the following methods (i) all
cash, (ii) a combination of cash and remaining consideration payable in the then most senior class of shares of the Purchaser
(the allocation to be determined by Purchaser in its sole discretion) or (iii) all consideration payable in the most senior class
of shares of the Purchaser authorized or outstanding as of the time that payment is due. In the case of (ii) and (iii), consideration
in shares will be based on the lowest price per share paid by any holder of Purchaser’s most senior class of shares in consideration
for the issuance thereof (such shares “Equity Contingent Consideration” and such price, the “Equity
Contingent Consideration Price”), provided that, to the extent that the Tax Ruling has not yet obtained by that
time or a Trigger Event has occurred prior to such date, at least [***] of the
applicable Contingent Consideration shall be made in cash (the “Minimum Cash Contingent Consideration”). In
case that the Application was rejected, the issuance of the Equity Contingent Consideration and the Cash Contingent Consideration
shall be subject to withholding Taxes in accordance with Section 2.10 hereto. In case that the Purchaser’s shares (or any
shares received by the Company’s shareholders as part of a merger with a public company) are traded on a public market, then the
price per share calculated as part of the payment under the Milestone Schedule, shall be calculated as set forth in Article 13.2
to the Amended Articles, provided that the distribution thereunder shall be deemed as the date of the notice of completion of
the applicable Milestone.

 

		2.4.2.3.	The Purchaser
will notify the Shareholders’ Representative, in writing, of its decision of how such Contingent Consideration is to be
paid in cash (the “Cash Contingent Consideration”) or Equity Contingent Consideration within fourteen (14)
Business Days from the date that the applicable Milestone was met (the “Payment Method Notice”).

 

    13

     

    

 

		2.4.2.4.	For the avoidance of doubt, in the event that the Tax
Ruling has been obtained by the time of the Contingent Consideration is due, then 100% of the Contingent Consideration may be
paid by issuance of Equity Contingent Consideration.

 

		2.4.3.	Source of Payment of the Milestone Payment, Payment
Schedule.

 

		2.4.3.1.	If the Purchaser is required to pay the Milestone Payment
Amount in accordance with Section 2.4.1, such amount shall be credited against the Contingent Consideration payment due for meeting
the Milestone listed under the Milestone Schedule (i.e. Purchaser shall not be required to pay the first [***]
in Contingent Consideration).

 

		2.4.3.2.	All payments of Cash Contingent Consideration and issuance
of the Equity Contingent Consideration due by the Purchaser to the Consideration Recipients shall be made within 30 Business Days
from the date of achievement of the applicable Milestone, provided, that with respect to Cash Contingent Consideration
other than the Minimum Cash Consideration (if applicable) due on account of Upfront Related Milestones (as defined in Section
4 of the Milestone Schedule) (the “Upfront Cash Payment”), such payment will be made [***]
from Purchaser’s or its Affiliates actual receipt of the payment on account of the relevant Qualifying Upfront Fee).
Consideration Recipients shall not have any claim against the Purchaser in case the Purchaser did not actually receive the payment
on account of the relevant Qualifying Upfront Fee and as a result did not pay the Consideration Recipients for such Milestone,
unless such payment has not been received due to any action or omission of the Purchaser.

 

		2.4.3.3.	The issuance of the Milestone Consideration Shares or
the payment of the Milestone Payment Amount shall be subject to withholding Taxes in accordance with Section 2.10.

 

		2.4.4.	If so elected by the Purchaser, the Shareholders’ Representative
shall appoint a paying agent (the “Paying Agent”) to handle all the withholdings and other payments required
under applicable Law with respect to receipt of all items of consideration due to the Consideration Recipients herein.

 

		2.4.5.	Redemption of Milestones. The Consideration Recipients
rights, if any, to receive the Milestone Consideration Shares (or the Milestone Payment Amount, if applicable) and the Contingent
Consideration (collectively, the “Milestone Consideration”) shall not be harmed or otherwise adversely affected
in an M&A Transaction and be fully assumed by acquirer or successor thereunder, provided that the acquiring or successor party
pursuant to such M&A Transaction shall be entitled, within no later than 30 days after the closing of such M&A Transaction,
to redeem itself from any obligations to pay future Contingent Consideration hereunder, by making the one-time payment, calculated
as set forth in Exhibit ‎2.4.5 attached hereto, to the Consideration Recipients in accordance with the allocation
between the Consideration Recipients as set forth in the Waterfall.

 

		2.4.6.	Occurrence of a Milestone. The occurrence of an applicable Milestone shall be deemed met
in accordance with the procedures set forth in the Milestone Schedule.

 

    14

     

    

 

		2.5.	The Purchaser shall use its commercially reasonable efforts to continue and develop the Company’s
Covered Product Candidates (as defined in the Milestone Schedule) (the “Development Undertaking”). Purchaser undertakes
to take and perform the actions listed in the Milestone roadmap attached hereto as Exhibit ‎2.5 (the “Milestone
Roadmap”), and its compliance with the Milestone Roadmap shall be deemed as compliance with the forgoing Development
Undertaking. Without derogating and subject to the foregoing, the Board of Directors of the Purchaser shall have sole and absolute
discretion to define, revise, terminate and amend Purchaser’s research, development and strategic growth plans, including
taking any act that has implications on the Company’s Covered Product Candidates or Computational Platform (as defined in
the Milestone Schedule). Additionally, without derogating and subject to the Purchaser undertaking to comply with the Milestone
Roadmap, the Purchaser may neglect, revise, abandon (and in the case of abandonment of a patent in all jurisdictions the resolution
of the Board of Directors of Purchaser will be required) or discontinue paying any registration or other fees related to Company
Intellectual Property Assets as it deems right in its sole and absolute discretion (provided that such actions do not impair Purchaser’s
undertaking to comply with the Milestone Roadmap).

 

		2.6.	Treatment of Warrants. All warrants held by Company Warrant Holders to purchase Company
Share Capital, as reflected in the Waterfall (the “Company Warrants”) shall expire and be cancelled and terminated
without payment and without Liability towards the holder thereof, except the right to receive (i) a warrant to purchase such number
of Preferred A-1 Shares of the Purchaser (constituting part of the Closing Shares) for no additional consideration, as set forth
in the Waterfall, in the form attached hereto as Exhibit ‎2.6 (the “Closing Warrants”), and
(ii) the right to receive additional consideration pursuant to Section ‎2.4 above in accordance with the allocation set forth
in the Waterfall.

 

		2.7.	Treatment of Stock Options.

 

		2.7.1.	No Company Option (whether vested or unvested) that is
outstanding immediately prior to the Closing shall be assumed by Purchaser. Each Company Option (whether vested or unvested) not
otherwise exercised before the Closing shall be cancelled immediately prior to the Closing. Any exercise of Company Option prior
to the Closing shall be reflected in the list of Shareholders set forth in Exhibit 2.2.1 and the Waterfall without
increasing the amount of the Closing Shares, Closing Warrants or the Cash Payment Amount.

 

		2.7.2.	Prior to Closing, the Company shall take all actions under
the Company Option Plan and otherwise to cause each of the Company Options to be cancelled and extinguished as of the Closing
Date and any other actions necessary to approve and confirm the treatment of the Company Options and any Ordinary Shares issued
thereunder as detailed above.

 

		2.8.	Allocation of the Consideration. The payment by the Purchaser of any consideration herein
to the Consideration Recipients per the allocation listed in the Waterfall shall constitute payment by the Purchaser to the Consideration
Recipients and satisfaction of the Purchaser’s obligation to pay such amount hereunder.

 

		2.9.	Tax Ruling.

 

		2.9.1.	The Purchaser and the Company shall make best efforts
to obtain a tax ruling from the ITA based on the application filed with the ITA on October 14, 2017 and attached hereto as Schedule
‎2.9 (the “Application” and the “Tax Ruling”, respectively).

 

		2.9.2.	To the extent that a Tax Ruling shall have been obtained,
the Purchaser hereby agrees and undertakes to make reasonable efforts to comply with the terms and conditions of the Purchaser’s
limitations, restrictions and obligations set forth in the Tax Ruling.

 

    15

     

    

 

		2.9.3.	In the event of any non-compliance by the Purchaser with
the provisions of the Tax Ruling that results in request of payment of taxes (the “Tax Payment Request”), and
other than in connection with a transfer of shares pursuant to an M&A Transaction in cash, the parties shall act as if no
Tax Ruling has been obtained or a Trigger Event has occurred, such that the provisions of Sections 2.2.2 and 2.4 above shall apply
as if no Tax Ruling has been obtained or a Trigger Event has occurred, mutatis mutandis.

 

		2.10.	Withholding Tax

 

		2.10.1.	Each of the Purchaser and the Paying Agent (to the extent
appointed) (each, a “Payor”), as the case may be, shall be entitled to deduct and withhold (and remit to the
appropriate Taxing Authority) from any consideration payable or otherwise deliverable to any Shareholder pursuant to this Agreement
such amounts as each Payor determines in good faith to be required to be deducted or withheld therefrom under any Applicable Law,
including, without limitation, the Israeli Tax Ordinance, provided, however, that in respect of Taxes arising under Applicable
Law, if Payor is provided, at least three (3) Business Days Prior to issuance of any shares or disbursement of funds, with a Valid
Certificate or ruling issued by the appropriate Taxing Authority regarding the deduction or withholding of Taxes (including the
reduction of Tax to be withheld, an exemption from withholding, or any other instructions regarding the payment of withholding,
whether general or referring specifically to any payment under this Agreement) (an “Israeli Tax Certificate”)
from any amounts payable hereunder, then the withholding (if any) of any amounts under Israeli Laws regarding Taxes from the amounts
payable hereunder, and the payment of the amounts or any portion thereof, shall be made only in accordance with the provisions
of such Israeli Tax Certificate. To the extent that such amounts are so withheld by a Payor, such withheld amounts shall be treated
for all purposes of this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid in respect
of whom such deduction and withholding was made by a Payor. In case no Israeli Tax certificate shall be provided, the Payor shall
use any or all of the Cash Payment Amount (if any) for payment of the tax amounts due for such issuance of the Closing Shares.
Each of the Consideration Recipients hereby irrevocably agrees and permits the Purchaser to use such Cash Payment Amount for the
payment of the withholding tax due for such sale in accordance with applicable Law as the Purchaser reasonably determines is required
to be deducted or withheld therefrom. In the event that the Payor shall notify the Shareholders Representative that the such Cash
Payment Amount (if any) is not sufficient for the payment of the Taxes due for each payment under this Agreement (including the
Contingent Consideration under the Milestone Schedule), each of the Consideration Recipient irrevocably undertakes to transfer
within 5 business days from first demand the amount that the Purchaser shall reasonably require to comply with the demands of
applicable Law.

 

		2.10.2.	a “Valid Certificate” shall be deemed
as being a valid and applicable certification or ruling issued by the ITA (i) exempting any Consideration Recipient from the duty
to withhold Israeli Taxes with respect to a Consideration Recipient, (ii) determining the applicable rate of Israeli Tax to be
withheld from such Consideration Recipient, or (iii) providing any other instructions regarding the payment or withholding with
respect to the applicable consideration of such Consideration Recipient. For such purpose, the Tax Ruling will be considered a
Valid Certificate providing full exemption from withholding.

 

    16

     

    

 

		2.11.	Adjustments. In the event of any share split, bonus shares, reverse share split, share dividend
(including any dividend or distribution of securities convertible into shares), consolidation, reorganization, reclassification,
combination, recapitalization or other like change with respect to the Purchaser’ shares occurring following the Closing,
all references in this Agreement to specified prices, numbers of shares affected thereby, or any value thereof, and all calculations
provided for that are based upon numbers of shares (or value thereof) affected thereby, shall be equitably adjusted to the extent
necessary to provide the parties hereto the same economic effect as contemplated by this Agreement prior to such share split, reverse
share split, share dividend, reorganization, reclassification, combination, recapitalization or other like change.

 

		3.	CLOSING

 

		3.1.	The closing of the purchase and sale of the Purchased Shares (the “Closing”)
shall take place at the offices of Zysman, Aharoni & Gayer, 45 Rothschild Blvd., Tel Aviv, Israel, within two (2) Business
Days after the satisfaction of all the conditions precedent to Closing as set out herein, or thereafter at such other time, date
and place as may be agreed by the Shareholders’ Representative and the Purchaser in writing (the time and date of the Closing
being herein referred to as the “Closing Date”).

 

		3.2.	At the Closing, the following actions and occurrences will take place, all of which shall be deemed
to have occurred simultaneously and no action shall be deemed to have been completed and no document or certificate shall be deemed
to have been delivered, until all actions are completed and all documents and certificates delivered:

 

		3.2.1.	The Shareholders and the Company shall deliver to the
Purchaser the following documents or cause the following actions to be completed:

 

		3.2.1.1.	share transfer forms for the Purchased Shares in the form attached hereto as Schedule ‎3.2.1.1,
duly executed by each Shareholder or, in the case of 102 Shares, by the 102 Trustee, transferring the Purchased Shares to of the
Purchaser;

 

		3.2.1.2.	Duly executed letters of resignation effective as of the Closing Date, by each of the existing
directors of the Company in the form attached hereto as Schedule ‎‎3.2.1.2;

 

		3.2.1.3.	A true and correct copy of the resolutions of the Board of Directors, substantially in the form
attached hereto as Schedule ‎3.2.1.3(a), approving, inter alia, the (i) execution and delivery by the Company
of this Agreement and the other Transaction Documents to which the Company is a party and the transactions contemplated hereby
and thereby, including the transfer by the Shareholders of the Purchased Shares to the Purchaser, (ii) the treatment of Company
Options and 102 Shares as detailed in this Agreement; (iii) purchase a run off, or tail insurance policy (the “Tail Insurance
Policy”); and (iv) approving the Shareholders Registrar in the form of Schedule 3.2.1.3(b).

 

		3.2.1.4.	True and correct copy of the resolutions of the shareholders of the Company, in substantially the
form attached hereto as Schedule ‎3.2.1.4, approving, among other things, the execution and delivery by the Company
of this Agreement, and purchase of the Tail Insurance Policy;

 

    17

     

    

 

		3.2.1.5.	Validly executed new share certificates covering the Purchased Shares, issued in the name of the
Purchaser, in substantially the form attached hereto as Schedule ‎3.2.1.5;

 

		3.2.1.6.	A true and complete copy of the Register of the Directors of the Company as in effect immediately
prior to Closing in the form of Schedule 3.2.1.6;

 

		3.2.1.7.	A certificate of the Company duly executed by its Chief Executive Officer, dated as of the Closing
Date, in the form attached hereto as Schedule 3.2.1.7;

 

		3.2.1.8.	Reserved.

 

		3.2.1.9.	The original copies of all of the Shareholders’ share certificates or in the event that any
certificates shall have been lost, stolen or destroyed, such Shareholders shall provide an affidavit to this effect substantially
in the form attached hereto as Schedule ‎3.2.1.9.

 

		3.2.1.10.	Each of the Shareholders shall have delivered an executed Shareholders Certificate, in the form
attached hereto as Schedule ‎3.2.1.10.

 

		3.2.1.11.	Each of the Option holders shall have delivered an executed Instrument, Waiver and Consent, in
the form attached hereto as Schedule 3.2.1.11.

 

		3.2.1.12.	The Company shall deliver to the Purchaser a certificate signed by an officer of the Company and
setting forth an extract from the Company’s bank(s) providing the Company’s bank accounts balance status as of three
(3) Business Days prior to the Closing and a good faith estimate of the amount of cash of the Company and the amount of Debt as
of the Closing (the “Closing Certificate”) in the form attached hereto as Schedule 3.2.1.12.

 

		3.2.1.13.	Executed termination notices of all of the employees of the Company and
waiver of certain rights in connection with termination of employment signed by all of the employees of the Company in the
form of Schedule ‎3.2.1.13.

 

		3.2.1.14.	A copy of a certificate of good standing for the Company from the Israeli Companies Registrar,
as of a date within ten (10) Business Days of the Closing Date.

 

		3.2.1.15.	Each of the Consideration Recipients other than 8VC Angel Fund I, LP and 8VC Angel Fund I Associates
L.P. shall have executed an irrevocable Proxy for the benefit of the Shareholders’ Representative to vote the shares held
by the Shareholders at any shareholders meeting or resolution, receive any information from the Company and otherwise represent
such Consideration Recipient in any communications with the Company, all as set forth in and substantially in the form of Schedule
‎3.2.1.15.

 

		3.2.1.16.	Any Consideration Recipient who is not a resident of the State of Israel that holds, as of immediately
post-Closing, more than 5% of Purchaser’s issued and outstanding share capital shall execute a Letter of Undertaking to the
IIA with respect to the subscription made under this Agreement in the form attached hereto as Schedule ‎3.2.1.16.

 

    18

     

    

 

		3.2.1.17.	8VC Angel Fund I LP shall execute a termination letter with respect to its right to appoint an
observer to the Company’s Board in the form attached hereto as Schedule 3.2.1.17.

 

		3.2.1.18.	Proof of cancellation of the credit and debit cards of the Company.

 

		3.2.1.19.	True and correct copies of any third party consents to the transaction contemplated under this
Agreement as listed in Schedule 3.2.1.19.

 

		3.2.1.20.	A non-competition and non-solicitation letter of undertaking executed by each of Shareholders listed
on Schedule ‎3.2.1.20(a) in the form attached hereto as Schedule ‎3.2.1.20(b).

 

		3.2.2.	The Company shall record the transfer of the Purchased
Shares to the Purchaser as contemplated hereunder, on the Company’s register of shareholders, reflecting the ownership of
100% of the Company share capital by the Purchaser, and shall provide the Purchaser with a certified copy of the Company’s
register of shareholders as of immediately after the Closing in the form attached hereto as Schedule ‎‎3.2.2.

 

		3.2.3.	The Purchaser shall issue and transfer to the Shareholders
the Closing Shares to be allocated to the Shareholder per the Waterfall and deliver to each Consideration Recipient validly executed
new share certificates covering its applicable Closing Shares, in substantially the form attached hereto as Schedule ‎3.2.3.

 

		3.2.4.	The Purchaser shall issue and transfer to the Warrant
Holders the Closing Warrants to be allocated to the Warrant Holders per the Waterfall and deliver to each Shareholder validly
executed Closing Warrants.

 

		3.2.5.	The Consideration Recipients, the Purchaser and the requisite
shareholders who are parties to the existing Investors Rights Agreement of the Purchaser (the “Existing IRA”)
shall execute an amendment to such Investors Rights Agreement granting the Consideration Recipients certain rights, in the form
attached hereto as Schedule ‎3.2.5 (the “Amended IRA”), and the Purchaser shall provide to
the Consideration Recipients a copy of the Amended IRA, executed by the Purchaser and the requisite shareholders who are parties
to the Existing IRA.

 

		3.2.6.	Copy of the amended and restated articles of association
of the Purchaser’s, to be in effect immediately following the Closing in the forms attached hereto as Schedule ‎3.2.6
(the “Amended Articles”), which shall be provided to the Consideration Recipients.

 

		3.2.7.	The Purchaser shall deliver to the Consideration Recipients
a true and correct copy of the resolutions of the Board of Directors of the Purchaser, substantially in the form attached hereto
as Schedule ‎3.2.7(a) and true and correct copy of the resolutions of the shareholders of the Purchaser, in
substantially the form attached hereto as Schedule ‎3.2.7(b).

 

		3.2.8.	The Purchaser shall record the issuance of the Closing
Shares to the Shareholders as contemplated hereunder, on the Purchaser’s register of shareholders, and shall provide the
Consideration Recipients with a certified copy of the Purchaser’s register of shareholders as of immediately after the Closing
in the form attached hereto as Schedule ‎3.2.8.

 

    19

     

    

 

		3.3.	Conditions to Closing of Each Party. The obligations of the Company, the Purchaser and the
Consideration Recipients to consummate the Transaction are subject to the satisfaction of the following condition:

 

		3.3.1.	No Injunction. No temporary restraining order,
preliminary or permanent injunction or other order or decree issued by any Governmental Authority of competent jurisdiction shall
be in effect and no applicable Law shall have been enacted or be deemed applicable to the Transaction which could reasonably be
expected to impair, prevent or prohibit the consummation of the Transaction.

 

		3.4.	Purchaser’s Conditions to Closing. The Purchaser’s obligations to consummate
the purchase of the Purchased Shares hereunder are subject to the fulfilment, prior to or at the Closing, of each of the following
conditions (any or all of which may be waived by the Purchaser):

 

		3.4.1.	The representations and warranties of the Company and
the Consideration Recipients contained herein were true and correct in all material respects when made and shall be true and correct
in all material respects at the time of the Closing as though made again at the Closing Date, except (i) for those representations
and warranties qualified by material, materiality or similar expressions which shall be true and correct in all respects, (ii)
changes contemplated by this Agreement, and (iii) for those representations and warranties that address matters only as of a particular
date, which representations and warranties shall have been true and correct as of such particular date.

 

		3.4.2.	The Consideration Recipients and the Company shall have
performed and complied in all material respects with the obligations and covenants required by this Agreement to be performed
or complied with by them prior to or at the Closing.

 

		3.4.3.	No action, proceeding or investigation shall have been
instituted, threatened or proposed before any court or Governmental Authority and no Order shall be in effect to enjoin, alter,
prevent, restrain , prohibit, materially delay, restrict the consummation of the Closing, or that shall impact materially and
adversely the operation of the business following the Closing. No proceeding challenging this Agreement, the Transaction Documents
or the Transactions contemplated by the Transaction Documents or seeking to obtain substantial damages in respect of, or which
is related to, or arises out of, the Transaction Documents or the consummation of the Transaction, shall have been instituted
by any Person before any Governmental Authority and be pending.

 

		3.4.4.	The execution, delivery and performance of the Transaction
by the Company and the Consideration Recipients shall be duly authorized by the Board of Directors and the shareholders of the
Company. Copies of the resolutions adopted by the Board of Directors and the shareholders of the Company, respectively approving
this Agreement substantially in the form attached hereto as Schedule ‎3.2.7(a) and Schedule ‎3.2.7(b)
shall have been provided to the Purchaser at or prior to the Closing.

 

		3.4.5.	All outstanding options, warrants and any other securities
convertible or exercisable into Ordinary Shares or Preferred Seed Shares, including those set out in Schedule ‎3.4.5,
shall have been exercised, converted, expired, repaid or cancelled, and all outstanding Security Interests on the Purchased Shares
shall have been discharged, such that immediately following the Closing, the Purchaser shall be the owner of 100% of the issued
and outstanding share capital of the Company on such date, free and clear of all Security Interests.

 

    20

     

    

 

		3.4.6.	There shall have been no Company Material Adverse Effect.

 

		3.4.7.	The Purchaser and
the Key Employees have executed the Key Employment Agreements, between the Purchaser
and each of the Key Employees.

 

		3.4.8.	All Closing deliverables set forth in Section ‎3.2
and Section ‎3.2.2 above shall have been duly received to the satisfaction of Purchaser.

 

		3.4.9.	The Closing Certificate provided shall indicate that there
is no Debt in the Company, other than as set forth in Schedule 4.22 of the Disclosure Schedule.

 

		3.4.10.	The Company shall have duly approved the purchase of,
and shall actually purchased the Tail Insurance Policy.

 

		3.4.11.	The Company shall have purchased a general third party
liability insurance policy (the “Third Party Insurance”).

 

		3.5.	Consideration Recipients’ Conditions to Closing. Consideration Recipients’ obligations
to consummate the sale of the Purchased Shares to the Purchaser at the Closing are subject to the fulfilment, prior to or at the
Closing, of each of the following conditions (any or all of which may be waived by the Shareholders’ Representative):

 

		3.5.1.	All representations and warranties of the Purchaser contained
herein were true and correct when made and shall be true and correct, in all material respects, at the time of the Closing as
though made again at the Closing Date.

 

		3.5.2.	The Purchaser shall have performed and complied in all
material respects with all obligations and covenants required by this Agreement to be performed or complied with by the Purchaser
prior to or at the Closing.

 

		3.5.3.	All Closing deliverables set forth in Sections ‎3.2
– ‎3.2.8 above shall have been duly received to the satisfaction of the Consideration Recipients.

 

		3.5.4.	No action, proceeding or investigation shall have been
instituted, threatened or proposed before any court or Governmental Authority and no Order shall be in effect to enjoin, alter,
prevent, restrain, prohibit, materially delay, restrict the consummation of the Closing, or that shall impact materially and adversely
the operation of the business following the Closing. No proceeding challenging this Agreement, the Transaction Documents or the
Transactions contemplated by the Transaction Documents or seeking to obtain substantial damages in respect of, or which is related
to, or arises out of, the Transaction Documents or the consummation of the Transaction, shall have been instituted by any Person
before any Governmental Authority and be pending.

 

		4.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

The Company
hereby represents and warrants to the Purchaser with respect to the Company as of the date hereof and as of the Closing Date as
follows, except as set forth herein or in the Company Disclosure Schedule delivered to the Purchaser concurrently herewith which
disclosures shall be deemed to be part of the representations and warranties of the Company):

 

		4.1.	Constitution and Compliance.

 

		4.1.1.	The Company is validly existing under the laws of the
State of Israel, with power and authority to carry on its business as currently conducted and as currently proposed to be conducted.
The Company has at all times carried on its business and affairs in all material respects in accordance with its Organizational
Documents and all applicable Laws and regulations, and there is no violation or material default with respect to any statute,
regulation, Order, decree, or judgment of any court or any Governmental Authority which could have a material adverse effect upon
the assets or business of the Company. The Company is duly qualified to do business and is in good standing in each jurisdiction
in which the Company currently conducts business.

 

    21

     

    

 

		4.1.2.	The Company has all requisite corporate power and authority
to execute and deliver the Transaction Documents, and to carry out and perform its obligations thereunder. All corporate action
on the part of the Company, its directors, and its shareholders necessary for the authorization and execution of this Agreement
by the Company has been taken. This Agreement constitutes the valid and legally binding obligation of the Company, and, assuming
due authorization, execution and delivery by the Purchaser and any other party thereto, is enforceable in accordance with its
terms, subject, in each case, to (i) laws of general application relating to bankruptcy, insolvency, reorganization, moratorium
and the relief of debtors, and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies.

 

		4.2.	No Conflict. The execution and delivery by the Company of the Transaction Documents to which
the Company is a party does not, and the consummation of the Transaction will not, (i) violate, conflict, or result in a breach
of any provisions of any Organizational Documents of the Company, (ii) result in the creation or enforcement of any Security Interest
upon any of the properties or assets of the Company, (iii) result in a default (with or without the giving of notice or lapse of
time, or both) under, or acceleration or termination of, or the creation in any Person of the right to accelerate, terminate, modify
or cancel, any material contract to which any Company is a party, (iv) require the consent or agreement of any governmental body,
entity or any other third party, except as provided in, or disclosed by this Agreement, or (v) constitute a material violation
(with or without the giving of notice or lapse of time, or both) of Law or any judgment, decree, Order, regulation or rule of any
Governmental Authority applicable to the Company or any of .

 

		4.3.	Subsidiaries. The Company does not own, directly or indirectly, any capital stock, membership
interests, or other securities of any Person. The Company does not have any Subsidiaries. The Company is not a participant in any
joint venture, special purpose entity, partnership or similar arrangement.

 

		4.4.	Capitalization.

 

		4.4.1.	Schedule ‎‎4.4.1 of the Disclosure
Schedule sets out the authorized and issued share capital of the Company as of the date of this Agreement and immediately prior
to the Closing.

 

		4.4.2.	Schedule ‎4.4.2 of the Disclosure Schedule
sets out, as of the date of this Agreement, a true, correct and complete list of any and all options, warrants and other Company
securities convertible into Ordinary Shares or Preferred Seed Shares or other type of shares which were issued by the Company
(the “Options”). Except for Ordinary Shares or Preferred Seed Shares the Company has not issued any other type
or class of shares.

 

		4.4.3.	Other than as listed in Schedules 4.4.1
and ‎4.4.2 of the Disclosure Schedule, there are no outstanding or authorized subscriptions, options, warrants,
calls, rights, commitments, or any other agreements of any character directly or indirectly obligating the Company to issue (i)
any additional shares or other securities or (ii) any securities or debt convertible into, or exchangeable for, or evidencing
the right to subscribe for, any shares or other securities.

 

    22

     

    

 

		4.4.4.	The Purchased Shares constitutes all of the issued and
outstanding share capital of the Company as of the Closing Date.

 

		4.5.	Financial Statements.

 

		4.5.1.	The Company has delivered to the Purchaser audited balance
sheets of the Company as of, and the related statements of income and cash flows, for the year ended December 31, 2015 and December
31, 2016, accompanied by the report of the Company’s independent public accountants thereon (the “Financial Statements”)
The Financial Statements are attached hereto as Schedule ‎4.5.1.

 

		4.5.2.	The Financial Statements (i) have been prepared from the
books and records of the Company, (ii) complied as to form in all material respects with applicable accounting requirements with
respect thereto as of their respective dates, (iii) have been prepared (other than the management reports) in accordance with
GAAP applied on a consistent basis throughout the periods indicated (except as may be indicated therein or in the notes thereto)
and consistent with each other and (iv) fairly present in all material respects in accordance with GAAP the financial position
of the Company as at the date thereof and, where applicable, the results of their operations and cash flows for the period indicated
(except as may be otherwise specified in the notes to such Financial Statements). The Company maintains a standard system of accounting
established and administered in accordance with GAAP.

 

		4.5.3.	The Company did not receive from its independent auditors,
and does not otherwise have knowledge of, any notice with respect to (A) any fraud or fraudulent concealment, whether or not material,
that involves the Company’s or management or other employees who have a role in the preparation of financial statements
or the internal controls utilized by the Company, or (B) any material claim or allegation regarding any of the foregoing.

 

		4.5.4.	All Liabilities of the Company, are reflected in or reserved
against in the Financial Statements (including the notes thereto) to the extent required by GAAP, other than Liabilities that
have arisen in the Ordinary Course of Business since December 31, 2016. Other than Liabilities required to be reflected or reserved
in the Financial Statements and other Liabilities that have arisen in the Ordinary Course of Business since December 31, 2016,
there are no Liabilities whatsoever of the Company. The Company is not in default with respect to any such Debt or any instrument
relating thereto.

 

		4.6.	Business to Date.

 

		4.6.1.	Except as contemplated by this Agreement and for actions
taken in connection with the negotiation of this Agreement and the Transaction which are reflected in Schedule ‎4.6.1
to the Disclosure Schedule, since December 31, 2016 until the date hereof (i) the Company conducted their business in
the Ordinary Course of Business, and (ii) there has not been any event, change, occurrence or circumstance that has had a Company
Material Adverse Effect on the Company. As amplification and not in limitation of the foregoing, except as set forth on Schedule ‎4.6.1
to the Disclosure Schedule, since December 31, 2016, there has been:

 

		4.6.1.1.	no event, occurrence, development, circumstance, or state of facts event or development which,
individually or in the aggregate, has had, or would reasonably be expected to have in the future, a Company Material Adverse Effect;

 

    23

     

    

 

		4.6.1.2.	no declaration, setting aside or payment of any dividend or other distribution with respect to,
or any direct or indirect redemption or acquisition of, any of the Company’s share capital by the Company or by any other
Person;

 

		4.6.1.3.	no waiver of any valuable right of the Company under any Material Contract;

 

		4.6.1.4.	no loan by the Company to any officer, director, employee or shareholder of the Company, or any
agreement or commitment therefor, or the engagement by the Company in any transaction with any employee, officer, director or security
holder of the Company, other than the payment of normal wages and salaries to employees in the Ordinary Course of Business and
advances to employees in the Ordinary Course of Business for travel and similar business expenses;

 

		4.6.1.5.	no material loss, destruction or damage to any property or assets of the Company, whether or not
insured;

 

		4.6.1.6.	no labor disputes or union organizing campaign involving the Company;

 

		4.6.1.7.	no acquisition, license or disposition of any material portion of the Company’s assets, including
any Company Intellectual Property Assets (or any Contract in respect of such assets), otherwise than for fair value in the Ordinary
Course of Business;

 

		4.6.1.8.	no Security Interest imposed or created on any of the assets or properties of the Company;

 

		4.6.1.9.	no assignment, termination, modification or amendment of any Material Contract to which the Company
was or is a party, except for any termination, modification or amendment made in the Ordinary Course of Business and which would
not, either individually or in the aggregate, be material to the results of operations;

 

		4.6.1.10.	no notice to the Company that any Material Contract to which the Company was or is a party has
been breached, repudiated or terminated or will be breached, repudiated or terminated, or for which any party other than the Company
has made a complaint, demand or claim against the Company for an amount in excess of US$ 10,000 based on such Material Contract;

 

		4.6.1.11.	no entering into, adoption or material modification of any employment or similar contract, or any
increase in the salary or other compensation of any employee, officer or director of the Company, or any increase in or any addition
to other benefits to which any such employee, officer or director may be entitled other than an Ordinary Course of Business annual
salary adjustment, in accordance with existing agreement or as required by Law;

 

		4.6.1.12.	no compensation, bonus, payment or distribution by the Company or any Affiliate thereof to any
employee, officer, director or consultant of the Company not consistent with past practices of the Company;

 

		4.6.1.13.	no failure to pay or discharge when due (after the application of any applicable grace periods)
any liabilities of the Company, except for liabilities contested in good faith by the Company, provided that, such liabilities
have been fully reflected and reserved for in the Financial Statements;

 

    24

     

    

 

		4.6.1.14.	no change in any of the accounting principles adopted by the Company, or any change in the Company’s
accounting policies, procedures, practices or methods (including Tax accounting methods) with respect to applying such principles,
other than as required by applicable Law;

 

		4.6.1.15.	no settlement or compromise of any Tax liability of the Company, no entry into any material agreement
with any Taxing Authority (or any other Governmental Authority) regarding the Company’s liability for Taxes, no amendment
of a Tax Return of the Company or filing of a claim for refund of Taxes previously paid by or on behalf of the Company, no consent
to any extension or waiver of the limitation period applicable to any claim or assessment in respect of material Taxes of the Company;

 

		4.6.1.16.	no adoption, revocation or modification of any material Tax election of the Company or filing of
any income or other material Tax Return of the Company;

 

		4.6.1.17.	no commencement of any legal proceeding by or against the Company;

 

		4.6.1.18.	no capital expenditure, purchase or commitment that will still be outstanding or in process at
the Closing in excess of [***] or series of capital expenditures, purchases or commitments
that will still be outstanding or in process in excess of [***] in the aggregate;

 

		4.6.1.19.	no incurrence of Debt by the Company;

 

		4.6.1.20.	no audit by any Governmental Authority or receipt of notice (written or, to the knowledge of the
Company, verbal) from any regulatory agency with respect to the business of or facilities used by the Company;

 

		4.6.1.21.	no settling of a legal dispute or legal proceeding involving the Company; and

 

		4.6.1.22.	no agreement, understanding or authorization (written
or verbal), for the Company to take any of the actions specified in this Section ‎4.6.1.

 

		4.6.2.	Full and accurate details of all bank accounts, overdrafts,
loans, guarantees or other financial facilities outstanding or available to the Company are contained in Schedule 4.6.2
of the Disclosure Schedule.

 

		4.7.	Taxation

 

		4.7.1.	The Company has timely filed, in accordance with all applicable
Laws, all Tax returns and reports required under applicable Laws to be filed by or on behalf of the Company, and all Taxes required
under applicable Law to be paid by or on behalf of the Company as of the date hereof and as of the December 31, 2016 have either
been paid by it or are reflected in accordance with GAAP as a reserve for Taxes on the most recent Financial Statements and all
such returns and reports are true, correct and complete in all material respects, and the Financial Statements reflect an adequate
reserve for all Taxes payable by the Company for all taxable periods and portions thereof through the date of such Financial Statements.

 

    25

     

    

 

		4.7.2.	All Taxes required by applicable Laws to be withheld by
the Company have been duly and properly withheld or collected and have been (or will be) duly and timely paid to the proper Taxing
Authority. No deficiencies, adjustment, underpayment for any Taxes have been proposed, asserted or assessed against the Company
that is still pending. Except as set forth in Schedule ‎4.7 of the Disclosure Schedule, no requests
for waivers of the time to assess any such Taxes have been made that are still pending.

 

		4.7.3.	The Company is not, and will not be required to pay any
Taxes for periods up to the Closing Date except to the extent adequate provision was made in the Financial Statements.

 

		4.7.4.	The Company has not (i) requested any extension of time
within which to file any Tax Return or (ii) been granted any extension or waiver of the statute of limitations with respect to
any Taxes.

 

		4.7.5.	There is no action, suit, proceeding, claim, audit, or
investigation currently in progress, pending or, to the knowledge of the Company, threatened by any Taxing Authority against or
with respect to the Company in respect of any Tax.

 

		4.7.6.	There are no Security Interests for Taxes upon the assets
of the Company, except Security Interests for current Taxes not yet due.

 

		4.7.7.	The Company is not a party to any Tax indemnity or Tax
Sharing Agreement with any Person, and the Company has no liability for the Taxes of any Person (other than the Company) by contract
or otherwise.

 

		4.7.8.	The Company has made available to Purchaser or its legal
counsel or accountants copies of all Tax Returns filed for the Company for all Taxable periods (or portion thereof) ending on
or before December 31, 2016 and since incorporation, and all private letter rulings, determination letters, closing agreements
and other correspondence received by them from any Taxing Authority since the same date or that may apply to the Company after
the December 31, 2016.

 

		4.7.9.	The Company is not (i) a party to any “reportable
transaction” within the meaning of Section 131(g) and Section 243 of the ITO and the respective regulations, (ii)
has been a party to any transaction or arrangement that could reasonably be expected to cause an extension of any statute of limitations
related to Taxes, including an extension because the transaction or arrangement was required to be, but was not, reported to any
Taxing Authority.

 

		4.7.10.	The Company is not engaged in or has ever been engaged
in a trade or business through a “permanent establishment” within the meaning of an applicable income Tax treaty in
any country other than the country in which the Company is formed or organized.

 

		4.7.11.	The Company has not granted a power of attorney to any
Person that is currently in force with respect to any Tax matter of the Company.

 

		4.7.12.	The Company is registered for VAT purposes and Schedule ‎4.7.12
contains full details of such registration, including any group registration details. The Company has not been, a member
of any other group of companies for VAT purposes other than the group disclosed on Schedule ‎4.7.12, and
no company other than the Company has been a member of such group.

 

    26

     

    

 

		4.7.13.	The Company has complied in all material respects with
all statutory provisions relating to VAT or other applicable sales Taxes, including requirements with respect to record keeping
and the making of returns, and has properly accounted to the relevant Taxing Authority for any such VAT or sales Taxes and, without
derogating from the generality of the foregoing, (i) no repayments of VAT have been claimed by the Company in the twelve (12)
months prior to the Closing from the Tax authorities of Israel except in accordance with applicable Law and (ii) the Company has
collected all amounts on account of any VAT required by applicable Law to be collected by it, and has remitted to the appropriate
Taxing Authority any such amounts required by applicable Law within the time prescribed by such requirements. The Company has
not deducted any input VAT, received any refund of VAT or claimed zero (0) rate VAT that such it was not so entitled to deduct,
receive or claim, as applicable.

 

		4.7.14.	The Company currently complies and has always timely complied
in the past with all the relevant requirements of Section 102, with respect to any award issued pursuant to the provisions
of such section, and the Company has complied with the requirements of Section 3(i) of the ITO with respect to grants to
independent contractors or “Controlling Shareholders” (as defined in the ITO). The Option Plan and, if applicable,
any amendments thereto, were timely and duly filed with the ITA and with the Company’s 102 Trustee.

 

		4.7.15.	Any Related Party transactions subject to Section 85A
of the ITO conducted by the Company has been on an arms-length basis in accordance with Section 85A of the ITO and the regulations
promulgated thereunder.

 

		4.7.16.	The Company and to the knowledge of the Company, any of
the holders of the securities (with respect to the securities held by them) is subject to restrictions or limitations pursuant
to Part E2 of the ITO or pursuant to any Tax ruling made in connection with the provisions of Part E2 of the ITO.

 

		4.7.17.	The Company has not made any application for or received,
on its behalf or on behalf on any of its shareholders or employees, and are not otherwise subject to, any “taxation decision”
(hachlatat misui) or Tax ruling from the ITA, whether or not in connection with the transactions contemplated by this Agreement,
other than the Application.

 

		4.7.18.	Schedule ‎4.7.18 of the
Disclosure Schedule sets forth all Tax exemptions, Tax holidays or other Tax reduction agreements or arrangements (including grants
or claims of “approved enterprise”, “benefitted enterprise” or “preferred enterprise” status)
made with, or applied for by, any of the Company. The Company has provided to Purchaser all documentation relating to any applicable
Tax holidays or incentives. Without limiting the generality of the foregoing, Schedule ‎4.7.18
of the Disclosure Schedule lists each Tax incentive granted to the Company under Israeli Law and the period for which such Tax
incentive applies. The Company has complied with all material requirements of Israeli Law to be entitled to claim all such incentives.
Subject to the receipt of the approvals set forth on Schedule ‎4.7.18 of the Disclosure Schedule and
compliance by the Company with the applicable requirements and conditions, the consummation of the transactions contemplated by
this Agreement will not adversely affect the remaining duration or the extent of any incentive or require any recapture of any
previously claimed incentive, and no consent, approval, clearance of, or filing with, any Governmental Authority or Taxing Authority
is required, prior to the consummation of such transactions in order to preserve the entitlement to any such incentive.

 

    27

     

    

 

		4.8.	Suppliers and Collaborators.

 

		4.8.1.	Schedule 4.8 of the Disclosure Schedule
sets forth the list of all the suppliers of services (“Suppliers”) to the Company and all of the collaborations
engagements of the Company (“Customers”) of the Company.

 

		4.8.2.	Except as indicated in Schedule ‎4.8
of the Disclosure Schedule, the Company has not received any written or verbal notice, of any default or event that with notice
or lapse of time, or both, would constitute a default by the Company under any engagement with any Supplier or Customer. None
of the Suppliers or Customers has indicated to the Company (nor does the Company has any knowledge of) any intent to discontinue
or alter in any manner adverse to the Company the terms of such Supplier’s or Customer’s relationship with the Company
(including with respect to non-renewal of maintenance agreements) or make any claim that would be reasonably expected to give
rise to a breach by the Company of its obligations to such Supplier or Customer, and there has been no negative developments with
respect to the relationships with any Supplier or Customer. The Company is in full compliance with its obligations under each
Contract with its Customers and Suppliers and in the event such Contract is no longer in effect, the Company was in full compliance
with their obligations under each Contract until the termination thereof. The Company has provided Purchaser with a copy of all
Contracts with Customers and Suppliers and termination agreements for any such Contracts that have since been terminated.

 

		4.8.3.	Except as indicated in Schedule ‎4.8.3
of the Disclosure Schedule, none of the engagements with any Supplier or any Customer have been terminated.

 

		4.9.	Litigation. (1) There is no claim, action, suit, injunction, arbitration, or administrative
or other proceeding pending or, to the knowledge of the Company, threatened against the Company or involves the Company’s
contractual relationships, properties or assets, (2) to the knowledge of the Company, there is no investigation or examination
pending or threatened against the Company or that involves the Company’s contractual relationships, properties or assets,
and, (3) to the knowledge of the Company, there is no basis for any such claim, action, suit, investigation, arbitration, or administrative
or other proceeding, including as a result of the consummation of the transactions contemplated by this Agreement, before any court,
arbitration tribunal or Governmental Authority. Neither the Company nor any of its respective properties, assets or business, is
subject to or bound by any Order.

 

		4.10.	Reserved.

 

		4.11.	Employees and Contractors.

 

		4.11.1.	Schedule ‎4.11.1
of the Disclosure Schedule sets forth a complete and accurate list of all employees of the Company (“Employees”).
The Company has furnished to Purchaser a list of all current Employees employed by the Company as of the date of this Agreement,
and such list correctly reflects: (i) their name and dates of hire; (ii) their position, full-time or part-time status, including
each Employee’s classification as either exempt or non-exempt from the overtime requirements under any applicable Law; (iii)
their monthly base salary or hourly wage rate, as applicable; (iv) any other compensation payable to them including housing allowances,
compensation payable pursuant to bonus, deferred compensation or commission arrangements, overtime payment, vacation entitlement
and accrued vacation or paid time-off balance, travel pay or car maintenance or car entitlement, sick leave entitlement and accrual,
recuperation pay entitlement and accrual, entitlement to pension arrangement and/or any other provident fund (including manager’s
insurance and education fund), their respective contribution rates and the salary basis for such contributions, and notice period
entitlement; and (v) any promises or commitments made to the Employees, whether in writing or not, with respect to any future
changes or additions to their compensation or benefits. Other than their salary, the Employees are not entitled to any payment
or benefit that may be reclassified as part of their determining salary for all intent and purposes, including for the social
contributions.

 

    28

     

    

 

		4.11.2.	The Company has complied in all material respects with
all Laws relating to employment, including without limitation all Laws concerning equal employment opportunity, nondiscrimination,
leaves and absences, immigration, wages, hours, benefits, collective bargaining, the payment of social security and similar Taxes,
and occupational safety and health. To the knowledge of the Company, no executive, key employee or group of employees has any
plans to terminate employment with any of the Company. There are no unresolved employment-related charges, claims, complaints
or lawsuits involving the Company. The Company is not a party to or bound by any collective bargaining agreement, collective labor
agreement or other Contract or arrangement with a labor union, trade union or other organization or body involving any of its
Israeli Employees, nor has it recognized or received a demand for recognition from any collective bargaining representative with
respect to any of its Israeli Employees. There are no (i) strikes, work stoppages, work slowdowns or lockouts pending or, to the
knowledge of the Company, threatened against or involving the Company, or (ii) unfair labor practice charges, other collective
bargaining disputes, grievances or complaints pending or, to the knowledge of the Company, threatened by or on behalf of any employee
or group of employees of the Company. The Company has not committed any unfair labor practice. To the knowledge of the Company,
there are no labor organizations representing, nor, organizational efforts presently being made or threatened by or on behalf
of any labor union with respect to employees of the Company.

 

		4.11.3.	The Company’s obligations towards the employees
to provide severance pay, including statutory severance pay to all Israeli Employees pursuant to the Severance Pay Law -1963,
and to redeem unused vacation pursuant to Contract, applicable Law (including the Annual Leave Law – 1951 with respect to
Israeli Employees) are fully funded or, if not required to be fully funded, is accrued on the Company’s Financial Statements.
All of the employees of the Company are subject to Section 14 Arrangement under the Israeli Severance Pay Law - 1963 (“Section
14 Arrangement”) and the Company has fully complied with all provisions related to such Section 14 Arrangement.

 

		4.11.4.	Schedule 4.11.4(i) of the Disclosure
Schedule contains an accurate and complete list of: (A) all current independent contractors, and Persons that have a consulting
or advisory relationship with the Company; (B) the location at which independent contractors, consultants and advisors have been
or are providing services; (C) the rate of all regular, bonus or any other compensation payable to the current independent contractors,
consultants and advisors; and (D) the start and termination date of any binding Contract between the Company and any Person that
has a current consulting or advisory relationship with the Company. Except as set forth on Schedule ‎4.11.4
of the Disclosure Schedule, all independent contractors, consultants and advisors of the Company can be terminated immediately
and without notice or liability on the part of the Company. The Company has no outstanding obligations with respect to former
independent contractors, consultants or advisors.

 

    29

     

    

 

		4.11.5.	The Company has no liability (including rights to severance
pay, vacation, recuperation pay (dmei havraa) and other employee-related statutory and contractual benefits) with respect
to any misclassification or treatment of any Person as an independent contractor (including consultant, sub-contractor, or the
like) rather than as an “employee” and with respect to any employee leased from another employer, or with respect
to any employee currently or formerly classified as exempt from overtime wages.

 

		4.11.6.	All employees have entered into written employment agreement
with the Company;

 

		4.11.7.	The Company is not subject to, and no employees is subject
to an extension order (“tzav harchava”) (other than extension orders that are generally applicable to all employers
in Israel);

 

		4.11.8.	Except as provided for in Schedule ‎4.11.8
of the Disclosure Schedule, the employment of each employee is subject to termination upon up to thirty (30) days’ prior
written notice under the termination notice provisions included in the applicable employment agreement with such employee or applicable
Laws; and

 

		4.11.9.	Except as provided for in Schedule ‎4.11.9,
there are no unwritten policies, practices or customs of the Company that entitles or could reasonably be expected to entitle
any Israeli Employee to benefits materially in addition to what such Israeli Employee is entitled to under applicable Laws or
under the terms of such Israeli Employee’s employment agreement (including unwritten customs or practices concerning bonuses
and the payment of statutory severance pay when it is not required under applicable Laws).

 

		4.11.10.	All amounts that the Company is legally or contractually
required either (x) to deduct from their employees’ salaries or to transfer to such employees’ pension or provident,
life insurance, incapacity insurance, continuing education fund or other similar funds or (y) to withhold from their employees’
salaries and benefits and to pay to any Governmental Authority as required by the ITO and Israeli National Insurance Law have,
in each case, been duly deducted, transferred, withheld and paid (other than routine payments, deductions or withholdings to be
timely made in the Ordinary Course of Business), and the Company has no any outstanding obligations to make any such deduction,
transfer, withholding or payment (other than such that has not yet become due); and

 

		4.11.11.	The Company has no unsatisfied obligations to any of its
former employees, and their termination was in compliance with all material applicable Laws and agreements.

 

		4.11.12.	The Company has not engaged any consultants, sub-contractors,
sales agents or freelancers who, according to Israeli Law, would be entitled to the rights of an employee of an Israeli company,
including rights to severance pay, vacation, recuperation pay (dmei havraa) and other employee-related statutory and contractual
benefits. The consultants, sub-contractors, sales agents or freelancers that supply services to the Company has in its engagement
agreements customary provisions regarding their non-employee status.

 

		4.11.13.	To the knowledge of the Company, no current employee:
(i) intends to terminate his or her employment with the Company; or (ii) is a party to or is bound by any confidentiality agreement,
noncompetition agreement or other Contract (with any Person other than the Company) that may have an adverse effect on: (A) the
performance by such employee of any of his or her duties or responsibilities as an employee of the Company; or (B) the Company’s
business or operations.

 

    30

     

    

 

		4.11.14.	The Company does not engage youth or foreign employees
in Israel.

 

		4.12.	Insurance. Other than the policies listed in Schedule ‎4.12 of the Disclosure
Schedule (the “Policies”), the Company does not have any insurance policies in effect. The Company’s insurance
policies are in full force and effect, and the Company has not undertaken any action or omitted to take any action which could
reasonably render any of its insurance policies void or voidable. As of the date hereof, no claims by the Company are pending under
any of such policies nor has the Company made any claim since inception. All premiums due and payable under the Policies have been
paid, and the Company has no liability for any retrospective premium adjustment, audit premium adjustment, experience based liability
or loss sharing cost adjustment under any of the Policies. The Company confirms that as of the date hereof the insurance coverage
of the Company under the Policies is customary for business entities of similar size engaged in similar lines of business and provides
adequate coverage for the risks the Company is exposed to. The Company has not received any written notice regarding any (i) cancellation
or invalidation of any Policy, (ii) refusal of any coverage or rejection of any material claim under any Policy or (iii) material
adjustment in the amount of premiums payable with respect to any Policy.

 

		4.13.	Intellectual Property

 

		4.13.1.	Schedule ‎4.13.1 of the
Disclosure Schedules contains a complete and accurate list of all (i) Company-Controlled Intellectual Property Assets that are
Registered Intellectual Property Assets, (ii) all material unregistered Marks or inventions for which the Company intends to file
a patent, that are Company Controlled Intellectual Property Assets, (iii) licenses of third party Intellectual Property Assets
by the Company that are material to the operation of the Company, other than shrink-wrap or off the shelf licenses (“Licenses
In”), and (iv) licenses or sublicenses granted by Company with respect to Company-Controlled Intellectual Property Assets
to any Person (“Licenses Out”). In the case of any licenses or sublicenses disclosed pursuant to the foregoing
clauses (iii) or (iv), Schedule ‎4.13.1 of the Disclosure Schedules also sets forth whether each
such license or sublicense is exclusive or non-exclusive.

 

			Other than as set forth in Schedule ‎4.13.1, the Company
                                                                            Intellectual Property Assets include all Intellectual Property Assets necessary and sufficient for the conduct of the
                                                                            businesses of the Company, free and clear of all Security Interests, without payment to a third party, by Purchaser
                                                                            immediately following the Closing in substantially the same manner as conducted by Company during the twelve (12) month
                                                                            period prior to Closing. Company Intellectual Property Assets constitutes the only Intellectual Property Assets used by the
                                                                            Company.

 

		4.13.2.	Except as set forth on Schedule ‎4.13.2
of the Disclosure Schedules:

 

		4.13.3.	the Company exclusively owns or is the exclusive licensee
of all right, title and interest in all Company-Controlled Intellectual Property Assets;

 

		4.13.4.	the Company has not transferred ownership of, or agreed
to transfer ownership of, or granted any exclusive licenses to, or agreed to grant any exclusive licenses to any Company-Controlled
Intellectual Property Assets to any third party. No third party has any joint ownership right to any Intellectual Property Assets
owned by Company nor, to Company’s knowledge, to any Intellectual Property Assets exclusively licensed to the Company;

 

    31

     

    

 

		4.13.5.	all Company Registered Intellectual Property Assets are
currently in compliance, in all material respects, with formal Legal Requirements with respect to registration, maintenance and
renewal fees, and filing of all necessary documents and articles, for the purpose of maintaining such Company Registered Intellectual
Property Assets. All Company Registered Intellectual Property Assets which are owned by Company have been filed in good faith
in accordance with regulatory requirements and, to Company’s knowledge, are valid and enforceable, with no basis for claims
of inequitable conduct. All Company Registered Intellectual Property Assets which are exclusively licensed to the Company are,
to the knowledge of the Company, valid and enforceable with no basis, to the knowledge of the Company, for claims of inequitable
conduct;

 

		4.13.6.	none of the Company Registered Intellectual Property Assets
is subject to any filing or maintenance fees or Taxes or actions falling due within ninety (90) days after the Closing Date;

 

		4.13.7.	to the Company’s knowledge, no Company Registered
Intellectual Property Assets has been or is now subject to any terminal disclosure and/or involved in any interference, reissue,
re-examination, inter-parties review, post-grant review, or opposition proceeding; to the knowledge of the Company, there is no
patent or patent application of any third party that potentially interferes with a Company Registered Intellectual Property Asset;

 

		4.13.8.	there are no pending or, to the knowledge of the Company,
threatened claims alleging that any Company-Controlled Intellectual Property Assets and/or the operation of the business or any
activity by the Company, or manufacture, sale, offer for sale, importation, and/or use or practice of any Company-Controlled Intellectual
Property Assets and/product candidates infringes or violates (or in the past infringed or violated) or would infringe or violate
the rights of others in or to any Intellectual Property Assets (“Third Party IP Assets”) or constitutes a misappropriation
of (or in the past constituted a misappropriation of) any subject matter of any Third Party IP Assets or that any of the Company
Intellectual Property Assets is invalid or unenforceable;

 

		4.13.9.	to the Company’s knowledge, neither the operation
of the business, nor any activity by the Company, nor any Company-Controlled Intellectual Property Assets infringes or violates
any Third Party IP Asset or constitutes a misappropriation of any subject matter of any Third Party IP Asset, and, to the Company’s
knowledge, neither the operation of the business, nor any activity by the Company, nor any Company Intellectual Property Assets
infringes or violates (or in the past infringed or violated) the rights of any Person under any Patent;

 

		4.13.10.	all rights in, to and under all Intellectual Property
Assets created by the Company’s founders for or on behalf or in contemplation of the Company (i) prior to the inception
of the Company or (ii) prior to their commencement of employment with the Company, have been duly and validly assigned to the
Company and all Company’s founders have expressly and irrevocably waived, all rights, title and interest in and to all such
Intellectual Property Assets;

 

    32

     

    

 

		4.13.11.	all former and current employees, consultants and contractors
of the Company, and any other individuals who contributed to the discovery or development of any Company Controlled Intellectual
Property Assets, have executed written instruments with the Company that (i) assign to the Company, and (ii) expressly and irrevocably
waive, all rights, title and interest in and to any and all (A) such contributions and any inventions, improvements, ideas, discoveries,
writings, works of authorship, other intellectual property, and information relating to the business of the Company and any of
the products or services being researched, developed, manufactured or sold by the Company or that may be used with any such products
or services, (B) Intellectual Property Assets relating thereto, and (C) any and all moral rights and rights to receive any compensation
and/or royalties in connection with the items included in (A) and (B), including without limitation under Section 134 of
the Patents Law, 5727-1967; in each case where a Company Patent is held by the Company by assignment, the assignment has been
duly recorded with the United Stated or Israeli Patent and Trademark Office and all similar offices and agencies anywhere in the
world in which foreign counterparts are registered or issued;

 

		4.13.12.	to the knowledge of the Company, (A) there is no, nor
has there been any, infringement or violation by any person or entity of any of the Company Controlled Intellectual Property Assets
or the Company’s rights therein or thereto and (B) there is no, nor has there been any, misappropriation by any person or
entity of any of the Company Controlled Intellectual Property Assets or the subject matter thereof;

 

		4.13.13.	the Company has taken commercially reasonable security
measures to protect the confidentiality and value of all Trade Secrets owned by the Company or exclusively licensed by Company
(the “Company Trade Secrets”), including, without limitation, requiring each employee and consultant of the
Company and any other Person with access to Company Trade Secrets to execute a binding confidentiality agreement, copies or forms
of which have been provided to the Purchaser and, to the knowledge of the Company, there has not been any breach by any party
to such confidentiality agreements; and

 

		4.13.14.	The Company has not disclosed, delivered or licensed to
any Person or agreed or obligated itself to disclose, deliver or license to any Person, or expressly permitted the disclosure
or delivery to any escrow agent or other Person of, any source code, other than disclosures to employees and consultants involved
in the Company’s research and development activity. To the Company’s knowledge, no event has occurred, and no circumstance
or condition exists, that (with or without notice or lapse of time, or both) will, or would reasonably be expected to, result
in the disclosure, delivery or license by the Company of any source code, other than disclosures to employees and consultants
involved in the Company’s research and development activity. Without limiting the foregoing, neither the execution of this
Agreement nor any of the transactions contemplated by this Agreement will result in a release from escrow or other delivery to
a third party of any source code.

 

		4.13.15.	the software within Company Controlled Intellectual Property
Asses does not contain, incorporate, link or call to, is not a derivative of and does not otherwise use any Open Source Software,
and

 

		4.13.16.	the Company is not now nor has ever been a member or promoter
of, or a contributor to, any industry standards body or any similar organization that has required or obligated the Company to
grant or offer to any other Person any license or right to any Company-Controlled Intellectual Property Assets. The Company has
no present obligation to grant or offer to any other Person any license or right to any Company- Controlled Intellectual Property
Assets by virtue of the Company’s or any other Person’s membership in, promotion of, or contributions to any industry
standards body or any similar organization.

 

    33

     

    

 

		4.13.17.	The electronic data processing software, information system,
record keeping software, communications systems, telecommunications systems, hardware, third party software, networks, peripherals
and computer systems, including any outsourced systems, services and processes, that are material to the operation of the business
of the Company (collectively, “Technology Systems”) are adequate in all material respects for the operation
of its business as conducted as of the date hereof.’ The Company owns or holds licenses or applicable rights for the Technology
Systems that are necessary for the business.

 

		4.13.18.	The Company is and has been in compliance with all applicable
privacy and data protection laws in all relevant jurisdictions (including without limitation in respect of security notification
obligations and protected health information) and all standards and requirements of any contract or codes of conduct to which
the Company is a party in connection with their collection, storage, transfer (including, without limitation, any transfer across
national borders) and/or processing of any personally identifiable information of any individuals. The Company is aware of no
complaint or claim regarding the Company’s collection, storage, transfer and/or processing of any personally identifiable
information.

 

		4.14.	Grants.

 

		4.14.1.	No (A) funding, personnel, contractors, facilities, resources,
grants, incentives, exemptions, qualifications or subsidies of any Governmental Authority, medical institution, hospital, university,
college, other educational institution, international organization or research center, including any multi-national, bi-national
or international project or research funding program (including OCS / IIA grants or other grants under the R&D Law) or (B)
funding from any Person (other than funds received in consideration for the Purchased Shares) (collectively, “Government
Grants”), was used in the development of the Company-Controlled Intellectual Property Assets or any products or services
currently under development by the Company.

 

		4.14.2.	Except as set forth in Schedule ‎4.14.2
of the Company Disclosure Schedule, no current or former director, employee, founder, consultant or independent contractor of
the Company (including any employees and consultants thereof) or any other Person, who was involved in, or who contributed to,
the creation or development of any Company-Controlled Intellectual Property Assets, has performed services for or otherwise was
under restrictions resulting from his/her relations with any government, university, medical institution, hospital, college or
any educational institution or research center during a period of time during which any Company-Controlled Intellectual Property
Assets were created or during such time that such director, employee, founder, consultant or independent contractor was also performing
services for or for the benefit of the Company, nor, has any such person created or developed any Company-Controlled Intellectual
Property Assets with any Government Grant.

 

		4.14.3.	Except as set forth in Schedule ‎4.14.3
of the Company Disclosure Schedule, no approval of, notice to or filing with any Government Authority is required in connection
with the execution or delivery of this Agreement or the other Transaction Documents nor for the consummation of the transactions
contemplated hereby or thereby.

 

		4.15.	Title to Property and Assets. The Company does not own any real estate. Except as set forth
in Schedule ‎4.15 of the Company Disclosure Schedule, the Company has good and valid title to all of its respective
tangible properties, and interests in properties and assets, real and personal, reflected on the Financial Statements, or, with
respect to leased tangible or intangible properties and assets, valid leasehold interests in such properties and assets which afford
the Company valid leasehold possession of the properties and assets that are the subject of such leases, in each case, free and
clear of all Security Interests. The tangible property and equipment of the Company that is used in the operations of its business
are in good operating condition and repair, subject to normal wear and tear, and are sufficient to conduct the business of the
Company in all material respects. All properties used in the operations of the Company are reflected on the Financial Statements
to the extent required under GAAP to be so reflected. Schedule ‎4.15 of the Company Disclosure
Schedule identifies each parcel of real property leased by the Company. Except as set forth in Schedule ‎4.15
of the Company Disclosure Schedule, no third party has any Security Interest (registered or not registered) on any of the Company’s
assets or rights.

 

    34

     

    

 

		4.16.	Compliance with Laws; Permits.

 

		4.16.1.	The Company has complied and is currently in compliance
with all applicable Laws and Orders in all material respects. The Company has not received, nor to the knowledge of the Company
there any issuance or proposed issuance of any notice by any Governmental Authority of any violation or any alleged violation
of any Law or Order.

 

		4.16.2.	The Company has obtained each governmental consent, license,
permit, grant, or other authorization of a Governmental Authority that is required for the operation of the Company’s business
or the holding of any interest in its assets or properties (all of the foregoing, the “Company Authorizations”),
and all of such Company Authorizations are in full force and effect. The Company has not received any notice or other communication
from any Governmental Authority regarding (i) any actual or possible violation of Law or any Company Authorization or any failure
to comply with any term or requirement of any Company Authorization or (ii) any actual or possible revocation, withdrawal, suspension,
cancellation, termination or modification of any Company Authorization and to the knowledge of the Company there does not exist
any facts or circumstances that would give rise to any such revocation, withdrawal, suspension, cancellation, termination or modification.

 

		4.16.3.	None of the Company or, to the knowledge of the Company,
any Person affiliated with the Company, including distributors, has directly or indirectly: (i) made any unlawful contributions,
gifts, entertainment or other unlawful expenses relating to political activity and related to the Company’s; (ii) made
any unlawful payment to any foreign or domestic government official or employee, foreign or domestic political parties or campaigns,
official of any public international organization, or official of any state-owned enterprise; (iii) violated any provision
of the Foreign Corrupt Practices Act-1977, as amended, Title 5 of the Israeli Penalty Law (Bribery Transactions), the Israeli
Prohibition on Money Laundering Law, 2000, or any other applicable anti-corruption statute; (iv) made any unlawful bribe,
favor, payoff, influence payment, kickback, anything of value or other similar unlawful payment; or (v) established or maintained
any unlawful fund of the Company’s moneys, or other assets, for the purpose of obtaining or paying for: (A) favorable
treatment in securing business or (B) any other special concession; or (vi) agreed, committed, offered or attempted
to take any of the actions described in clauses (i) through (v) above.

 

    35

     

    

 

		4.16.4.	The Company has conducted its business at all times in
a manner that is in compliance in all material respects with Israel’s Law Governing the Control of Commodities and Services,
The Order Governing the Control of Commodities and Services (Engagement in Encryption Items) – 1974, and all other applicable
export control Laws administered by Israel’s Ministry of Defense and including Israel’s Trading With the Enemy Ordinance.
None of the technologies, products or services of the Company is regulated under the Israeli Ministry of Defense. The Company
is not and is not required to be registered with the Israeli Ministry of Defense as a security exporter. The business of the Company
does not involve the use or development of, or engagement in, encryption technology, or other technology whose development, commercialization
or export is restricted under Israeli Law, and the business of the Company does not require the Company to obtain a license from
the Israeli Ministry of Defense or an authorized body thereof pursuant to Section 2(a) of the Control of Products and Services
Declaration (Engagement in Encryption), 1974 or other legislation regulating the development, commercialization or export of technology.

 

		4.17.	Contracts.

 

		4.17.1.	Except (i) for this Agreement and the Transaction Documents,
and (ii) as disclosed on Schedule ‎4.17.1 of the Company Disclosure Schedule, the Company is not a party to
or bound by any of the following agreements (whether written or oral);

 

		4.17.1.1.	any partnership, joint venture, special purpose entity or other similar Contract or arrangement,
or any Contract relating to the acquisition or disposition of any business (whether by merger, sale of stock, sale of assets, or
otherwise);

 

		4.17.1.2.	any Contract relating to borrowed money;

 

		4.17.1.3.	any Contract that limits the Company from marketing, selling, or otherwise distributing its products
or merchandise or providing its services in any geographic area, or from competing in any line of business or geographic area or
with any Person;

 

		4.17.1.4.	any Contract or arrangement with (i) any Shareholder or any of its Affiliates, (ii) any Person,
that to the Company’s knowledge, directly or indirectly owning controlling, or holding with power to vote, five percent (5%)
or more of the outstanding voting securities of any Shareholder’s Affiliates, or (iii) any director, manager or officer of
the Company or with any Affiliate or “family relative” (as such terms are respectively defined in the Companies Law)
of any such director, manager or officer;

 

		4.17.1.5.	any management service, consulting, or any other similar type of Contract;

 

		4.17.1.6.	any warranty, guaranty, or other similar undertaking with respect to a contractual performance
extended by the Company other than in the Ordinary Course of Business;

 

		4.17.1.7.	any employment, deferred compensation, severance, bonus, retirement, or other similar Contract;

 

		4.17.1.8.	any Contract involving payments by or to the Company of more than US $5,000 in the latest twelve
month period;

 

		4.17.1.9.	any Contract with any agency, dealer, sales representative, or distributor for the marketing, selling
and distribution of the Company’s products and services;

 

		4.17.1.10.	any leases of Company Real Property or material personal property;

 

		4.17.1.11.	any Contract with any labor organization;

 

    36

     

    

 

		4.17.1.12.	any Contract or commitment providing for payments based in any manner upon the sales, purchases,
receipts, income or profits of the Company;

 

		4.17.1.13.	any Contract that would prevent consummation of the transactions contemplated by this Agreement
and the Transaction Documents; or

 

		4.17.1.14.	any agreement with Governmental Authority.

 

		4.17.1.15.	any Contract pursuant to which the Company (i) is granted or obtains or agrees to obtain any right
to use any material Intellectual Property Right (other than standard form Contracts granting rights to use readily available shrink
wrap or click wrap software), (ii) is restricted in its right to use or register any Intellectual Property Rights, or (iii) permits
or agrees to permit any other Person to use, enforce, or register the Company owned, used, or held, Intellectual Property Rights,
including any license agreements, coexistence agreements, and covenants not to sue related to such Intellectual Property Rights;
or

 

		4.17.1.16.	any other Contract not made in the Ordinary Course of Business or that is material to the Company.

 

		4.17.2.	Each Contract disclosed on Schedule ‎4.17.1
of the Company Disclosure Schedule or required to be so disclosed (each a “Material Contract”) is a
valid and binding Contract of the Company and is in full force and effect, and neither the Company nor any of its Affiliates nor,
to the knowledge of the Company, any other party thereto, is in default or breach in any material respect under the terms of any
such Material Contract. To the knowledge of the Company, there is no event, occurrence, condition, or act (including the consummation
of the transactions contemplated by this Agreement and the Transaction Documents) that, with the giving of notice or the passage
of time, could reasonably become a default or event of default under any such Material Contract by any of the parties thereto.
The Company has delivered to the Purchaser true and complete copies of each written Material Contract and true and complete summaries
of all oral Material Contracts.

 

		4.17.3.	No party to any Material Contract has given notice to
the Company or made a claim against the Company in respect of any breach or default thereunder.

 

		4.18.	Environmental Matters. (i) All Hazardous Materials and wastes of the Company has been
disposed of in accordance in all material respects with all Environmental and Safety Laws; (ii) the Company has not received
any notice of any noncompliance of the Facilities or its past or present operations with Environmental and Safety Laws; (iii) no
notices, administrative actions or suits are pending or threatened relating to an actual or alleged violation of any applicable
Environmental and Safety Laws by the Company; (iv) to the knowledge of the Company, there have not been in the past, and are
not now, any Hazardous Materials on, under or migrating to or from any of the Facilities or any Property; (v) to the knowledge
of the Company, there have not been in the past, and are not now, any underground tanks or underground improvements at, on or under
any Property, including treatment or storage tanks, sumps, or water, gas or oil wells; and (vi) the Facilities and the Company’s
uses and activities therein have at all times materially complied with all Environmental and Safety Laws. “Environmental
and Safety Laws” shall mean any Laws applicable to the Company that are intended to assure the protection of the environment,
or that classify, regulate, call for the remediation of, require reporting with respect to, or list or define air, water, groundwater,
solid waste, hazardous or toxic substances, materials, wastes, pollutants or contaminants, or which are intended to protect the
safety of employees, workers or other persons, including the public. “Facilities” shall mean all buildings and
improvements on the Property. “Hazardous Materials” shall mean any toxic or hazardous substance, material or
waste or any pollutant or contaminant, or infectious or radioactive substance, material or waste defined in or regulated under
any Environmental and Safety Laws, but excludes office and janitorial supplies properly and safely maintained.

 

    37

     

    

 

		4.19.	Brokers and Finders. The Company has not employed or made any agreement with any broker,
finder or similar agent or any Person (including, for the avoidance of doubt, to any employee of the Company), which will result
in the obligation of the Company or the Purchaser to pay any finder’s fee, brokerage fees or commission or similar payment
in connection with the Transaction.

 

		4.20.	Bank Accounts. Schedule ‎4.20 of the Disclosure Schedule provides the
following information with respect to each account maintained by or for the benefit of the Company at any bank or other financial
institution: (i) the name of the bank or other financial institution at which such account is maintained; (ii) the account number;
(iii) the type of account; and (iv) the names of all Persons who are authorized to sign checks or other documents with respect
to such account

 

		4.21.	Interested Party Transactions. Schedule ‎4.21 contains a complete list
of (i) all amounts and obligations owed between any director, executive officer, Related Party, Shareholder or any of its Affiliates,
on the one hand, and the Company, on the other hand, and (ii) transactions and services provided between any director, executive
officer Related Party, Shareholder or any of its Affiliates, on the one hand, and the Company, on the other hand. Except as disclosed
on Schedule ‎4.21, there has not been any accrual of liability or incurrence of an obligation by the Company
to any Shareholder or any of its Affiliates or between the Company and any Shareholder or any of its Affiliates or any action taken
(other than this Agreement) or any payment of dividends or other payments of cash or property by the Company to any Shareholder
or any of its Affiliates, or the incurrence of any legal or financial obligation to any such Person.

 

		4.22.	No Debt. Except as disclosed on Schedule 4.22 of the Disclosure Schedule,
as of, and after giving effect to, the Closing, the Company will not have any Debt.

 

		4.23.	Full Disclosure. Neither this Agreement nor any certificates made or delivered by the Company
in connection herewith contains any untrue statement of a material fact or omits to state a material fact known to Company necessary
to make the statements herein or therein not misleading, in view of the circumstances in which they were made. There is no material
fact or information relating to the business, condition (financial or otherwise), affairs, operations, or assets of the Company
known by the Company, that has not been disclosed to the Purchaser in writing by the Company in this Agreement, the Transaction
Documents or in the schedules hereto except for such material fact or information that would not constitute a Company Material
Adverse Effect.

 

		4.24.	No Other Representations and Warranties. Except as set forth in this Section 4 (as modified
by the Company Disclosure Schedule) the Company, does not make any representation or warranty, express or implied, at law or in
equity, in respect of the Company.

 

    38

     

    

 

		5.	REPRESENTATIONS AND WARRANTIES OF EACH CONSIDERATION RECIPIENT

 

Each Consideration
Recipient, severally with respect to itself only, represents and warrants to the Purchaser as follows, except as set forth herein
or in the Consideration Recipients Disclosure Schedule delivered to the Purchaser concurrently herewith which disclosures shall
be deemed to be part of the representations and warranties of the Company):

 

		5.1.	Incorporation. Such Consideration Recipient (if not an individual) is duly incorporated
and validly existing under the Laws of its jurisdiction of incorporation, with power and authority to carry on its business as
now being conducted.

 

		5.2.	Authority to Transact. Such Consideration Recipient has the capacity and authority to execute
and deliver this Agreement, to perform hereunder and to consummate the Transaction. All corporate actions, if applicable, on the
part of such Consideration Recipient, its directors, and its shareholders necessary for the authorization and execution of this
Agreement, the authorization, sale and delivery of the Purchased Shares (with respect to the Shareholders) and the performance
of all of such Consideration Recipient’s obligations hereunder, have been taken. This Agreement constitutes and, when signed
by its duly authorized representatives, all other documents contemplated hereby will constitute, valid and legally binding obligations
of such Consideration Recipient, and, assuming the due authorization, execution and delivery by the Purchaser (if party thereto),
enforceable in accordance with their terms, in each case, subject to (a) laws of general application relating to bankruptcy, insolvency
and the relief of debtors, and (b) rules of law governing specific performance, injunctive relief and other equitable remedies.

 

		5.3.	Purchased Shares.

 

		5.3.1.	Each Shareholder has good, valid and marketable title
to such number of the Purchased Shares as is set out next to the name of such Shareholder in Schedule A-1 and such
Purchased Shares shall be at the Closing free and clear of Security Interests. Such Shareholder is not a party to any option,
warrant, purchase right or other Contract that could require such Shareholder to sell, transfer or otherwise dispose of any Shares
(other than this Agreement). Such Shareholder is not a party to any voting trust, proxy or other agreement or understanding with
respect to the voting of any Shares. Except as set forth in the Waterfall next to such Shareholder’s name, such Shareholder
does not own any securities of the Company or any right to acquire any securities of the Company.

 

		5.3.2.	Each Shareholder is entitled to sell the full legal and
beneficial interest in the Purchased Shares owned by such Shareholder (as set out next to the name of such Shareholder in Schedule
A-1), or, in the case of Purchased Shares held by a trustee on behalf of such Shareholder, such Shareholder is entitled
to sell the full beneficial interest in such Purchased Shares and has directed the trustee to transfer, and there is no legal
or other impediment to the trustee transferring, such Purchased Shares, to the Purchaser on the terms set out in this Agreement.

 

		5.4.	Non-Contravention; No Consents or Approvals. Neither: (1) the execution, delivery or performance
of this Agreement or any of the other agreements, documents or instruments referred to in this Agreement, by each Consideration
Recipient; nor (2) any of the transactions contemplated by this Agreement or any such other agreement, document or instrument,
will (with or without notice or lapse of time):

 

		5.4.1.	contravene, conflict with or result in a violation of
any Legal Requirement or any Order, writ, injunction, judgment or decree to which such Consideration Recipient is subject; or

 

		5.4.2.	contravene, conflict with or result in a violation or
breach of, or result in a default under, any provision of any Contract to which such Consideration Recipient is a party or by
which such Consideration Recipient is bound.

 

    39

     

    

 

		5.5.	No Consents. Each Consideration Recipient is not (and such Consideration Recipient will
not be) required to make any filing with or give any notice to, or to obtain any consent from, any Person in connection with: (x)
the performance of this Agreement or any of the other agreements, documents or instruments referred to in this Agreement; or (y)
any of the transactions contemplated by this Agreement or by any of the other agreements, documents or instruments referred to
in this Agreement; except for such corporate approvals previously obtained by such Consideration Recipient.

 

		5.6.	No Legal Proceedings. There is no pending legal proceeding against such Consideration Recipient
and, to the knowledge of such Consideration Recipient, no Person has threatened to commence any such legal proceeding, that challenges,
or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the entry into, performance
of, compliance with and enforcement of any of the obligations of such Consideration Recipient under this Agreement. To the knowledge
of such Consideration Recipient, no event has occurred, and no claim, dispute or other condition or circumstance exists, that will
or would reasonably be expected to give rise to or serve as a reasonable basis for any such legal proceeding.

 

		5.7.	No Bankruptcy. The Consideration Recipient is not insolvent, and there has been no request
for, nor has there been issued, any bankruptcy decree against the Consideration Recipient, whether temporary or permanent; nor
has any legal, administrative or other proceeding concerning the bankruptcy of the Consideration Recipient been commenced.

 

		5.8.	Purchase for Own Account. Each Consideration Recipient severally, and not jointly, represents
that such Consideration Recipient intends to acquire the shares of the Purchaser for its own account or for the account of its
Affiliates and that the shares to be purchased by such Shareholder will be acquired by it for investment for the Shareholder’s
own account or for the account of its Affiliates and not with a view to the distribution or resale thereof; subject, nevertheless,
to the condition that the disposition of the property of each Consideration Recipient shall at all times be within its control.

 

		5.9.	Investment Experience; Disclosure of Information.Without derogating from and subject
to the Purchaser’s representations and warranties provided herein, each Consideration Recipient further represents and warrants
to the Purchaser with respect to its purchase of the shares of the Purchaser as follows: (a) the Consideration Recipient has
the requisite knowledge and experience in financial and business matters to be capable of evaluating the merits and risks of being
a shareholder of the Purchaser, and has evaluated the risk of receiving the shares of the Purchaser; (b) the Consideration
Recipient is able to bear the economic risk if the value of such Consideration Recipient’s holdings in the Purchaser equity
securities is diminished; and (c) the Consideration Recipient acknowledges that it has had an opportunity to ask questions
of, and receive answers from the Purchaser concerning the Purchaser’s business and the terms and conditions of this Agreement.

 

		5.10.	IIA. Such Consideration Recipient is aware that the Purchaser is subject to IIA regulations
and applicable Laws. Each Consideration Recipient acknowledges that the Purchaser has received funds from the IIA and is subject
to the Law of Encouragement of Research and Development in the Industry and the rules and regulations promulgated thereunder. Each
Consideration Recipient acknowledges that it is specifically aware that production or products developed by the Company with IIA
funding anywhere outside of Israel and the transfer of know-how developed by the Company with IIA funding are subject to the Law
of Encouragement of Research and Development in the Industry and the rules and regulations promulgated thereunder.

 

    40

     

    

 

		5.11.	Further Representations by US Investors. To the extent that the Consideration Recipient
is a United States person, the Consideration Recipient hereby represents that such Consideration Recipient has satisfied himself
as to the full observance of the laws of his or her jurisdiction in connection with any invitation to subscribe for the shares
of the Purchaser or any use of the Agreement, including (a) the legal requirements within his jurisdiction to subscribe for
the shares of the Purchaser, (b) any foreign exchange restrictions applicable to such subscription, (c) any governmental
or other consents that may need to be obtained, and (d) the income tax and other tax consequences, if any, that may be relevant
to the subscription, holding, redemption, sale, or transfer of the shares of the Purchaser. The Consideration Recipient’s
subscription and his continued beneficial ownership of the shares of the Purchaser, will not violate any applicable securities
or other laws of his jurisdiction.

 

		5.12.	No Market for Shares. Each Consideration Recipient acknowledges that the Purchaser is a
privately held company and that its shares are not registered or listed for trade on any stock exchange.

 

		5.13.	No Other Representations and Warranties. Except for representations and warranties expressly
and specifically made by such Consideration Recipient in this Section 5 (as modified by the Shareholder Disclosure Schedule) and
in any certificate required to be delivered by such Consideration Recipient hereunder, neither such Consideration Recipient nor
any Affiliate thereof, makes any representation or warranty, whether expressed or implied, and such Shareholder hereby disclaim
all other representations and warranties of any kind or nature, express or implied.

 

		6.	REPRESENTATIONS AND WARRANTIES OF THE PURCHASER

 

The Purchaser
hereby represents and warrants to the Consideration Recipients as follows:

 

		6.1.	The representations and warranties made by the Purchaser in Section 3 of that certain Series A-1
Preferred Share Purchase Agreement by and among the Purchaser, OrbiMed Israel Partners, Limited Partnership, Johnson and Johnson
Innovation – JJDC, Inc., Takeda Ventures, Inc. and other investors, dated February 7, 2017, as amended on March 26, 2017)
(the “Purchaser Investment Agreement”), including the updated Purchaser Disclosure Schedule attached hereto
as Schedule 6, are true and correct in all respects as of the Closing, and shall be deemed to be made by Purchaser
to the Consideration Recipients under this Agreement, mutatis mutandis, provided, that:

 

		6.1.1.	any reference to the “Company” under Section
3 of the Purchaser Investment Agreement shall be deemed as reference to the Purchaser herein;

 

		6.1.2.	any reference to the “Investors” under Section
3 of the Purchaser Investment Agreement shall be deemed as reference to the Consideration Recipients herein;

 

		6.1.3.	any reference to the “Shares” under Section
3 of the Purchaser Investment Agreement shall be deemed as reference to the Closing Shares, the shares included in the Milestone
Consideration Shares, and the Equity Contingent Consideration, collectively;

 

		6.1.4.	any reference to the “Financial Statements”
under Section 3 of the Purchaser Investment Agreement shall be deemed as reference to the Purchaser’s audited financial
statements as of December 31, 2016;

 

		6.1.5.	any reference to the “Current Articles” under
Section 3 of the Purchaser Investment Agreement shall be deemed as reference to the Purchaser’s articles of association
in effect immediately prior to the Closing;

 

		6.1.6.	any reference to the “Agreement” and the “Ancillary
Agreements” under Section 3 of the Purchaser Investment Agreement shall be deemed as reference to the Agreement and the
Transaction Documents herein, respectively;

 

    41

     

    

 

		6.1.7.	any reference to the “First Closing” under
Section 3 of the Purchaser Investment Agreement shall be deemed as reference to the Closing herein; and

 

		6.2.	Authority to Transact. The Purchaser has the capacity and authority to execute and deliver
the Transaction Documents and the Amended IRA, to perform hereunder and to consummate the Transaction. All corporate actions on
the part of the Purchaser necessary for the authorization and execution of this Agreement, the Transaction Documents, the Amended
IRA, the purchase of the Purchased Shares and the performance of all of the Purchaser’s obligations hereunder and thereunder
have been taken. The Amended IRA and each Transaction Document constitutes and, when signed by its duly authorized representatives,
all other documents contemplated hereby will constitute, valid and legally binding obligations of the Purchaser, and, assuming
due authorization, execution and delivery by all other parties thereto, enforceable in accordance with their terms, in each case,
subject to (a) laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (b) rules of law governing
specific performance, injunctive relief and other equitable remedies.

 

		6.3.	Execution of Agreement. The execution and delivery of this Agreement by the Purchaser does
not, and the consummation of the transactions contemplated hereby will not, violate any provisions of the Organizational Documents
of the Purchaser.

 

		6.4.	Investment Intent. Purchaser is purchasing the Purchased Shares for investment for its own
account and not with a view to, or for sale in connection with, any distribution thereof. Purchaser confirms that it has such knowledge
and experience in financial and business matters as to be capable of evaluating the merits and risks relating to entering into
this Agreement.

 

		6.5.	No Other Representations and Warranties. Except for representations and warranties expressly
and specifically made by the Purchaser in this Section 6.5 (as modified by the Purchaser Disclosure Schedule) and in any certificate
required to be delivered by such Purchaser hereunder, neither the Purchaser nor any Affiliate thereof, makes any representation
or warranty, whether expressed or implied, and Purchaser hereby disclaim all other representations and warranties of any kind or
nature, express or implied.

 

		7.	COVENANTS

 

		7.1.	Conduct of the Business Pending the Closing. Except as otherwise contemplated by this Agreement
or with the prior written consent of Purchaser, during the period commencing on the date of this Agreement and continuing until
the earlier of the termination of this Agreement and the Closing (the “Interim Period”):

 

		7.1.1.	the Company shall conduct its respective businesses and
operations only in the Ordinary Course of Business and in substantially the same manner as such business and operations have been
conducted prior to the date of this Agreement;

 

		7.1.2.	the Company shall use its commercially reasonable efforts
to (A) preserve its present business operations, organization and goodwill, (B) preserve its present relationships and goodwill
with all of its customers, suppliers, landlords, creditors, employees, consultants and other Persons having business relationships
with the Company, and (C) keep available the services of its current employees and consultants;

 

		7.1.3.	the Company shall keep in full force all insurance policies
referred to in Schedule 4.12 of the Disclosure Schedule;

 

		7.1.4.	the Company shall report regularly (but in no event less
frequently than weekly) to Purchaser concerning the status of the Company’s business;

 

    42

     

    

 

		7.1.5.	the Company shall not declare, accrue, set aside or pay
any dividend or make any other distribution in respect of any shares of the Company, and shall not repurchase, redeem or otherwise
reacquire any shares or other securities of the Company;

 

		7.1.6.	the Company shall not sell, issue or authorize the issuance
of (i) any capital stock, except for the issuance of capital stock upon the exercise or conversion of securities that were outstanding
prior to the date hereof, (ii) any option or right to acquire any capital stock of the Company, or (iii) any instrument convertible
into or exchangeable for any capital stock or other security of the Company;

 

		7.1.7.	the Company shall not amend or waive any of its rights
under, or permit the acceleration of vesting under, (i) any provision of any share or option plan, (ii) any provision of any agreement
evidencing any outstanding securities of the Company, or (iii) any provision of any share purchase agreement;

 

		7.1.8.	the Company shall not amend or permit the adoption of
any amendment to the Organizational Documents, including all amendments thereto, or effect or permit the Company to become a party
to any Acquisition Transaction, recapitalization, reclassification of shares, split, reverse split or similar transaction;

 

		7.1.9.	the Company shall not form any Subsidiary or acquire any
equity interest or other interest in any other Person;

 

		7.1.10.	the Company shall not make any capital expenditure, during
the Interim Period in an amount exceeding US $5,000;

 

		7.1.11.	the Company shall not, other than in the Ordinary Course
of Business consistent with past practice, (i) enter into, or permit any of the assets owned or used by it to become bound by,
any Contract that is or would constitute a Material Contract, or (ii) amend or prematurely terminate, or waive any material right
or remedy under, any such Contract;

 

		7.1.12.	the Company shall not, (i) acquire, lease or license any
right or other asset from any other Person, except for rights or other assets acquired, leased or licensed in the Ordinary Course
of Business consistent with past practice, (ii) sell or otherwise dispose of, or lease or license, any right or other asset to
any other Person, except for rights or other assets disposed of, leased or licensed in the Ordinary Course of Business consistent
with past practice, or (iii) waive or relinquish any material right;

 

		7.1.13.	the Company shall not (i) lend money to any Person or
Persons, except for advances of business expenses in the Ordinary Course of Business consistent with past practice, or (ii) incur
or guarantee any Debt for borrowed money;

 

		7.1.14.	the Company shall not (i) except as may be required
by an applicable Legal Requirement or any Contract then in effect, pay any bonus or make any profit-sharing payment, cash incentive
payment or similar payment to, or increase the amount of the wages, salary, commissions, fringe benefits or other compensation
or remuneration payable to, any of its directors, officers, employees or consultants, or make any arrangement with regard to any
of the foregoing, (ii) hire any new employee or consultant, (iii) amend or prematurely terminate any of the existing
agreements with any employees or consultants, or (iv) enter into any arrangement with the Consideration Recipients;

 

		7.1.15.	the Company shall not change any of its methods of accounting
or accounting practices in any material respect, or alter its practices with respect to the collection of receivables or payment
of payables except as required by concurrent changes in GAAP;

 

    43

     

    

 

		7.1.16.	the Company shall not make any Tax election;

 

		7.1.17.	the Company shall not commence or settle any material
legal proceeding;

 

		7.1.18.	the Company shall not provide or grant any Security Interest
in any of its assets or rights.

 

		7.1.19.	the Company shall not enter into any transaction or relationship
with any Related Party; and

 

		7.1.20.	the Company shall not agree or commit to take any of the
actions described in Section ‎7.1.1 through Section ‎7.1.20 above.

 

		7.2.	During the Interim Period, each Shareholder covenants with the Purchaser that such Shareholder
shall not dispose of any interest in the Purchased Shares or any of them or grant any option over or create or allow to exist any
Security Interest over the Purchased Shares or any of them.

 

		7.3.	During the Interim Period, Each Company Warrant Holder covenants with the Purchaser that such Company
Warrant Holder shall not dispose of any interest in the Company Warrants or grant any option over or create or allow to exist any
Security Interest over the Company Warrants.

 

		7.4.	During the Interim Period, the Company and the Purchaser covenant that they shall co-operate in
addressing any third party being a contract party to any Material Contract with the mutual purpose of avoiding the termination
or alteration of any material contract due to the change of ownership of the Company contemplated by this Agreement.

 

		7.5.	No announcement or other disclosure concerning the sale and purchase of the Purchased Shares, the
Transaction or any ancillary matter shall be made before Closing by the Parties save in a form agreed between the Shareholders’
Representative and the Purchaser or otherwise as required by Law or as required for the Company or any Shareholder to secure any
required consent or approval to the transactions contemplated hereby or by a party to its representatives, management, professional
advisors, or to other shareholders or option holders of the Company, in each case subject to strict confidentiality undertakings
and to the extent necessary for purposes of the Transaction.

 

		7.6.	All of the Parties to this Agreement will after, as well as before and upon, the Closing Date do
all acts and things and sign and execute all documents and deeds reasonably required for the purpose of implementing the terms
of this Agreement.

 

		7.7.	No Negotiation. During the Interim Period, neither the Company, the Consideration Recipients
nor any of its Representatives shall directly or indirectly:

 

		7.7.1.	solicit or encourage the initiation of any inquiry, proposal
or offer from any Person (other than Purchaser) relating to a possible Acquisition Transaction;

 

		7.7.2.	participate in any discussions or negotiations or enter
into any agreement with, or provide any information to, any Person (other than Purchaser) relating to or in connection with a
possible Acquisition Transaction; or

 

		7.7.3.	accept any proposal or offer from any Person (other than
Purchaser) relating to a possible Acquisition Transaction.

 

The Company
shall promptly notify Purchaser in writing of any inquiry, proposal or offer relating to a possible Acquisition Transaction that
is received by the Company or any Representatives thereof during the Interim Period, including the material terms thereof.

 

    44

     

    

 

		7.8.	Access to Information.

 

		7.8.1.	During the Interim Period, (i) the Company shall afford
Purchaser and their accountants, counsel and other Representatives, reasonable access upon reasonable prior notice and during
normal business hours to (A) all of the Company’s properties, books, Contracts and records and (B) all other information
concerning the business, properties and personnel (subject to restrictions imposed by applicable Legal Requirements) of the Company
as Purchaser may reasonably request, and (ii) the Company shall make available to Purchaser and their accountants, counsel and
other representatives correct and complete copies of the Company’s: (a) internal financial statements, (b) Tax Returns,
Tax elections and all other records and work papers relating to Taxes and (c) receipts for any Taxes paid to foreign Taxing Authorities,
if any.

 

		7.8.2.	Subject to compliance with applicable Legal Requirements,
during the Interim Period, the Company shall confer from time to time as requested by Purchaser with one or more Representatives
of Purchaser to discuss any material changes or developments in the operational matters of the Company the general status of the
ongoing operations of the Company.

 

		7.9.	Directors’ and Officers’ Insurance.

 

		7.9.1.	Prior to the Closing, the Company shall purchase Tail
Insurance Policy for the present and former directors and officers of the Company at any time prior to the Closing and their respective
successors and heirs (the “Covered Persons”), which shall provide the Covered Persons with coverage for seven
(7) years following the Closing Date, to the extent permitted by Law, Purchaser shall cause the Company and its successors and
assigns not to cancel or reduce the Tail Insurance Policy and continue to honor the obligations thereunder in accordance with
its terms, to the extent permitted by Law.

 

		7.9.2.	Without derogating from the other provisions of this Agreement,
the Company shall pay for such expense prior to the Closing.

 

		7.10.	Immediately following the date hereof (but no later than three (3) Business Days thereafter), each
of the Company and the Purchaser shall file with any other Governmental Authority any filings (including without limitation any
regulatory filings) that are required for the consummation of the Transaction and shall use its reasonable best efforts to obtain
all such approvals.

 

		7.11.	No Leakage.

 

		7.11.1.	The Company undertakes to the Purchaser that, between
the signing of this Agreement and the Closing, the Company will not pay, or accrue, any Leakage Payments.

 

		7.11.2.	The Company undertakes to the Purchaser that, if there
is a breach of Section 7.11.1, then as a sole remedy, the amount of Closing Shares and the Closing Warrants shall be reduced by
dividing the Leakage Payments made or accrued between the signing of this Agreement and the Closing, by US$10.22. Three days before
the contemplated Closing hereunder, the Company shall provide to the Purchaser the certified Closing Certificate confirming the
amount of Leakage Payments (if any) for the purpose of adjustment of the Waterfall.

 

    45

     

    

 

		8.	RELEASES

 

		8.1.	By signing this Agreement or by accepting payment of the applicable part of the Closing Payment,
as of and subject to the Closing each of the Consideration Recipients hereby waives, releases and absolutely and forever discharges
the Company, from and against any and all Claims, demands, actions, judgments, liabilities, Damages, losses and Debt of every kind
and nature whatsoever, known to such Consideration Recipient, that have arisen or will arise due to actions or events that have
occurred prior to the Closing and all reasonable costs incurred in investigating or pursuing any of the foregoing or any proceeding
relating to any of the foregoing (collectively, “Consideration Recipient Claims”); provided, however,
that this release does not extend to any Consideration Recipient Claims to enforce the terms of, or any breach of, this Agreement,
or any document or agreement delivered hereunder or thereunder or any of the provisions set forth herein or therein (collectively,
“Retained Claims”).

 

		8.2.	The Consideration Recipients hereby waive any and all first refusal, first offer, notification,
veto or other rights under the Organizational Documents of the Company or any agreement to which any of them are a party with respect
to the execution of this Agreement and the consummation of the Transaction.

 

		8.3.	Without limitation of the foregoing, each Shareholder and the Company hereby agrees and confirms
that effective as of the Closing, each Contract by and between the Company and any Shareholder is hereby terminated, including,
without limitation the agreements identified in Schedule 8.3, and excluding specifically such agreements identified
as such in Schedule 8.3.

 

		9.	INDEMNIFICATION AND REMEDIES

 

		9.1.	Survival. The representations and warranties of the Parties contained in this Agreement
or in any certificates or other writing delivered pursuant to this Agreement or in connection herewith will survive the Closing
for twenty-four (24) months thereafter; provided, however, that (a) the representations and warranties contained
in Section ‎4.7 (Taxation) (the “Tax Representations”) shall survive the Closing for thirty (30) months
thereafter, (b) the representations and warranties contained in Section ‎4.13 (Intellectual Property) (the “IP Representations”)
shall survive the Closing for forty-two (42) months thereafter, and (d) the Fundamental Representations shall survive the Closing
until the expiration of the statute of limitations applicable to the subject matter underlying such Fundamental Representation.
The Parties agree that so long as due written notice of a claim in accordance with the terms herein is given on or prior to the
applicable survival date with respect to such claim, such claim shall continue to survive until it is finally resolved. All covenants
and agreements to be performed in whole or in part after the Closing Date shall survive in accordance with their terms. The right
to indemnification hereunder shall not be limited or affected by any diligence conducted or knowledge acquired by any Party, before
or after the Closing.

 

		9.2.	Subject to the limitations set forth in this Section ‎9, each Consideration Recipient (“Indemnifying
Parties”), severally and not jointly agrees to indemnify, and hold the Purchaser and its officers, shareholders, directors,
employees and Affiliates (the “Indemnified Parties”) harmless from and against and in respect of such Consideration
Recipient’s Pro Rata Portion of the entirety of any and all losses, Debt, liabilities, obligations, damages, fees, interest,
costs and expenses, including costs of investigation by Governmental Authority and defense and reasonable fees and expenses of
counsel, experts and other professionals (excluding incidental damages) (“Damages”), actually incurred or suffered
by the Indemnified Parties as a result of, or arising out of:

 

		9.2.1.	any failure of any representation or warranty in this
Agreement or in any certificate, Schedule or Exhibit to this Agreement made by the Company, to be true and correct as of the date
hereof and as of the Closing, except that any such representation and warranties which by their express terms are made solely
as of a specified earlier date shall be true, correct and complete only as of such specified earlier date;

 

    46

     

    

 

		9.2.2.	any breach of any covenant of the Company in any of the
Transaction Documents;

 

		9.2.3.	any inaccuracy, misstatement or omission in the allocation
of the payments and rights listed in the Waterfall;

 

		9.2.4.	any liability for Taxes of the Company attributable to
the period prior to the Closing and any Taxes payable in connection with the transfer of the Purchased Shares required to be paid
by the holders of Purchased Shares; and

 

		9.2.5.	any amount which would have been reimbursed to the Company
under, and in accordance with the terms of, the Third Party Insurance due to occurrence of any event prior to Closing, had such
Third Party Insurance was in effect upon occurrence of such event.

 

		9.3.	Subject to the limitations set forth in this Section ‎9, each Indemnifying Party, severally
and not jointly, agrees to indemnify the Indemnified Parties harmless from and against and in respect of the entirety of any and
all Damages actually incurred or suffered by the Indemnified Parties as a result of, or arising out of:

 

		9.3.1.	any failure of any representation or warranty made by
such Consideration Recipient to be true and correct as of the date hereof and as of the Closing; and

 

		9.3.2.	any breach of any covenant of such Consideration Recipient
in any of the Transaction Documents.

 

Notwithstanding
anything to the contrary in this Section ‎9, in the event that an Indemnified Party brings a claim for indemnification
under Section 9.3 (a “Shareholder Claim”), then, solely for purposes of this Section ‎9 (i) only the
Consideration Recipient(s) that is or are subject to such Shareholder Claim (the “Indemnifying Shareholder(s)”)
shall be considered an Indemnifying Party, and (ii) the Indemnifying Consideration Recipient shall serve the role of Shareholders’
Representative for purposes of the Shareholder Claim under this Section ‎9, mutatis mutandis (all of the foregoing,
without derogating from any other provision of this Section ‎9 which shall apply mutatis mutandis).

 

		9.4.	Notwithstanding anything in this Agreement to the contrary, for purposes of the Parties’
indemnification obligations under this Section 9, all of the representations and warranties set forth in this Agreement or any
certificate or schedule that are qualified as to “material”, “materiality”, “Material respects”,
“Company Material Adverse Effect” or words or similar import or effect shall be deemed to have been made without any
such qualification solely for purposes of determining the amount of Damages resulting from, or arising out of any such breach of
representation or warranty.

 

		9.5.	In no event shall any Indemnifying Party seek contribution or any other legal, financial or equitable
relief from the Company or any of its Affiliates in respect of such Indemnifying Party’s indemnification obligations.

 

    47

     

    

 

		9.6.	Procedures.

 

		9.6.1.	Third Party Claims. Promptly after receipt by the
Indemnified Party of notice of the commencement of any Claim against such Indemnified Party with respect to which the Indemnifying
Party is obligated to provide indemnification under this Agreement; the Indemnified Party shall provide the Shareholders’
Representative with prompt written notice thereof, but in any event not later than fifteen (15) days after receipt of such written
notice of the Claim (including, to the extent possible under applicable law, copies of the applicable statement of Claim and all
other court documents which were received) and will provide, when known, the facts constituting the basis of such Claim in reasonable
detail and all other available materials and other available information in its possession or control that may be necessary to
the defense of such Claim, including the amount of Damages asserted by such third party. Purchaser shall also provide any other
additional information reasonably requested by the Shareholders’ Representative.

 

		9.6.2.	Purchaser shall have the right, at its election, to assume
and proceed, through counsel of its own choosing, the defense of any such Claim including the right to consent to any settlement,
compromise or discharge (including the consent to entry of any judgment) of the Claim, as specified herein; provided, however,
that if the Purchaser settles, adjusts or compromises any such Claim without the consent of the Shareholders’ Representative,
(i) such settlement, adjustment or compromise shall not include any admission of liability on behalf of any of the Consideration
Recipients and shall not be conclusive evidence of the amount of Damages incurred by the Indemnified Party in connection with
such Claim (it being understood that if the Purchaser requests that the Shareholders’ Representative consent to a settlement,
adjustment or compromise, the Shareholders’ Representative shall not unreasonably withhold or delay such consent), and (ii) any
amount of such settlement in excess of amounts consented to by the Shareholder’s Representative shall be deemed a Contested
Amount (as defined below). In the event that Purchaser declines or fails to assume and proceed the defense of any Claim described
in the preceding sentence within fifteen (15) days of receiving notice of such Claim, the Shareholders’ Representative shall
be entitled to assume and control the defense of such Claim, at its own expense with counsel selected by the Shareholders’
Representative. Should the Shareholders’ Representative so elect to assume the defense of a Claim, the Purchaser will reasonably
cooperate with the Shareholders’ Representative with the defense thereof if requested by the Shareholders’ Representative, at
the cost and expense of the Shareholders’ Representative, and Shareholders’ Representative will not be liable to the Indemnified
Party for any legal or other expenses subsequently incurred by the Indemnified Party in connection with the defense thereof as
long as the Shareholders’ Representative diligently conducts such defense provided that, if in Purchaser’s reasonable judgment
a conflict of interest exists, in the opinion of Purchaser’s external legal counsel, in respect of the Claim, Purchaser
will have the right to employ separate counsel to represent Purchaser and in that event the reasonable fees and expenses of such
separate counsel will be paid by the Shareholders’ Representative. Without the prior written consent of the Purchaser (which consent
may not be unreasonably withheld or delayed), the Shareholders’ Representative will not enter into any settlement of any
Claim. The Parties will in any event cooperate with each other in dealing with any Claim with respect to which the Indemnifying
Party is obligated to provide indemnification under this Agreement, other than in the event of a conflict of interest, and, other
than in the event of a conflict of interest, will allow their respective representatives and advisers reasonable access to all
Books and Records which might be useful for such purpose during normal business hours and at the place where they are normally
kept, with full right to make copies thereof or take extracts there from. Such Books and Records shall be subject to a duty of
confidentiality except for disclosure necessary for resolving such Claim or otherwise required by applicable Law.

 

    48

     

    

 

		9.6.3.	Claims and Procedures. Any claim by an Indemnified
Party on account of Damages and which entitles an Indemnified Party to indemnification pursuant to this Section ‎9, will be
asserted by giving the Shareholders’ Representative written notice thereof within sixty (60) days after the Indemnified
Party becomes aware of such Damages, signed by an officer of the Indemnified Party (a “Claim Certificate”):

 

		9.6.3.1.	stating that an Indemnified Party determines in good
faith that there is a breach of a representation, warranty or covenant contained in this Agreement or that such Indemnified Person
is or may otherwise be entitled to indemnification under this Section ‎9;

 

		9.6.3.2.	specifying in reasonable detail the material facts known to the Indemnified Party giving rise to
such claim; and

 

		9.6.3.3.	containing a good-faith estimated amount, if reasonably practicable, of Damages that has been or
may be sustained by the Indemnified Party.

 

		9.6.4.	The Shareholders’ Representative will have a period
of thirty (30) days commencing on the date that a Claim Certificate was duly given pursuant to Section ‎9.6.3 to respond in
writing to such Claim Certificate. If the Shareholders’ Representative does not so respond within such thirty (30)-day period,
the Shareholders’ Representative will be deemed to have accepted such direct Claim.

 

		9.6.5.	A failure to give timely notice or to include any specified
information in any notice as provided in this Section ‎9.6 will not affect the rights or obligations of any Party, except
and only to the extent that, as a result of such failure, any Party that was entitled to receive such notice was deprived of its
right to recover any payment under its applicable insurance coverage or was otherwise materially prejudiced as a result of such
failure (including in connection with the defense of a Claim).

 

		9.6.6.	To the extent that within the thirty (30)-day period referred
to in Section ‎9.6.4 the Shareholders’ Representative provides the Indemnified Party with notice of its objection
to the Claim Certificate and/or that it disagrees with the amount (the “Contested Amount”) or method of determination
set forth in any such notice (the “Disagreement Notice”), the Parties shall resolve such conflict in accordance
with the procedures set forth in Section ‎9.6.7.

 

		9.6.7.	If the Shareholders’ Representative has provided
a Disagreement Notice, the Parties shall attempt in good faith to agree upon the rights of the respective Parties with respect
to each of such claims. If the Parties should so agree, a memorandum setting forth such agreement shall be prepared and signed
by Purchaser, on the one hand, and the Shareholders’ Representative. In the event the parties fail to reach an agreement
within thirty (30) days after the date on which the Purchaser received the Disagreement Notice (the “Dispute Resolution
Period”), the dispute may be submitted by the Indemnified Person seeking indemnification for the formal resolution of
such dispute in accordance with Section ‎11.9, provided, however, that to the extent that the Indemnified
Party fails to initiate formal resolution of such dispute by initiation of legal proceedings in accordance with Section ‎11.9
below within one hundred and twenty (120) days from expiration of the Dispute Resolution Period, the Indemnified Party will be
deemed to have waived any indemnification to Damages pursuant to the applicable Claim Certificate.

 

    49

     

    

 

		9.7.	Threshold. The Indemnified Parties shall only be entitled to claim Damages pursuant to this
Section 9 if and insofar the aggregate amount of all Damages that would otherwise be indemnifiable under this Agreement exceeds
US$ 25,000, in which event the Indemnifying Parties shall be liable to indemnify the Indemnified Parties for the full amount of
Damages from the first dollar. Notwithstanding, the foregoing threshold shall not apply to claims for Damages resulting from fraud,
willful breach or intentional misrepresentation.

 

		9.8.	Cap. Other than for claims for Damages resulting from fraud, willful breach or intentional
misrepresentation, the maximum aggregate liability for any claims for Damages pursuant to Section ‎9 shall be limited to an
amount equal to [***] Contingent Consideration to be paid to the Indemnifying Party(s),
but not more than [***] in the aggregate, provided, however, that:

 

		9.8.1.	The maximum aggregate liability for any claims for Damages
with respect breach of the IP Representations and the Tax Representations shall be limited to an amount equal to [***]
of the Contingent Consideration to be paid to the Indemnifying Party(s);

 

		9.8.2.	The maximum aggregate liability for breach of the Company
Fundamental Representations and for the events set forth in Sections 9.2.2 - 9.2.5 shall be limited to the Aggregate Consideration
actually received by the Consideration Recipients;

 

		9.8.3.	The maximum aggregate liability for breach of the Shareholders
Fundamental Representations and for the events set forth in Section 9.3 shall be limited to the Aggregate Consideration actually
received by the applicable Indemnifying Party(s);

 

		9.8.4.	For the avoidance of doubt, , and notwithstanding anything
to the contrary in this Agreement, in no event shall a Consideration Recipient be liable for any Damages resulting from any breach
of a representation or covenant by another Consideration Recipient.

 

		9.8.5.	For the avoidance
of doubt, with respect to the caps and limitations provided for in the first paragraph of this Section 9.8, Sub Section 9.8.1,
Sub Section 9.8.2, and Sub Section 9.8.3 (each, a “Caps Alternative”), any Damages paid under one Cap Alternative
shall be deemed to have been paid under and toward all other greater Cap Alternatives with respect to future indemnifiable claims
under this Section 9.  For purposes of example only: [***].

 

		9.8.6.	Furthermore, for the avoidance of doubt and notwithstanding
anything to the contrary in this Agreement, in no event shall a Consideration Recipient be liable for any Damages or obligations
in excess of its, his or her Pro Rata Portion.

 

		9.9.	Exclusive Remedy. The indemnification rights of any Indemnified Party pursuant to this Section
‎9 shall be the sole and exclusive remedy available to the Indemnified Parties under or in connection with this Agreement and
the Transaction Documents against the Consideration Recipients, except for liabilities arising out of or based on fraud, intentional
misrepresentation or willful breach or conduct and for equitable remedies.

 

		9.10.	Insurance Recovery. In determining the liability of an Indemnifying Party for any Damages
pursuant to this Section, no loss, liability, damage or expense shall be deemed to have been sustained by an Indemnified Party
to the extent of any proceeds previously received by such Indemnified Party from any insurance recovery (net of (i) all out of
pocket costs directly related to such recovery, (ii) increases in premiums or (iii) any deductible incurred in obtaining such recovery).

 

    50

     

    

 

		9.11.	Offset as an Exclusive Remedy. Notwithstanding anything to the contrary, any of the Indemnified
Parties may collect and recover any and all monetary Damages with respect to which it is entitled to be indemnified under this
Section 9, solely by setting off such Damages against future Contingent Consideration to be paid to the applicable Indemnifying
Party(s). The above limitation shall not apply to (i) Damages arising out of or based on fraud, intentional misrepresentation or
willful breach or conduct, (ii) Damages arising out of or based on any failure of any representation or warranty under the Fundamental
Representations, and (iii) Damages pursuant to Sections 9.2.2-‎9.2.5.

 

		9.12.	Method of Payment.

 

Any indemnification
sought pursuant to this Section ‎9 (either by way of setoff or otherwise) shall be effected in accordance with and in the same
proportions of the method of payment of the Contingent Consideration being set-off, as notified under the Payment Method Notice
(i.e., (i) in cash, (ii) in Equity Contingent Consideration or (iii) in a combination of cash and Equity Contingent Consideration),
or with respect to Damages arising out of or based on any claim for Damages pursuant to this Section ‎9, any indemnification
sought pursuant to this Section ‎9 with respect to such Damages shall be effected in accordance with and in the same proportions
of the portion of the Aggregate Consideration actually paid to the Indemnifying Party(s) as of receipt by such Indemnifying Party(s)
of a notice regarding commencement of a Claim under Section ‎9.6.1 (i.e., (i) in cash, (ii) Purchaser’s Shares or (iii)
in a combination of both (i) and (ii).

 

		9.13.	Consideration Adjustment. The Parties agree that any indemnification payment made pursuant
to this Agreement shall be treated as an adjustment to the Aggregate Consideration for Tax purposes, unless otherwise required
by Law.

 

		10.	TERMINATION

 

		10.1.	At any time prior to the Closing, this Agreement may be terminated:

 

		10.1.1.	by mutual written consent of the Purchaser and the Shareholders’
Representative;

 

		10.1.2.	by Purchaser or the Company if the transactions contemplated
hereby have not been consummated by December 19, 2017; provided, however, that the Purchaser or the Company, as
applicable, will not be entitled to terminate this Agreement pursuant to this Section ‎10.1.2 if the Purchaser’s
breach of this Agreement, on the one hand, or the Company’s breach of this Agreement, on the other hand, has prevented the
consummation of the transactions contemplated by this Agreement.

 

		10.2.	In the event of termination of this Agreement as provided in Section ‎10.1.1 or Section ‎10.1.2,
this Agreement shall forthwith become void and there shall be no liability or obligation on the part of Purchaser or the Company
or any Consideration Recipient, or any of their respective directors, officers or other employees, or shareholder, if applicable;
provided, however, that each Party hereto shall remain liable for any willful and intentional breaches of this Agreement
by such Party that occurred prior to its termination.

 

    51

     

    

 

		11.	MISCELLANEOUS

 

		11.1.	Communications. All notices or other communications hereunder shall be in writing and shall
be given in person, by registered mail (registered international air mail if mailed internationally), by an overnight courier service
which obtains a receipt to evidence delivery, by electronic mail or by facsimile transmission (provided that written confirmation
of receipt is provided for facsimile transmission) with a copy by mail, addressed as set forth below:

 

	 	
        If to the Company:
	
        RondinX LTD

        HaKfar Hayarok, Ramat Hasharon, 47800 Israel

        Fax: [***]

        Attn: [***]

        Email: [***]

	 	 	 
	 	With a mandatory copy (which shall not constitute notice) to:	
        Meitar Liquornik Geva Leshem Tal, Law Offices

        16 Abba Hillel Rd Ramat Gan, 5250608 Israel

        Fax: [***]

        Attn: [***]

        Email: [***]

	 	 	 
	 	If to the Shareholders:	As stated in Schedule A-1 hereto.
	 	 	 
	 	If to the Consideration Recipients:	As stated in Schedule A-2 hereto.
	 	 	 
	 	If to the Purchaser:	
        BiomX Ltd.

        7 Sapir Street, Ness Ziona, Israel

        Attn: [***]

        Email:
        [***]

	 	 	 
	 	With a mandatory copy (which shall not constitute notice) to:	
        Zysman, Aharoni, Gayer &
        Co.

        41-45 Rothschild Blvd., Beit
        Zion, Tel Aviv 6578401, Israel

        Fax: [***]

        Attn: [***]

        Email:
        [***]

 

or such
other address as any Party may designate to the other in accordance with the aforesaid procedure. All communications delivered
in person or by courier service shall be deemed to have been given upon delivery, those given by electronic mail immediately upon
delivery by email (with an electronic confirmation of receipt), or, if transmitted ad received on a non-Business Day, on the first
Business Day following transmission and electronic confirmation of full receipt, those given by facsimile transmission shall be
deemed given on the Business Day following transmission with confirmed answer back, and all notices and other communications sent
by registered mail, return receipt requested, postage prepaid (or air mail if the posting is international) shall be deemed given
five (g) Business Days after having been sent.

 

		11.2.	Successors and Assignees 

 

		11.2.1.	No assignment of this Agreement or of any rights or obligations
hereunder may be made by either the Consideration Recipients or the Purchaser, without the prior written consent of the other
Parties hereto and any attempted assignment without the required consents shall be void. Notwithstanding the foregoing, after
or in connection with the Closing, Purchaser may assign all of its respective rights under this Agreement to any of its Affiliate,
but no such assignment shall relieve Purchaser of any liability or obligation hereunder or enlarge, alter or change any obligation
of any other party hereto due to the Purchaser.

 

    52

     

    

 

		11.2.2.	This Agreement shall be binding upon and inure to the
benefit of and be enforceable by the Parties and their respective successors and assigns.

 

		11.3.	Expenses. All costs, fees and expenses incurred in connection with this Agreement and the
other transactions contemplated hereby shall be paid by the party incurring such costs, fees or expenses, whether or not the Closing
is consummated.

 

		11.4.	Delays or Omissions; Waiver.

 

		11.4.1.	The rights of a Party may be waived by such Party only
in writing and specifically; the conduct of any one of the Parties shall not be deemed a waiver of any of its rights pursuant
to this Agreement or as a waiver or consent on its part as to any breach or failure to meet any of the terms of this Agreement
or as an amendment hereto. A waiver by a Party in respect of a breach by the other Party of its obligations shall not be construed
as a justification or excuse for a further breach of its obligations.

 

		11.4.2.	No delay or omission to exercise any right, power, or
remedy accruing to any Party upon any breach or default by the other under this Agreement shall impair any such right or remedy
nor shall it be construed to be a waiver of any such breach or default, or any acquiescence therein or in any similar breach or
default thereafter occurring.

 

		11.5.	Amendment. This Agreement may be amended or modified only by a written document signed by
the Purchaser and the Shareholders’ Representative (acting exclusively for and on behalf of all of the Consideration Recipients).

 

		11.6.	Entire Agreement. This Agreement (together with the recitals, schedules, appendices, annexes
and exhibits attached hereto, which are deemed an integral part of this Agreement) contains the entire understanding of the Parties
with respect to its subject matter and all prior negotiations, discussions, agreements, commitments and understandings between
them with respect thereto not expressly contained herein shall be null and void in their entirety, effective immediately with no
further action required.

 

		11.7.	Severability.

 

		11.7.1.	If a provision of this Agreement is or becomes illegal,
invalid or unenforceable in any jurisdiction, that shall not affect the validity or enforceability in that jurisdiction of any
other provision hereof or the validity or enforceability in other jurisdictions of that or any other provision hereof.

 

		11.7.2.	Where provisions of any applicable Law resulting in such
illegality, invalidity or unenforceability may be waived, they are hereby waived by each Party to the full extent permitted so
that this Agreement shall be deemed valid and binding, in each case enforceable in accordance with its terms.

 

		11.8.	Counterparts, Facsimile Signatures. This Agreement may be executed in any number of counterparts,
each of which shall be deemed an original but all of which together shall constitute one and the same instrument. A signed Agreement
received by a Party via facsimile or electronic mail will be deemed an original, and binding upon the Party who signed it.

 

		11.9.	Governing Law and Venue. The Agreement shall be governed by and construed in accordance
with the laws of the State of Israel, without giving effect to the principles thereof relating to conflict of Laws. Subject to
the arbitration proceedings referred to in the Milestone Schedule, the competent courts of Tel-Aviv Jaffa shall have exclusive
jurisdiction to hear all disputes arising in connection with this Agreement and no other courts shall have any jurisdiction whatsoever
in respect of such disputes.

 

    53

     

    

 

		11.10.	No Third-Party Beneficiaries. Nothing in this Agreement shall create or confer upon any
Person, other than the Parties and the Indemnified Parties or their respective successors and permitted assigns, any rights, remedies,
obligations or liabilities, except as expressly provided herein.

 

		11.11.	Shareholders’ Representative.

 

		11.11.1.	By virtue of the execution of this Agreement, each Consideration
Recipient herby irrevocably agrees, constitutes and appoints Guy Harmelin as the true, exclusive and lawful agent and attorney
in fact of the Consideration Recipients (i) to act as the Shareholders’ Representative for and on behalf of the Consideration
Recipients and to have the right, power and authority to perform all actions (or refrain from taking any actions) the Shareholder’s
Representative shall deem necessary, appropriate or advisable in connection with, or related to, this Agreement and the transactions
contemplated herein (the “Transaction”), (ii) to act in the name, place and stead of each Consideration Recipient
(A) in connection with the Transaction, in accordance with the terms and provisions of this Agreement, and (B) in any Claim involving
this Agreement, and (iii) to do or refrain from doing all such further acts and things, and to execute all such documents as the
Shareholders’ Representative shall deem necessary or appropriate in connection with the Transaction (including any Transaction
Document). Without derogating from the generality of the above, the Shareholders’ Representative shall have the right, power
and authority to act for the Consideration Recipients in connection with indemnification to be provided under Section ‎9 and
to agree to, negotiate, and enter into settlements, adjustments and compromises of, and comply with orders of courts and awards
of arbitrators with respect to, such claims, and to take all other actions that are either (i) necessary or appropriate in the
judgment of the Shareholders’ Representative for the accomplishment of the foregoing or (ii) specifically mandated or permitted
by the terms of this Agreement. The Consideration Recipients will be bound by all actions taken by Shareholders’ Representative
in connection with the Transaction Documents. The Shareholders’ Representative may resign at any time; provided, that
the Shareholders’ Representative may not be removed unless a majority of the Consideration Recipients (as determined by
the vote of the majority holders of the shares issued herein) agree in writing to such removal and that a new substituted Shareholders’
Representative is being appointed (whose identity shall be determined by such then majority of Consideration Recipients, as determined
by the vote of the holders of the majority of the BiomX shares issued herein). A vacancy (including by way of a Deemed Resignation)
in the position of the Shareholders’ Representative may be filled by a majority of the Consideration Recipients (as determined
by the vote of the majority holders of the shares issued herein) and subject to Purchaser’s approval of such successor Shareholders’
Representative, not to be unreasonably withheld or delayed. No bond shall be required of the Shareholders’ Representative,
and the Shareholders’ Representative shall not receive any compensation for its services. Notices or communications to or
from the Shareholders’ Representative shall constitute notice to or from the Consideration Recipients. The Consideration
Recipients shall cause a Person to be appointed promptly as the Shareholders’ Representative if at any time there is no
Person serving as the Shareholders’ Representative for any reason.

 

    54

     

    

 

		11.11.2.	A decision, act, consent or instruction of the Shareholders’
Representative, including an amendment, extension or waiver of the Transaction Documents, shall constitute a decision of all the
Consideration Recipients and shall be final, binding and conclusive upon the Consideration Recipients. Purchaser is entitled to
rely upon any such decision, act, consent or instruction of the Shareholders’ Representative as being the decision, act,
consent or instruction of all the Consideration Recipients. The Purchaser is hereby relieved from any Liability to any Person
for any acts done by them in accordance with such decision, act, consent or instruction of the Shareholders’ Representative.

 

[Signature Page to Follow]

 

    55

     

    

  

[Signature Page of Share Purchase Agreement]

 

IN WITNESS WHEREOF, this Share Purchase
Agreement has been duly executed on the date herein above set forth.

 

	BiomX Ltd. 

 

	By:	/s/ Jonathan Solomon 	 
	 	Name: Jonathan Solomon	 
	 	Title: CEO	 

 

	RondinX Ltd. 

 

	By:	/s/ Guy Harmelin	 
	 	Name: Guy Harmelin	 
	 	Title: Director	 

 

    56

     

    

 

[Signature Page of Share Purchase Agreement]

 

IN WITNESS WHEREOF, this Share Purchase
Agreement has been duly executed on the date herein above set forth.

 

	/s/ Guy Harmelin	 
	Guy Harmelin (as Shareholder Representative)
	 
	/s/ Guy Harmelin	 
	Guy Harmelin
	 
	/s/ Rafi Gidron	 
	Rafi Gidron
	 
	/s/ Alon Hirsch	 
	Alon Hirsch

 

8VC Angel Fund
I, L.P.

 

By: 8VC Angel
GP I, LLC

 

Its General Partner

 

	By:	/s/ Drew Oetting	 
	 	Name: Drew Oetting	 
	 	Title: Managing Member	 

 

8VC Angel Fund
I Associates, L.P.

 

By: 8VC Angel
GP I, LLC

 

Its General Partner

 

	By: 	/s/ Drew Oetting	 
	 	Name: Drew Oetting	 
	 	Title: Managing Member	 

 

    57

     

    

 

Baruch Family
Revocable Trust

 

	By:	/s/ Thomas Baruch	 
	 	Name: Thomas Baruch	 
	 	Title: Manager	 

 

Elevator Venture
Holdings Ltd.

 

	By:	/s/ Ori Glezer / /s/ Tom Bronfeld / /s/ Lior Prosor	 
	 	Name: Ori Glezer / Tom Bronfeld / Lior Prosor	 
	 	Title: Managing Directors	 

 

Elinav Research
and Biological Services Ltd.

 

	By:	/s/ Eran Elinav	 
	 	Name: Eran Elinav	 
	 	Title: Professor	 

 

	/s/ Gigi Levy	 
	Gigi Levy	 
	 	 
	/s/ Tamar Lifshitz	 
	Tamar Lifshitz	 

 

33Steps Ltd.

 

	By:	/s/ Yossi Matus 	 
	 	Name: Yossi Matus	 
	 	Title:	 

 

	/s/ Noa Eliasaf-Shoham	 
	Noa Eliasaf-Shoham	 

 

Nhaft, LLC

 

	By:	/s/ Nicholas Haft 	 
	 	Name: Nicholas Haft	 
	 	Title: Manager	 

 

    58

     

    

 

Yeda Research
and Development Co. Ltd.

 

	By:	/s/ Gil Granot-Mayer	/	/s/ Prof. Mudi Shevee	 
	 	Name: Gil Granot-Mayer	/	Prof. Mudi Shevee	 
		Title: C.E.O	/	Chairman	 

 

Eran Segal Consultancy
Ltd.

 

	By:	/s/ Eran Segal	 
	 	Name: Eran Segal	 
	 	Title: Professor	 

 

    59

     

    

 

Exhibit 2.4.1

 

MILESTONES SCHEDULE

 

[***].

 

    60

     

    

 

Appendix 1

 

[***]

 

    61

     

    

 

Exhibit 2.4.5

 

REDEMPTION OF MILESTONES

 

[***]

 

    62

     

    

 

Exhibit 2.5

 

MILESTONE ROADMAP

 

Capitalized terms used but not defined
in this Schedule shall have the meanings ascribed to them in that certain Share Purchase Agreement by and among the Company, the
Purchaser listed therein, the Shareholders listed therein and the Shareholders Representative listed therein, dated November 19,
2017, to which this Milestones Roadmap is attached (the “Agreement”).

 

[***]

 

    63

     

    

 

Schedule A-1

 

LIST OF
COMPANY SHAREHOLDERS

 

	Shareholders	 	Address	 	Type of Shares	 	Number of Shares
	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]
	Total	 	 	 	 	 	[***]

 

    64

     

    

 

Schedule A-2

 

LIST OF COMPANY WARRANT HOLDERS

 

	Name	 	Address	 	Number of Warrants
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

 

 

65Exhibit 10.10

 

CHARDAN
HEALTHCARE ACQUISITION CORP.

 

2019
OMNIBUS LONG-TERM INCENTIVE PLAN

 

TABLE
OF CONTENTS

 

	 	 	 	 	Page
	SECTION
    1	 	GENERAL	 	D-1
	1.1.	 	Purpose	 	D-1
	1.2.	 	Participation	 	D-1
	1.3.	 	Foreign
    Participants	 	D-1
	1.4.	 	Operation
    and Administration	 	D-1
	1.5.	 	History	 	D-1
	SECTION
    2	 	DEFINITIONS	 	D-1
	SECTION
    3	 	SHARES
    AND PLAN LIMITS	 	D-4
	3.1.	 	Shares
    of Stock and Other Amounts Subject to Plan	 	D-4
	3.2.	 	Adjustments	 	D-5
	3.3.	 	Plan
    Limitations	 	D-5
	SECTION
    4	 	OPTIONS	 	D-5
	4.1.	 	Grant
    of Options	 	D-5
	4.2.	 	Option
    Agreement	 	D-5
	4.3.	 	Term
    of Option	 	D-5
	4.4.	 	Exercise
    Price	 	D-5
	4.5.	 	Minimum
    Vesting	 	D-6
	4.6.	 	Payment
    of Option Exercise Price	 	D-6
	4.7.	 	No
    Repricing	 	D-6
	SECTION
    5	 	FULL
    VALUE AWARDS	 	D-6
	5.1.	 	Grant
    of Full Value Award	 	D-6
	5.2.	 	Full
    Value Award Agreement	 	D-6
	5.3.	 	Conditions	 	D-6
	5.4.	 	Minimum
    Vesting	 	D-6
	SECTION
    6	 	CHANGE
    IN CONTROL	 	D-7
	6.1.	 	Double
    Trigger Vesting	 	D-7
	6.2.	 	Committee
    Actions On a Change in Control	 	D-7
	SECTION
    7	 	COMMITTEE	 	D-7
	7.1.	 	Administration	 	D-7
	7.2.	 	Selection
    of Committee	 	D-7
	7.3.	 	Powers
    of Committee	 	D-7
	7.4.	 	Delegation
    by Committee	 	D-8
	7.5.	 	Information
    to be Furnished to Committee	 	D-8
	7.6.	 	Liability
    and Indemnification of Committee	 	D-8
	SECTION
    8	 	AMENDMENT
    AND TERMINATION	 	D-8
	SECTION
    9	 	GENERAL
    PROVISIONS	 	D-8
	9.1.	 	General
    Restrictions	 	D-8
	9.2.	 	Tax
    Withholding	 	D-8
	9.3.	 	Grant
    and Use of Awards	 	D-9
	9.4.	 	Dividends
    and Dividend Equivalents	 	D-9
	9.5.	 	Settlement
    of Awards	 	D-9
	9.6.	 	Transferability	 	D-9
	9.7.	 	Form
    and Time of Elections	 	D-9
	9.8.	 	Agreement
    With Company	 	D-9
	9.9.	 	Action
    by Company or Subsidiary	 	D-9
	9.10.	 	Gender
    and Number	 	D-9
	9.11.	 	Limitation
    of Implied Rights	 	D-10
	9.12.	 	Evidence	 	D-10
	9.13.	 	Limitations
    under Section 409A	 	D-10
	APPENDIX.	 	Israeli
    Appendix	 	D-10

 

    D-i

     

    

 

Chardan
Healthcare Acquisition Corp.

2019 OMNIBUS LONG-TERM INCENTIVE PLAN

 

SECTION
1

GENERAL

 

1.1.
Purpose. The Chardan Healthcare Acquisition Corp. 2019 Omnibus Long-Term Incentive Plan (the “Plan”) has been
established by Chardan Healthcare Acquisition Corp., a Delaware corporation, (the “Company”) to (i) attract and retain
persons eligible to participate in the Plan; (ii) motivate Participants, by means of appropriate incentives, to achieve long-range
goals; (iii) provide incentive compensation opportunities that are competitive with those of other similar companies; and (iv)
further align the interests of Participants with those of the Company’s other stockholders through compensation that is
based on the Company’s shares; and thereby promote the long-term financial interest of the Company and the Related Companies
including the growth in value of the Company’s shares and enhancement of long-term stockholder return. Capitalized terms
in the Plan are defined in Section 2.

 

1.2.
Participation. Subject to the terms and conditions of the Plan, the Committee shall determine and designate, from time
to time, from among the Eligible Individuals, those persons who will be granted one or more Awards under the Plan, and thereby
become “Participants” in the Plan.

 

1.3.
Foreign Participants. In order to assure the viability of Awards granted to Participants who are subject to taxation in
foreign countries, the Committee may provide for such special terms as it may consider necessary or appropriate to accommodate
differences in local law, tax policy, or custom. Moreover, the Committee may approve such appendixes, supplements to, or amendments,
restatements, or alternative versions of, the Plan as it may consider necessary or appropriate for such purposes without thereby
affecting the terms of the Plan as in effect for any other purpose; provided, however, that no such supplements, amendments, restatements,
or alternative versions shall increase the share limitations contained in Section 3.1 of the Plan.

 

1.4.
Operation and Administration. The operation and administration of the Plan, including the Awards made under the Plan, shall
be subject to the provisions of Section 7 (relating to operation and administration).

 

1.5.
History. The Plan was adopted by the Company on September 17, subject to approval by stockholders. To the extent not prohibited
by Applicable Laws, Awards which are to use shares of Stock reserved under the Plan that are contingent on the approval by the
Company’s stockholders may be granted prior to that meeting contingent on such approval. The Plan shall be unlimited in
duration and, in the event of Plan termination, shall remain in effect as long as any Awards under it are outstanding; provided,
however, that no Awards may be granted under the Plan after the ten-year anniversary of the date on which the stockholders approved
the Plan.

 

SECTION
2

Definitions

 

2.1.
“Administrator” means the Board or any of its Committees as will be administering the Plan, in accordance with Section
7.

 

2.2.
“Applicable Laws” means the requirements relating to the administration of equity-based awards under U.S. state corporate
laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed
or quoted and the applicable laws of any foreign country or jurisdiction where Awards are, or will be, granted under the Plan.

 

    D-1

     

    

 

2.3.
“Award Agreement” means the written agreement, including an electronic agreement, setting forth the terms and conditions
applicable to each Award granted under the Plan. The Award Agreement is subject to the terms and conditions of the Plan.

 

2.4.
“Award” means any award or benefit granted under the Plan, including, without limitation, the grant of Options and
Full Value Awards.

 

2.5.
“Board” means the Board of Directors of the Company.

 

2.6.
“Change in Control” means the first to occur of any of the following:

 

		(a)	the
consummation of a purchase or other acquisition by any person, entity or group of persons (within the meaning of Section 13(d)
or 14(d) of the Exchange Act or any comparable successor provisions, other than an acquisition by a trustee or other fiduciary
holding securities under an employee benefit plan or similar plan of the Company or a Related Company), of “beneficial ownership”
(within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 50% or more of either the outstanding shares of Stock
or the combined voting power of the Company’s then outstanding voting securities entitled to vote generally;

 

		(b)	the
consummation of a reorganization, merger, consolidation, acquisition, share exchange or other corporate transaction of the Company,
in each case, with respect to which persons who were stockholders of the Company immediately prior to such reorganization, merger
or consolidation do not, immediately thereafter, own more than 50% of the combined voting power entitled to vote generally in
the election of directors of the reorganized, merged or consolidated company’s then outstanding securities;

 

		(c)	the
consummation of any plan of liquidation or dissolution of the Company providing for the sale or distribution of substantially
all of the assets of the Company and its Subsidiaries or the consummation of a sale of substantially all of the assets of the
Company and its Subsidiaries; or

 

		(d)	at
any time during any period of two consecutive years, individuals who at the beginning of such period were members of the Board
cease for any reason to constitute at least a majority thereof (unless the election, or the nomination for election by the Company’s
stockholders, of each new director was approved by a vote of at least two-thirds of the directors still in office at the time
of such election or nomination who were directors at the beginning of such period).

 

2.7.
“Code” means the United States Internal Revenue Code of 1986, as amended. A reference to any provision of the Code
shall include reference to any successor provision of the Code.

 

2.8.
“Committee” has the meaning set forth in Section 7.1.

 

2.9.
“Common Stock” or “Stock” means the common stock of the Company.

 

2.10.
“Company” has the meaning set forth in Section 1.1.

 

2.11.
“Consultant” means any natural person engaged as a consultant or advisor by the Company or a Parent or Subsidiary
or other Related Company (as determined by the Committee) to render bona fide services to such entity and such services are not
in connection with the sale of shares of Stock in a capital-raising transaction, and do not directly or indirectly promote or
maintain a market for the Company’s securities.

 

2.12.
“Director” means a member of the Board.

 

2.13.
“Eligible Individual” means any Employee, Consultant or Director; provided, however, that to the extent required by
the Code, an ISO may only be granted to an Employee of the Company or a Parent or Subsidiary. An Award may be granted to an Employee,
Consultant or Director, in connection with hiring, retention or otherwise, prior to the date the Employee, Consultant or Director
first performs services for the Company or the Subsidiaries, provided that such Awards shall not become vested prior to the date
the Employee, Consultant or Director first performs such services.

 

2.14.
“Employee” means any person, including officers and Directors, employed by the Company or any Parent or Subsidiary
of the Company or a Related Company (as determined by the Committee). Neither service as a Director nor payment of a director’s
fee by the Company will be sufficient to constitute “employment” by the Company.

 

2.15.
“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

2.16.
“Exercise Price” of each Option granted under this Plan shall be established by the Committee or shall be determined
by a method established by the Committee at the time the Option is granted.

 

2.17.
“Expiration Date” has the meaning set forth in Section 4.6.

 

2.18.
“Fair Market Value” means, as of any date, the value of Common Stock determined as follows:

 

		(a)	If
the Common Stock is listed on any established stock exchange or a national market system, including without limitation the New
York Stock Exchange, its Fair Market Value will be the closing sales price for such stock (or the closing bid, if no sales were
reported) as quoted on such exchange or system on the last previous trading day prior to such date of determination, as reported
in The Wall Street Journal or such other source as the Administrator deems reliable;

 

    D-2

     

    

 

		(b)	If
the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value
of a share of Stock will be the mean between the high bid and low asked prices for the Common Stock on the last previous trading
day prior to such date of determination (or, if no bids and asks were reported on that date, as applicable, on the last trading
date such bids and asks were reported), as reported in The Wall Street Journal or such other source as the Administrator
deems reliable; or

 

		(c)	In
the absence of an established market for the Common Stock, the Fair Market Value will be determined in good faith by the Administrator.

 

2.19.
A “Full Value Award” is a grant of one or more shares of Stock or a right to receive one or more shares of Stock in
the future, with such grant subject to one or more conditions, as determined by the Committee.

 

2.20.
An “Incentive Stock Option” or an “ISO” is an Option that is intended to satisfy the requirements applicable
to an “incentive stock option” described in Section 422(b) of the Code.

 

2.21.
A “Non-Qualified Option or an “NQO” is an Option that is not intended to be an “incentive stock option”
as that term is described in Section 422(b) of the Code.

 

2.22.
An “Option” entitles the Participant to purchase shares of Stock at an Exercise Price established by the Committee.
Any Option granted under this Plan may be either an ISO or an NQO as determined in the discretion of the Committee.

 

2.23.
“Outside Director” means a Director of the Company who is not an officer or employee of the Company or the Related
Companies.

 

2.24.
“Parent” means a parent corporation within the meaning of Section 424(e) of the Code.

 

2.25.
“Participant” means the holder of an outstanding Award.

 

2.26.
“Performance Measures” means performance goals based on any one or more of the following Company, Subsidiary,
operating unit or division performance measures: (i) earnings, including, but not limited to, operating income, earnings
before or after taxes, earnings before or after interest, depreciation, amortization, or extraordinary or special items or
book value per share (which may exclude nonrecurring items); (ii) pre-tax income or after-tax income; (iii) earnings per
share of Stock (basic or diluted); (iv) operating profit; (v) revenue, revenue growth or rate of revenue growth; (vi) return
on assets (gross or net), return on investment, return on capital, or return on equity; (vii) returns on sales or revenues;
(viii) operating expenses; (ix) stock price appreciation; (x) cash flow(s); (xi) implementation or completion of critical
projects or processes; (xii) economic value created; (xiii) cumulative earnings per share growth; (xiv) operating margin or
profit margin; (xv) common stock price or total stockholder return; (xvi) cost targets, reductions and savings, productivity
and efficiencies; (xvii) regulatory achievements; and implementation, completion or attainment of measurable objectives with
respect to research, development, products or projects, production volume levels; (xviii) the filing of a new drug
application (“NDA”) or the approval of the NDA by the Food and Drug Administration, the achievement of a launch
of a new drug, and research and development milestones; (xix) entry into a collaboration, development, joint venture or
licensing agreement relating to product candidates or to commercialization of products; and (xx) any combination of any of
the foregoing. Each goal may be expressed on an absolute and/or relative basis, may be based on or otherwise
employ comparisons based on internal targets, the past performance of the Company and/or the past or current performance of
other companies or may be applied to the performance of the Company relative to a market index, a group of other companies or
a combination thereof, and in the case of earnings-based measures, may use or employ comparisons relating to capital,
stockholders equity and/or shares outstanding, investments or to assets or net assets, and may (but need not) provide for
adjustments for restructurings, extraordinary, and any other unusual, non-recurring, or similar changes.

 

2.27.
“Period of Restriction” means the period during which the transfer of shares of Stock are subject to restrictions
and therefore, the shares of Stock are subject to a substantial risk of forfeiture. Such restrictions may be based on the passage
of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator.

 

2.28.
“Plan” has the meaning set forth in Section 1.1.

 

2.29.
“Related Company” means any corporation, partnership, joint venture, limited liability company or other entity during
any period in which a controlling interest in such entity is owned, directly or indirectly, by the Company (or by any entity that
is a successor to the Company), and any other business venture designated by the Committee in which the Company (or any entity
that is a successor to the Company) has, directly or indirectly, a significant interest (whether through the ownership of securities
or otherwise), as determined in the discretion of the Committee.

 

2.30.
“Securities Act” means the Securities Act of 1933, as amended.

 

2.31.
“Subsidiary” means a “subsidiary corporation,” whether now or hereafter existing, as defined in Section 424(f)
of the Code.

 

    D-3

     

    

 

2.32.
“Termination Date” means the date on which a Participant both ceases to be an employee of the Company and the Related
Companies and ceases to perform material services for the Company and the Related Companies (whether as a director or otherwise),
regardless of the reason for the cessation; provided that a “Termination Date” shall not be considered to have occurred
during the period in which the reason for the cessation of services is a leave of absence approved by the Company or the Related
Company which was the recipient of the Participant’s services; and provided, further that, with respect to an Outside Director,
“Termination Date” means the date on which the Outside Director’s service as an Outside Director terminates
for any reason. If, as a result of a sale or other transaction, the entity for which the Participant performs services ceases
to be a Related Company (and such entity is or becomes an entity separate from the Company), the occurrence of such transaction
shall be the Participant’s Termination Date. With respect to Awards that constitute deferred compensation subject to Section
409A of the Code, references to the Participant’s termination of employment (including references to the Participant’s
employment termination, and to the Participant terminating employment, a Participant’s separation from service, and other
similar reference) and references to a Participant’s termination as a Director (including separation from service and other
similar references) shall mean the date that the Participant incurs a “separation from service” within the meaning
of Section 409A of the Code.

 

SECTION
3

shares of Stock and plan limits

 

3.1.
Shares of Stock and Other Amounts Subject to Plan. The shares of Stock for which Awards may be granted under the Plan shall
be subject to the following:

 

		(a)	Subject
to the following provisions of this Section 3.1, the maximum number of shares of Stock that may be delivered to Participants and
their beneficiaries under the Plan shall be 1,000 shares of Stock (which number includes all shares available for delivery under
this Section 3.1(a) since the establishment of the Plan, determined in accordance with the terms of the Plan). Shares of Stock
issued by the Company in connection with awards that are assumed or substituted in connection with a reorganization, merger, consolidation,
acquisition, share exchange or other corporate transaction shall not be counted against the number of shares of Stock that may
be issued with respect to Awards under the Plan.

 

		(b)	The
aggregate number of shares of Stock that may be delivered pursuant to the Plan as specified in Section 3.1(a) will automatically
increase on January 1 of each year, for a period of not more than ten (10) years, commencing on January 1 of the year following
the year in which the Effective Date occurs and ending on (and including) January 1, 2029, in an amount equal to four percent
(4%) of the total number of shares of Stock outstanding on December 31 of the preceding calendar year. Notwithstanding the foregoing,
the Committee may act prior to January 1 of a given year to provide that there will be no January 1 increase for such year or
that the increase for such year will be a lesser number of Shares than provided herein.

 

		(c)	Only
shares of Stock, if any, actually delivered to the Participant or beneficiary on an unrestricted basis with respect to an Award
shall be treated as delivered for purposes of the determination under Section 3.1(a) above, regardless of whether the Award is
denominated in shares of Stock or cash. Consistent with the foregoing:

 

		(i)	To
the extent any shares of Stock covered by an Award are not delivered to a Participant or beneficiary because the Award is forfeited
or cancelled, or the shares of Stock are not delivered on an unrestricted basis (including, without limitation, by reason of the
Award being settled in cash), such shares of Stock shall not be deemed to have been delivered for purposes of the determination
under Section 3.1(a) above.

 

		(ii)	Subject
to the provisions of paragraph (i) above, the total number of shares of Stock covered by an Award will be treated as delivered
for purposes of this paragraph (b) to the extent payments or benefits are delivered to the Participant with respect to such shares.
Accordingly (A) if shares covered by an Award are used to satisfy the applicable tax withholding obligation or Exercise Price,
the number of shares held back by the Company to satisfy such withholding obligation or Exercise Price shall be considered to
have been delivered; (B) if the Exercise Price of any Option granted under the Plan is satisfied by tendering shares of Stock
to the Company (by either actual delivery or by attestation, including shares of Stock that would otherwise be distributable upon
the exercise of the Option), the number of shares tendered to satisfy such Exercise Price shall be considered to have been delivered;
and (C) if shares of Stock are repurchased by the Company with proceeds received from the exercise of an option issued under this
Plan, the total number of such shares repurchased shall be deemed delivered.

 

		(d)	The
shares of Stock with respect to which Awards may be made under the Plan shall be: (i) shares currently authorized but unissued;
(ii) to the extent permitted by Applicable Law, shares currently held or acquired by the Company as treasury shares, including
shares purchased in the open market or in private transactions; or (iii) shares purchased in the open market by a direct or indirect
wholly-owned subsidiary of the Company (as determined by the Chief Executive Officer or the Chief Financial Officer of the Company).
The Company may contribute to the subsidiary or trust an amount sufficient to accomplish the purchase in the open market of the
shares of Stock to be so acquired (as determined by the Chief Executive Officer or the Chief Financial Officer of the Company).

 

    D-4

     

    

 

3.2.
Adjustments. In the event of a corporate transaction involving the Company (including, without limitation, any share dividend,
share split, extraordinary cash dividend, recapitalization, reorganization, merger, amalgamation, consolidation, share exchange
split-up, spin-off, sale of assets or subsidiaries, combination or exchange of shares), the Committee shall, in the manner it
determines equitable in its sole discretion, adjust Awards to reflect the transactions. Action by the Committee may include: (i)
adjustment of the number and kind of shares which may be delivered under the Plan; (ii) adjustment of the number and kind of shares
subject to outstanding Awards; (iii) adjustment of the Exercise Price of outstanding Options; and (iv) any other adjustments that
the Committee determines to be equitable (which may include, without limitation, (A) replacement of Awards with other Awards which
the Committee determines have comparable value and which are based on shares of a company resulting from the transaction, and
(B) cancellation of the Award in return for cash payment of the current value of the Award, determined as though the Award is
fully vested at the time of payment, provided that in the case of an Option, the amount of such payment will be the excess of
value of the shares of Stock subject to the Option at the time of the transaction over the Exercise Price). However, in no event
shall this Section 3.2 be construed to permit a modification (including a replacement) of an Option if such modification either:
(i) would result in accelerated recognition of income or imposition of additional tax under Section 409A of the Code; or (ii)
would cause the Option subject to the modification (or cause a replacement Option) to be subject to Section 409A of the Code,
provided that the restriction of this clause (ii) shall not apply to any Option that, at the time it is granted or otherwise,
is designated as being deferred compensation subject to Section 409A of the Code.

 

3.3.
Plan Limitations. Subject to Section 3.2, the following additional maximums are imposed under the Plan:

 

		(a)	The
maximum number of shares of Stock that may be delivered to Participants and their beneficiaries with respect to ISOs granted under
the Plan shall be 1,000 shares of Stock (which number includes all shares of Stock available for delivery under this Section 3.3(a)
since the establishment of the Plan, determined in accordance with the terms of the Plan); provided, however, that to the extent
that shares of Stock not delivered must be counted against this limit as a condition of satisfying the rules applicable to ISOs,
such rules shall apply to the limit on ISOs granted under the Plan; [provided, further, that such limit will automatically increase
on January 1 of each year, for a period of not more than ten (10) years, commencing on January 1 of the year following the year
in which the Effective Date occurs and ending on (and including) January 1, 2029, in an amount equal to four percent (4%) of the
total number of shares of Stock outstanding on the date that this Plan is adopted].

 

		(b)	The
maximum total annual compensation, including the value of any Awards made pursuant to this Plan (determined as of the date of
grant), that may be paid or granted to any one Participant who is a member of the Board but who is not an employee of the Company
or a Related Company during any one-year period for service on the Board shall be $500,000 dollars; provided, that, such limit
shall be $750,000 during the first year of service for a member of the Board who is not an employee.

 

		(c)	Notwithstanding
the provisions of Sections 4.5 and 5.4 of the Plan, the Committee may grant Awards that are not subject to the minimum vesting
limitations of Sections 4.5 (with respect to Options) and of Section 5.4 (with respect to Full Value Awards) in certain circumstances
as determined by the Committee in its sole discretion.

 

SECTION
4

OPTIONS

 

4.1.
Grant of Options. Subject to the terms and conditions of the Plan, the Administrator, at any time and from time to time,
may grant Options to an Eligible Individual in such amounts as the Administrator, in its sole discretion, will determine. Each
Option will be designated in the Award Agreement as either an ISO or an NQO. Notwithstanding a designation for a grant of Options
as ISOs, however, to the extent that the aggregate Fair Market Value of the shares of Stock with respect to which ISOs are exercisable
for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds
$100,000, such Options will be treated as NQOs. For purposes of this Section 4.1, ISOs will be taken into account in the order
in which they were granted, the Fair Market Value of the shares of Stock will be determined as of the time the Option with respect
to such shares of Stock is granted, and calculation will be performed in accordance with Section 422 of the Code and Treasury
Regulations promulgated thereunder.

 

4.2.
Option Agreement. Each Award of an Option will be evidenced by an Award Agreement that will specify the date of grant of
the Option, the Exercise Price, the term of the Option, the number of shares of Stock subject to the Option, the exercise restrictions,
if any, applicable to the Option, including the dates upon which the Option is first exercisable in whole and/or part, and such
other terms and conditions as the Administrator, in its sole discretion, may determine.

 

4.3.
Term of Option. The term of each Option will be stated in the Award Agreement; provided, however, that the term will be
no more than 10 years from the date of grant thereof. In the case of an ISO granted to a Participant who, at the time the ISO
is granted, owns capital stock representing more than 10% of the total combined voting power of all classes of capital stock of
the Company or any Parent or Subsidiary, the term of the ISO will be five years from the date of grant or such shorter term as
may be provided in the Award Agreement.

 

4.4.
Exercise Price. The Exercise Price shall not be less than 100% of the Fair Market Value of a share of Stock on the date
of grant (or, if greater, the par value, if any, of a share of Stock). In addition, in the case of an ISO granted to an Employee
who owns capital stock representing more than 10% of the voting power of all classes of capital stock of the Company or any Parent
or Subsidiary, the per share Exercise Price will be no less than 110% of the Fair Market Value per share of Stock on the date
of grant. Notwithstanding the foregoing provisions of this Section 4.4, Options may be granted with a per share Exercise Price
of less than 100% of the Fair Market Value per share of Stock on the date of grant pursuant to a transaction described in, and
in a manner consistent with, Section 424(a) of the Code.

 

    D-5

     

    

 

4.5.
Minimum Vesting. Notwithstanding the foregoing, and subject to Section 3.3(e), in no event shall an Option granted to any
Participant become exercisable or vested prior to the first anniversary of the date on which it is granted (subject to acceleration
of exercisability and vesting, to the extent permitted by the Committee, in the event of the Participant’s death, disability,
Change in Control or involuntary termination).

 

4.6.
Payment of Option Exercise Price. The payment of the Exercise Price of an Option granted under this Section 4 shall be
subject to the following:

 

		(a)	Subject
to the following provisions of this Section 4.8, the full Exercise Price for shares of Stock purchased upon the exercise of any
Option shall be paid at the time of such exercise (except that, in the case of an exercise arrangement approved by the Committee
and described in Section 4.8(c), payment may be made as soon as practicable after the exercise).

 

		(b)	Subject
to Applicable Law, the full Exercise Price shall be payable in cash, by promissory note, or by tendering, by either actual delivery
of shares or by attestation, shares of Stock acceptable to the Committee (including shares otherwise distributable pursuant to
the exercise of the Option), and valued at Fair Market Value as of the day of exercise, or in any combination thereof, as determined
by the Committee.

 

		(c)	Subject
to Applicable Law, if shares are publicly traded, the Committee may permit a Participant to elect to pay the Exercise Price upon
the exercise of an Option by irrevocably authorizing a third party to sell shares of Stock (or a sufficient portion of the shares
of Stock) acquired upon exercise of the Option and remit to the Company a sufficient portion of the sale proceeds to pay the entire
Exercise Price and any tax withholding resulting from such exercise.

 

4.7.
No Repricing. Except for either adjustments pursuant to Section 3.2 (relating to the adjustment of shares of Stock), or
reductions of the Exercise Price approved by the Company’s stockholders, the Exercise Price for any outstanding Option may
not be decreased after the date of grant nor may an outstanding Option granted under the Plan be surrendered to the Company as
consideration for the grant of a replacement Option with a lower Exercise Price. Except as approved by Company’s stockholders,
in no event shall any Option granted under the Plan be surrendered to Company in consideration for a cash payment or the grant
of any other Award if, at the time of such surrender, the Exercise Price of the Option is greater than the then current Fair Market
Value of a share of Stock. In addition, no repricing of an Option shall be permitted without the approval of Company’s stockholders
if such approval is required under the rules of any stock exchange on which Stock is listed.

 

SECTION
5

FULL VALUE AWARDS

 

5.1.
Grant of Full Value Award. Subject to the terms and conditions of the Plan, the Administrator, at any time and from time
to time, may grant Full Value Awards to Eligible Individuals in such amounts as the Administrator, in its sole discretion, will
determine.

 

5.2.
Full Value Award Agreement. Each Full Value Award will be evidenced by an Award Agreement that will specify the Period
of Restriction, the number of shares of Stock granted, and such other terms and conditions as the Administrator, in its sole discretion,
may determine.

 

5.3.
Conditions. A Full Value Award may be subject to one or more of the following, as determined by the Committee:

 

		(a)	The
grant shall be in consideration of a Participant’s previously performed services, or surrender of other compensation that
may be due.

 

		(b)	The
grant shall be contingent on the achievement of performance or other objectives during a specified period.

 

		(c)	The
grant shall be subject to a risk of forfeiture or other restrictions that will lapse upon the achievement of one or more goals
relating to completion of service by the Participant, or achievement of performance or other objectives.

 

The
grant of Full Value Awards may also be subject to such other conditions, restrictions and contingencies, as determined by the
Committee.

 

5.4.
Minimum Vesting.

 

		(a)	Notwithstanding
the foregoing, and subject to Section 3.3(e), if a Participant’s right to become vested in a Full Value Award is conditioned
on the completion of a specified period of service with the Company or the Related Companies, without achievement of performance
targets or other performance objectives (whether or not related to performance measures) being required as a condition of vesting,
and without it being granted in lieu of other compensation, then the required period of service for vesting shall be not less
than one year (subject, to the extent provided by the Committee, to acceleration of vesting in the event of the Participant’s
death, disability, Change in Control or involuntary termination). The foregoing requirements shall not apply to grants that are
a form of payment of earned performance awards or other incentive compensation.

 

    D-6

     

    

 

		(b)	Notwithstanding
the foregoing, and subject to Section 3.3(e), if a Participant’s right to become vested in a Full Value Award is conditioned
on the achievement of performance targets or other performance objectives (whether or not related to performance measures and
whether or not such Full Value Award is designated as “Performance-Based Compensation”), then the required performance
period for determining the achievement of such performance targets or other performance objectives for vesting shall be not less
than one year (subject, to the extent provided by the Committee, to acceleration of vesting in the event of the Participant’s
death, disability, Change in Control or involuntary termination).

 

SECTION
6

CHANGE IN CONTROL

 

6.1.
Change in Control. Subject to the provisions of Section 3.2 and the authority of the Committee to take the actions permitted
pursuant to Section 6.2, the occurrence of a Change in Control shall have the effect, if any, with respect to any Award as set
forth in the Award Agreement or, to the extent not prohibited by the Plan or the Award Agreement, as provided by the Committee.

 

6.2.
Committee Actions On A Change in Control. On a Change in Control, if the Plan is terminated by the Company or its successor
without provision for the continuation of outstanding Awards hereunder, the Committee may cancel any outstanding Awards in return
for cash payment of the current value of the Award, determined with the Award fully vested at the time of payment, provided that
in the case of an Option, the amount of such payment will be the excess of value of the shares of Stock subject to the Option
at the time of the transaction over the Exercise Price; provided, further, that in the case of an Option, such Option will be
cancelled with no payment if, as of the Change in Control, the value of the shares of Stock subject to the Option at the time
of the transaction are equal to or less than the Exercise Price. However, in no event shall this Section 6.2 be construed to permit
a payment if such payment would result in accelerated recognition of income or imposition of additional tax under Section 409A
of the Code.

 

SECTION
7

COMMITTEE

 

7.1.
Administration. The authority to control and manage the operation and administration of the Plan shall be vested in a committee
(the “Committee”) in accordance with this Section 7. The Committee shall be selected by the Board, and shall consist
of two or more members of the Board. Unless otherwise provided by the Board, the Compensation Committee of the Board shall serve
as the Committee. As a committee of the Board, the Committee is subject to the overview of the Board. If the Committee does not
exist, or for any other reason determined by the Board, and to the extent not prohibited by Applicable Law, the Board may take
any action under the Plan that would otherwise be the responsibility of the Committee.

 

7.2.
Selection of Committee. So long as the Company is subject to Section 16 of the Exchange Act, the Committee shall be selected
by the Board and shall consist of not fewer than two members of the Board or such greater number as may be required for compliance
with Rule 16b-3 issued under the Exchange Act and shall be comprised of persons who are independent for purposes of applicable
stock exchange listing requirements and who would meet the requirements of a “non-employee director” within the meaning
of Rule 16b-3 under the Securities Exchange Act of 1934.

 

7.3.
Powers of Committee. The Committee’s administration of the Plan shall be subject to the following:

 

		(a)	Subject
to the provisions of the Plan, the Committee will have the authority and discretion to select individuals who shall be Eligible
Individuals and who, therefore, are eligible to receive Awards under the Plan. The Committee shall have the authority to determine
the time or times of receipt of Awards, to determine the types of Awards and the number of shares of Stock covered by the Awards,
to establish the terms, conditions, performance targets, restrictions, and other provisions of such Awards, to cancel or suspend
Awards, and to accelerate the exercisability or vesting of any Award under circumstances designated by it. In making such Award
determinations, the Committee may take into account the nature of services rendered by the respective employee, the individual’s
present and potential contribution to the Company’s or a Related Company’s success and such other factors as the Committee
deems relevant.

 

		(b)	To
the extent that the Committee determines that the restrictions imposed by the Plan preclude the achievement of the material purposes
of the Awards in jurisdictions outside the United States, the Committee will have the authority and discretion to modify those
restrictions as the Committee determines to be necessary or appropriate to conform to applicable requirements or practices of
jurisdictions outside of the United States.

 

		(c)	The
Committee will have the authority and discretion to interpret the Plan, to establish, amend, and rescind any rules and regulations
relating to the Plan, to determine the terms and conditions of any Award Agreement made pursuant to the Plan, and to make all
other determinations that may be necessary or advisable for the administration of the Plan.

 

		(d)	Any
interpretation of the Plan by the Committee and any decision made by it under the Plan is final and binding on all persons.

 

		(e)	In
controlling and managing the operation and administration of the Plan, the Committee shall take action in a manner that conforms
to applicable corporate law.

 

    D-7

     

    

 

		(f)	Notwithstanding
any other provision of the Plan, no benefit shall be distributed under the Plan to any person unless the Committee, in its sole
discretion, determines that such person is entitled to benefits under the Plan.

 

7.4.
Delegation by Committee. Except to the extent prohibited by Applicable Law, the Committee may allocate all or any portion
of its responsibilities and powers to any one or more of its members and may delegate all or any part of its responsibilities
and powers to any person or persons selected by it. Any such allocation or delegation may be revoked by the Committee at any time.

 

7.5.
Information to be Furnished to Committee. The Company, Subsidiaries and any applicable Related Company shall furnish the
Committee with such data and information as it determines may be required for it to discharge its duties. The records of the Company,
Subsidiaries and any applicable Related Company as to an employee’s or Participant’s employment (or other provision
of services), termination of employment (or cessation of the provision of services), leave of absence, reemployment and compensation
shall be conclusive on all persons unless determined to be incorrect. Participants and other persons entitled to benefits under
the Plan must furnish the Committee such evidence, data or information as the Committee considers desirable to carry out the terms
of the Plan.

  

7.6.
Liability and Indemnification of Committee. No member or authorized delegate of the Committee shall be liable to any person
for any action taken or omitted in connection with the administration of the Plan unless attributable to his own fraud or willful
misconduct; nor shall the Company or any Related Company be liable to any person for any such action unless attributable to fraud
or willful misconduct on the part of a director or employee of the Company or Related Company. The Committee, the individual members
thereof, and persons acting as the authorized delegates of the Committee under the Plan, shall be indemnified by the Company against
any and all liabilities, losses, costs and expenses (including legal fees and expenses) of whatsoever kind and nature which may
be imposed on, incurred by or asserted against the Committee or its members or authorized delegates by reason of the performance
of a Committee function if the Committee or its members or authorized delegates did not act dishonestly or in willful violation
of the law or regulation under which such liability, loss, cost or expense arises. This indemnification shall not duplicate but
may supplement any coverage available under any applicable insurance.

 

SECTION
8

AMENDMENT AND TERMINATION

 

The
Board may, at any time, amend or terminate the Plan, and the Board or the Committee may amend any Award Agreement, provided that
no amendment or termination may, in the absence of written consent to the change by the affected Participant (or, if the Participant
is not then living, the affected beneficiary), adversely affect the rights of any Participant or beneficiary under any Award granted
under the Plan prior to the date such amendment is adopted by the Board (or the Committee if applicable); and further provided
that adjustments pursuant to Section 3.2 shall not be subject to the foregoing limitations of this Section 8; and further
provided that the provisions of Section 4.7 (relating to Option repricing) cannot be amended unless the amendment is approved
by the Company’s stockholders. Approval by the Company’s stockholders will be required for any material revision to
the terms of the Plan, with the Committee’s determination of “material revision” to take into account the exemptions
under applicable stock exchange rules. No amendment or termination shall be adopted or effective if it would result in accelerated
recognition of income or imposition of additional tax under Section 409A of the Code or, except as otherwise provided in the amendment,
would cause amounts that were not otherwise subject to Section 409A of the Code to become subject to Section 409A of the Code.

 

SECTION
9

general provisions

 

9.1.
General Restrictions. Delivery of shares of Stock or other amounts under the Plan shall be subject to the following:

 

		(a)	Notwithstanding
any other provision of the Plan, the Company shall have no obligation to recognize an exercise of an Option or deliver any shares
of Stock or make any other distribution of benefits under the Plan unless such exercise, delivery or distribution complies with
all Applicable Laws (including, without limitation, the requirements of the United States Securities Act of 1933 and the securities
laws of any other applicable jurisdiction), and the applicable requirements of any securities exchange or similar entity or other
regulatory authority with respect to the issue of shares and securities by the Company.

 

		(b)	To
the extent that the Plan provides for issuance of share certificates to reflect the issuance of shares of Stock, the issuance
may be effected on a non-certificated basis, to the extent not prohibited by Applicable Law, the By-laws of the Company.

 

		(c)	To
the extent provided by the Committee, any Award may be settled in cash rather than shares of Stock.

 

9.2. Tax
Withholding. All distributions under the Plan are subject to withholding of all applicable taxes, and the Committee may
condition the delivery of any shares of Stock or other benefits under the Plan on satisfaction of the applicable
withholding obligations. Except as otherwise provided by the Committee and subject to Applicable Law, such withholding
obligations may be satisfied (i) through cash payment by the Participant; (ii) through the surrender of shares of Stock which
the Participant already owns; or (iii) through the surrender of shares of Stock to which the Participant is otherwise
entitled under the Plan (including shares otherwise distributable pursuant to the Award); provided, however, that such shares
of Stock under this clause (iii) may be used to satisfy not more than the maximum individual tax rate for the Participant in
applicable jurisdiction for such Participant (based on the applicable rates of the relevant tax authorities (for example,
federal, state, and local), including the Participant’s share of payroll or similar taxes, as provided in tax law,
regulations, or the authority’s administrative practices, not to exceed the highest statutory rate in that
jurisdiction, even if that rate exceeds the highest rate that may be applicable to the specific Participant).

 

    D-8

     

    

 

9.3.
Grant and Use of Awards. In the discretion of the Committee, an Eligible Individual may be granted any Award permitted
under the provisions of the Plan, and more than one Award may be granted to an Eligible Individual. Subject to Section 4.7 (relating
to repricing), Awards may be granted as alternatives to or replacement of awards granted or outstanding under the Plan, or any
other plan or arrangement of the Company or a Subsidiary or a Related Company (including a plan or arrangement of a business or
entity, all or a portion of which is acquired by the Company or a Subsidiary or a Related Company). Subject to the overall limitation
on the number of shares of Stock that may be delivered under the Plan, the Committee may use available shares of Stock as the
form of payment for compensation, grants or rights earned or due under any other compensation plans or arrangements of the Company
or a Subsidiary or a Related Company, including the plans and arrangements of the Company or a Subsidiary or a Related Company
assumed in business combinations. Notwithstanding the provisions of Section 4.4, Options granted under the Plan in replacement
for awards under plans and arrangements of the Company or a Subsidiary or a Related Company assumed in business combinations may
provide for Exercise Prices that are less than the Fair Market Value of the shares of Stock at the time of the replacement grants,
if the Committee determines that such Exercise Price is appropriate to preserve the economic benefit of the award. The provisions
of this Section shall be subject to the provisions of Section 9.13.

 

9.4.
Dividends and Dividend Equivalents. An Award (other than an Option) may provide the Participant with the right to receive
dividend or dividend equivalent payments with respect to shares of Stock subject to the Award; provided, however, that no dividend
or dividend equivalents granted in relation to Full Value Awards that are subject to vesting shall be settled prior to the date
that such Full Value Award (or applicable portion thereof) becomes vested and is settled. Any such settlements, and any such crediting
of dividends or dividend equivalents or reinvestment in shares of Stock, will be subject to the Company’s By-laws as well
as Applicable Law and further may be subject to such conditions, restrictions and contingencies as the Committee shall establish,
including the reinvestment of such credited amounts in share of Stock equivalents. The provisions of this Section shall be subject
to the provisions of Section 9.13.

 

9.5.
Settlement of Awards. The obligation to make payments and distributions with respect to Awards may be satisfied through
cash payments, the delivery of shares of Stock, the granting of replacement Awards, or combination thereof as the Committee shall
determine. Satisfaction of any such obligations under an Award, which is sometimes referred to as “settlement” of
the Award, may be subject to such conditions, restrictions and contingencies as the Committee shall determine. The Committee may
permit or require the deferral of any Award payment or distribution, subject to such rules and procedures as it may establish,
which may include provisions for the payment or crediting of interest or dividend equivalents, and may include converting such
credits into deferred share of Stock equivalents. Except for Options designated at the time of grant or otherwise as intended
to be subject to Section 409A of the Code, this Section 9.5 shall not be construed to permit the deferred settlement of Options,
if such settlement would result in deferral of compensation under Treas. Reg. §1.409A-1(b)(5)(i)(A)(3) (except as permitted
in Sections (i) and (ii) of that section). Each Subsidiary shall be liable for payment of cash due under the Plan with respect
to any Participant to the extent that such benefits are attributable to the services rendered for that Subsidiary by the Participant.
Any disputes relating to liability of a Subsidiary for cash payments shall be resolved by the Committee. The provisions of this
Section shall be subject to the provisions of Section 9.13.

 

9.6.
Transferability. Except as otherwise provided by the Committee, Awards under the Plan are not transferable except as designated
by the Participant by will or by the laws of descent and distribution.

 

9.7.
Form and Time of Elections. Unless otherwise specified herein, each election required or permitted to be made by any Participant
or other person entitled to benefits under the Plan, and any permitted modification, or revocation thereof, shall be in writing
filed with the Committee at such times, in such form, and subject to such restrictions and limitations, not inconsistent with
the terms of the Plan, as the Committee shall require.

 

9.8.
Agreement With Company. An Award under the Plan shall be subject to such terms and conditions, not inconsistent with the
Plan, as the Committee shall, in its sole discretion, prescribe. The terms and conditions of any Award to any Participant shall
be reflected in such form of written (including electronic) document as is determined by the Committee. A copy of such document
shall be provided to the Participant, and the Committee may, but need not require that the Participant sign a copy of such document.
Such document is referred to in the Plan as an “Award Agreement” regardless of whether any Participant signature is
required.

 

9.9.
Action by Company or Subsidiary. Any action required or permitted to be taken by the Company or any Subsidiary or Related
Company shall be by resolution of its board of directors, or by action of one or more members of the board (including a committee
of the board) who are duly authorized to act for the board, or (except to the extent prohibited by Applicable Law or applicable
rules of any stock exchange) by a duly authorized officer of such company.

 

9.10.
Gender and Number. Where the context admits, words in any gender shall include any other gender, words in the singular
shall include the plural and the plural shall include the singular.

 

    D-9

     

    

 

9.11.
Limitation of Implied Rights.

 

		(a)	Neither
a Participant nor any other person shall, by reason of participation in the Plan, acquire any right in or title to any assets,
funds or property of the Company or any Subsidiary or Related Company whatsoever, including, without limitation, any specific
funds, assets, or other property which the Company or any Subsidiary or Related Company, in its sole discretion, may set aside
in anticipation of a liability under the Plan. A Participant shall have only a contractual right to the shares of Stock or amounts,
if any, payable under the Plan, unsecured by any assets of the Company or any Subsidiary or Related Company, and nothing contained
in the Plan shall constitute a guarantee that the assets of the Company or any Subsidiary or Related Company shall be sufficient
to pay any benefits to any person.

 

		(b)	The
Plan does not constitute a contract of employment, and selection as a Participant will not give any participating employee or
other individual the right to be retained in the employ of the Company or any Subsidiary or Related Company or the right to continue
to provide services to the Company or any Subsidiary or Related Company, nor any right or claim to any benefit under the Plan,
unless such right or claim has specifically accrued under the terms of the Plan. Except as otherwise provided in the Plan, no
Award under the Plan shall confer upon the holder thereof any rights as a stockholder of the Company prior to the date on which
the individual fulfills all conditions for receipt of such rights and is registered in the Company’s Register of share of
stockholders.

 

		(c)	All
Stock and shares issued under any Award or otherwise are to be held subject to the provisions of the Company’s By-laws and
each Participant is deemed to agree to be bound by the terms of the Company’s By-laws as they stand at the time of issue
of any shares of Stock under the Plan.

 

9.12.
Evidence. Evidence required of anyone under the Plan may be by certificate, affidavit, document or other information which
the person acting on it considers pertinent and reliable, and signed, made or presented by the proper party or parties.

 

9.13.
Limitations under Section 409A. The provisions of the Plan shall be subject to the following:

 

		(a)	Awards
will be designed and operated in such a manner that they are either exempt from the application of, or comply with, the requirements
of Section 409A of the Code, except as otherwise determined in the sole discretion of the Administrator. The Plan and each Award
Agreement under the Plan is intended to meet the requirements of Section 409A of the Code and will be construed and interpreted
in accordance with such intent, except as otherwise determined in the sole discretion of the Administrator. To the extent that
an Award or payment, or the settlement or deferral thereof, is subject to Section 409A of the Code the Award will be granted,
paid, settled or deferred in a manner that will meet the requirements of Section 409A of the Code, such that the grant, payment,
settlement or deferral will not be subject to the additional tax or interest applicable under Section 409A of the Code.

 

		(b)	Neither Section 9.3
                                                                                                                                                              nor any other provision of the Plan shall be construed to permit the grant of an Option if such action would cause the Option
                                                                                                                                                              being granted or the option or stock appreciation right being replaced to be subject to Section 409A of the Code,
                                                                                                                                                              provided that this Section (b) shall not apply to any Option (or option or stock appreciation right granted under another
                                                                                                                                                              plan) being replaced that, at the time it is granted or otherwise, is designated as being deferred compensation subject to
                                                                                                                                                              Section 409A of the Code.

 

		(c)	Except
with respect to an Option that, at the time it is granted or otherwise, is designated as being deferred compensation subject to
Section 409A of the Code, no Option shall condition the receipt of dividends with respect to an Option on the exercise of such
Award, or otherwise provide for payment of such dividends in a manner that would cause the payment to be treated as an offset
to or reduction of the Exercise Price of the Option pursuant Treas. Reg. §1.409A-1(b)(5)(i)(E).

 

		(d)	The
Plan shall not be construed to permit a modification of an Award, or to permit the payment of a dividend or dividend equivalent,
if such actions would result in accelerated recognition of taxable income or imposition of additional tax under Section 409A of
the Code.

 

CHARDAN
HEALTHCARE ACQUISITION CORP.

2019 OMNIBUS LONG-TERM INCENTIVE PLAN

 

ISRAELI
APPENDIX

 

This
Israeli Appendix (the “Appendix”) to the 2019 Omnibus Long-Term Incentive Plan (as amended from time to time,
the “Plan”) of CHARDAN HEALTHCARE ACQUISITION CORP. (the “Company”) shall apply only to
Participants (as defined in the Plan) who are, or are deemed to be, residents of the State of Israel for Israeli tax purposes.
This Appendix is made pursuant to Section 1.3 of the Plan.

 

		1.	GENERAL

 

1.1.
The Committee, in its discretion, may grant Awards to eligible Participants and shall determine whether such Awards intended to
be 102 Awards or 3(9) Awards. Each Award shall be evidenced by an Award Agreement, which shall expressly identify the Award type,
and be in such form and contain such provisions, as the Committee shall from time to time deem appropriate.

 

    D-10

     

    

 

1.2.
The Plan shall apply to any Awards granted pursuant to this Appendix, provided, that the provisions of this Appendix shall supersede
and govern in the case of any inconsistency or conflict, either explicit or implied, arising between the provisions of this Appendix
and the Plan.

 

1.3.
Unless otherwise defined in this Appendix, capitalized terms contained herein shall have the same meanings given to them in the
Plan.

 

		2.	DEFINITIONS.

 

2.1.
“3(9) Award” means any Award representing a right to purchase shares of Common Stock granted by the Company
to any Participant who is not an Employee pursuant to Section 3(9) of the Ordinance.

 

2.2.
“102 Award” means any Award intended to qualify (as set forth in the Award Agreement) and which qualifies under
Section 102, provided it is settled only in shares of Common Stock.

 

2.3.
“102 Capital Gain Track Award” means any Award granted by the Company to an Employee pursuant to Section 102(b)(2)
or (3) (as applicable) of the Ordinance under the capital gain track.

 

2.4.
“102 Non-Trustee Award” means any Award granted by the Company to an Employee pursuant to Section 102(c) of
the Ordinance without a Trustee.

 

2.5.
“102 Ordinary Income Track Award” means any Award granted by the Company to an Employee pursuant to Section
102(b)(1) of the Ordinance under the ordinary income track.

 

2.6.
“102 Trustee Awards” means, collectively, 102 Capital Gain Track Awards and 102 Ordinary Income Track Awards.

 

2.7.
“Affiliate” means, for purpose of 102 Trustee Award, an “employing company” within the meaning
and subject to the conditions of Section 102(a) of the Ordinance.

 

2.8.
“Applicable Law” shall mean any applicable law, rule, regulation, statute, pronouncement, policy, interpretation,
judgment, order or decree of any federal, provincial, state or local governmental, regulatory or adjudicative authority or agency,
of any jurisdiction, and the rules and regulations of any stock exchange, over-the-counter market or trading system on which the
common stock of the Company are then traded or listed.

 

2.9.
“Controlling Stockholder” means as to such term is defined in Section 32(9) of the Ordinance.

 

2.10.
“Election” as defined in Section 3.2 below.

 

2.11.
“Employee” means an “employee” within the meaning of Section 102(a) of the Ordinance (which as
of the date of the adoption of this Appendix means (i) an individual employed by an Israeli company being an Affiliate, and (ii)
an individual who is serving and is engaged personally (and not through an entity) as an “office holder” by an Affiliate,
excluding, in any event, Controlling Stockholders).

 

2.12.
“ITA” means the Israel Tax Authority.

 

2.13.
“Ordinance” means the Israeli Income Tax Ordinance (New Version), 1961, including the Rules and any other regulations,
rules, orders or procedures promulgated thereunder, as may be amended or replaced from time to time.

 

2.14.
“Required Holding Period” as defined in Section 3.5.1 below.

 

2.15.
“Rules” means the Income Tax Rules (Tax Reliefs in Stock Issuance to Employees) 5763-2003.

 

2.16.
“Section 102” means Section 102 of the Ordinance.

 

2.17.
“Trust Agreement” means the agreement to be signed between the Company, an Affiliate and the Trustee for the
purposes of Section 102.

 

2.18.
“Trustee” means the trustee appointed by the Company’s Board of Directors and/or by the Committee to
hold the Awards and approved by the ITA.

 

2.19.
“Withholding Obligations” as defined in Section 5.5 below.

 

		3.	102
AWARDS

 

3.1.
Tracks. Awards granted pursuant to this Section 3 are intended to be granted as either 102 Capital Gain Track Awards or
102 Ordinary Income Track Awards. 102 Trustee Awards shall be granted subject to the special terms and conditions contained in
this Section 3 and the general terms and conditions of the Plan, except for any provisions of the Plan applying to Awards under
different tax laws or regulations.

 

    D-11

     

    

 

3.2.
Election of Track. Subject to Applicable Law, the Company may grant only one type of 102 Trustee Award at any given time
to all Participants who are to be granted 102 Trustee Awards pursuant to this Appendix, and shall file an election with the ITA
regarding the type of 102 Trustee Award it elects to grant before the date of grant of any 102 Trustee Award (the “Election”).
Such Election shall also apply to any other securities received by any Participant as a result of holding the 102 Trustee Awards.
The Company may change the type of 102 Trustee Award that it elects to grant only after the expiration of at least 12 months from
the end of the year in which the first grant was made in accordance with the previous Election, or as otherwise provided by Applicable
Law. Any Election shall not prevent the Company from granting 102 Non-Trustee Awards.

 

3.3.
Eligibility for Awards. Subject to Applicable Law, 102 Awards may only be granted to Employees. Such 102 Awards may either
be granted to a Trustee or granted under Section 102 without a Trustee.

 

3.4.
102 Award Grant Date.

 

(a)
Each 102 Award will be deemed granted on the date determined by the Committee, subject to the provisions of the Plan, provided
that (i) the Participant has signed all documents required by the Company or pursuant to Applicable Law, and (ii) with respect
to any 102 Trustee Award, the Company has provided all applicable documents to the Trustee in accordance with the guidelines published
by the ITA.

 

(b)
Unless otherwise permitted by the Ordinance, any grants of 102 Trustee Awards that are made on or after the date of the adoption
of the Plan and this Appendix or an amendment to the Plan or this Appendix, as the case may be, that may become effective only
at the expiration of thirty (30) days after the filing of the Plan and this Appendix or any amendment thereof (as the case may
be) with the ITA in accordance with the Ordinance shall be conditional upon the expiration of such 30-day period, and such condition
shall be read and is incorporated by reference into any corporate resolutions approving such grants and into any Award Agreement
evidencing such grants (whether or not explicitly referring to such condition), and the date of grant shall be at the expiration
of such 30-day period, whether or not the date of grant indicated therein corresponds with this Section. In the case of any contradiction,
this provision and the date of grant determined pursuant hereto shall supersede and be deemed to amend any date of grant indicated
in any corporate resolution or Award Agreement. Nevertheless, this 30-day period may be waived subject to a special tax ruling
to be obtained from the ITA and pursuant to its terms, or may not apply to any exchange of equity pursuant to a special tax ruling
and its terms.

 

3.5.
102 Trustee Awards.

 

(a)
Each 102 Trustee Award, each share of Common Stock issued pursuant to the grant, exercise or vesting of any 102 Trustee Award
and any rights granted thereunder, shall be allocated or issued to and registered in the name of the Trustee and shall be held
in trust or controlled by the Trustee (pursuant to an approval from the ITA) for the benefit of the Participant for the requisite
period prescribed by the Ordinance or such longer period as set by the Committee (the “Required Holding Period”).
In the event that the requirements under Section 102 to qualify an Award as a 102 Trustee Award are not met, then the Award may
be treated as a 102 Non-Trustee Award or 3(9) Award (as determined by the Company), all in accordance with the provisions
of the Ordinance. After the expiration of the Required Holding Period, the Trustee may release such 102 Trustee Awards and any
such shares of Common Stock, provided that (i) the Trustee has received an acknowledgment from the ITA that the Participant has
paid any applicable taxes due pursuant to the Ordinance, or (ii) the Trustee and/or the Company and/or the Affiliate withhold(s)
all applicable taxes and compulsory payments due pursuant to the Ordinance arising from the 102 Trustee Awards and/or any shares
of Common Stock issued upon exercise or (if applicable) vesting of such 102 Trustee Awards. The Trustee shall not release
any 102 Trustee Awards or shares of Common Stock issued upon exercise or (if applicable) vesting thereof, or any rights received
with respect to such Awards, prior to the payment in full of the Participant’s tax and compulsory payments arising from
such 102 Trustee Awards and/or shares of Common Stock or the withholding referred to in (ii) above.

 

(b)
Each 102 Trustee Award shall be subject to the relevant terms of the Ordinance, the Rules and any determinations, rulings or approvals
issued by the ITA, which shall be deemed an integral part of the 102 Trustee Awards and shall prevail over any term contained
in the Plan, this Appendix or the Award Agreement that is not consistent therewith. Any provision of the Ordinance, the Rules
and any determinations, rulings or approvals by the ITA not expressly specified in the Plan, this Appendix or Award Agreement
that are necessary to receive or maintain any tax benefit pursuant to Section 102 shall be binding on the Participant. The Participant
granted a 102 Trustee Award shall comply with the Ordinance and the terms and conditions of the Trust Agreement entered into between
the Company and the Trustee. The Participant shall execute any and all documents that the Company and/or the Affiliate and/or
the Trustee determine from time to time to be necessary in order to comply with the Ordinance and the Rules.

 

(c)
During the Required Holding Period, the Participant shall not release from trust or sell, assign, transfer or give as collateral,
the shares of Common Stock issuable upon the exercise or (if applicable) vesting of a 102 Trustee Award and/or any securities
issued or distributed with respect thereto, until the expiration of the Required Holding Period. Notwithstanding the above, if
any such sale, release or other action occurs during the Required Holding Period it may result in adverse tax consequences to
the Participant under Section 102 and the Rules, which shall apply to and shall be borne solely by such Participant. Subject to
the foregoing, the Trustee may, pursuant to a written request from the Participant, but subject to the terms of the Plan and this
Appendix, release and transfer such shares of Common Stock to a designated third party, provided that both of the following conditions
have been fulfilled prior to such release or transfer: (i) payment has been made to the ITA of all taxes and compulsory payments
required to be paid upon the release and transfer of the shares of Common Stock, and confirmation of such payment has been received
by the Trustee and the Company, and (ii) the Trustee has received written confirmation from the Company that all requirements
for such release and transfer have been fulfilled according to the terms of the Company’s corporate documents, any agreement
governing the shares of Common Stock, the Plan, this Appendix, the Award Agreement and any Applicable Law.

 

    D-12

     

    

 

(d)
If a 102 Trustee Award is exercised or (if applicable) vested, the shares of Common Stock issued upon such exercise or (if applicable)
vesting shall be issued in the name of the Trustee for the benefit of the Participant, or shall be deposited with the Trustee,
or be subject to the Trustee’s control, if approved by the ITA.

 

(e)
Upon or after receipt of a 102 Trustee Award, if required, the Participant may be required to sign an undertaking to release the
Trustee from any liability with respect to any action or decision duly taken and executed in good faith by the Trustee in relation
to the Plan, this Appendix, or any 102 Trustee Awards granted to such Participant hereunder.

 

3.6.
102 Non-Trustee Awards. The foregoing provisions of this Section 3 relating to 102 Trustee Awards shall not apply with
respect to 102 Non-Trustee Awards, which shall, however, be subject to the relevant provisions of Section 102 and the applicable
Rules. The Committee may determine that 102 Non-Trustee Awards, the shares of Common Stock issuable upon the exercise or (if applicable)
vesting of a 102 Non-Trustee Award and/or any securities issued or distributed with respect thereto, shall be allocated or issued
to the Trustee, who shall hold such 102 Non-Trustee Award and all accrued rights thereon (if any) in trust for the benefit of
the Participant and/or the Company, as the case may be, until the full payment of tax arising from the 102 Non-Trustee Awards,
the shares of Common Stock issuable upon the exercise or (if applicable) vesting of a 102 Non-Trustee Award and/or any securities
issued or distributed with respect thereto. The Company may choose, alternatively, to require the Participant to provide the Company
with a guarantee or other security, to the satisfaction of each of the Trustee and the Company, until the full payment of the
applicable taxes.

 

3.7.
Written Participant Undertaking. With respect to any 102 Trustee Award, as required by Section 102 and the Rules, by virtue
of the receipt of such Award, the Participant is deemed to have undertaken and confirmed in writing the following (and such undertaking
is deemed incorporated into any documents signed by the Participant in connection with the employment or service of the Participant
and/or the grant of such Award). The following written undertaking shall be deemed to apply and relate to all 102 Trustee Awards
granted to the Participant, whether under the Plan and this Appendix or other plans maintained by the Company, and whether prior
to or after the date hereof:

 

(a)
The Participant shall comply with all terms and conditions set forth in Section 102 with regard to the “Capital Gain Track”
or the “Ordinary Income Track”, as applicable, and the applicable rules and regulations promulgated thereunder, as
amended from time to time;

 

(b)
The Participant is familiar with, and understands the provisions of, Section 102 in general, and the tax arrangement under the
“Capital Gain Track” or the “Ordinary Income Track” in particular, and its tax consequences; the Participant
agrees that the 102 Trustee Awards and shares of Common Stock that may be issued upon exercise or (if applicable) vesting of the
102 Trustee Awards (or otherwise in relation to the Awards), will be held by a trustee appointed pursuant to Section 102 for at
least the duration of the “Holding Period” (as such term is defined in Section 102) under the “Capital Gain
Track” or the “Ordinary Income Track”, as applicable. The Participant understands that any release of such 102
Trustee Awards or shares of Common Stock from trust, or any sale of the shares of Common Stock prior to the termination of the
Holding Period, as defined above, will result in taxation at the marginal tax rate, in addition to deductions of appropriate social
security, health tax contributions or other compulsory payments; and

 

(c)
The Participant agrees to the trust deed signed between the Company, his employing company and the trustee appointed pursuant
to Section 102.

 

		4.	3(9)
AWARDS

 

4.1.
Awards granted pursuant to this Section 4 are intended to constitute 3(9) Awards and shall be granted subject to the general terms
and conditions of the Plan, except for any provisions of the Plan applying to Awards under different tax laws or regulations.
In the event of any inconsistency or contradictions between the provisions of this Section 4 and the other terms of the Plan,
this Section 4 shall prevail.

 

4.2.
To the extent required by the Ordinance or the ITA or otherwise deemed by the Committee to be advisable, the 3(9) Awards and/or
any shares of Common Stock or other securities issued or distributed with respect thereto granted pursuant to the Plan and this
Appendix shall be issued to a trustee nominated by the Committee in accordance with the provisions of the Ordinance. In such event,
the trustee shall hold such Awards and/or any shares of Common Stock or other securities issued or distributed with respect thereto
in trust, until exercised by the Participant or (if applicable) vested, and the full payment of tax arising therefrom, pursuant
to the Company’s instructions from time to time as set forth in a trust agreement, which will have been entered into between
the Company and the trustee. If determined by the Committee, and subject to such trust agreement, the Trustee shall be responsible
for withholding any taxes to which a Participant may become liable upon issuance of shares of Common Stock, whether due to the
exercise or (if applicable) vesting of Awards.

 

4.3.
Shares of Common Stock pursuant to a 3(9) Award shall not be issued, unless the Participant delivers to the Company payment in
cash or by bank check or such other form acceptable to the Committee of all withholding taxes due, if any, on account of the Participant
acquiring shares of Common Stock under the Award or the Participant provides other assurance satisfactory to the Committee of
the payment of those withholding taxes.

 

    D-13

     

    

 

		5.	AGREEMENT
REGARDING TAXES; DISCLAIMER

 

5.1.
If the Committee shall so require, as a condition of exercise of an Award or the release of shares of Common Stock by the Trustee,
a Participant shall agree that, no later than the date of such occurrence, the Participant will pay to the Company (or the Trustee,
as applicable) or make arrangements satisfactory to the Committee and the Trustee (if applicable) regarding payment of any applicable
taxes and compulsory payments of any kind required by Applicable Law to be withheld or paid.

 

5.2.
TAX LIABILITY. ALL TAX CONSEQUENCES UNDER ANY APPLICABLE LAW WHICH MAY ARISE FROM THE GRANT OF ANY AWARDS OR THE EXERCISE
THEREOF, THE SALE OR DISPOSITION OF ANY SHARES OF COMMON STOCK GRANTED HEREUNDER OR ISSUED UPON EXERCISE OR (IF APPLICABLE) VESTING
OF ANY AWARD, THE ASSUMPTION, SUBSTITUTION, CANCELLATION OR PAYMENT IN LIEU OF AWARDS OR FROM ANY OTHER ACTION IN CONNECTION WITH
THE FOREGOING (INCLUDING WITHOUT LIMITATION ANY TAXES AND COMPULSORY PAYMENTS, SUCH AS SOCIAL SECURITY OR HEALTH TAX PAYABLE BY
THE PARTICIPANT OR THE COMPANY IN CONNECTION THEREWITH) SHALL BE BORNE AND PAID SOLELY BY THE PARTICIPANT, AND THE PARTICIPANT
SHALL INDEMNIFY THE COMPANY, THE AFFILIATE AND THE TRUSTEE, AND SHALL HOLD THEM HARMLESS AGAINST AND FROM ANY LIABILITY FOR ANY
SUCH TAX OR PAYMENT OR ANY PENALTY, INTEREST OR INDEXATION THEREON. EACH PARTICIPANT AGREES TO, AND UNDERTAKES TO COMPLY WITH,
ANY RULING, SETTLEMENT, CLOSING AGREEMENT OR OTHER SIMILAR AGREEMENT OR ARRANGEMENT WITH ANY TAX AUTHORITY IN CONNECTION WITH
THE FOREGOING WHICH IS APPROVED BY THE COMPANY.

 

5.3.
NO TAX ADVICE. THE PARTICIPANT IS ADVISED TO CONSULT WITH A TAX ADVISOR WITH RESPECT TO THE TAX CONSEQUENCES OF RECEIVING,
EXERCISING OR DISPOSING OF AWARDS HEREUNDER. THE COMPANY DOES NOT ASSUME ANY RESPONSIBILITY TO ADVISE THE PARTICIPANT ON SUCH
MATTERS, WHICH SHALL REMAIN SOLELY THE RESPONSIBILITY OF THE PARTICIPANT.

 

5.4.
TAX TREATMENT. THE COMPANY DOES NOT UNDERTAKE OR ASSUME ANY LIABILITY OR RESPONSIBILITY TO THE EFFECT THAT ANY AWARD SHALL
QUALIFY WITH ANY PARTICULAR TAX REGIME OR RULES APPLYING TO PARTICULAR TAX TREATMENT, OR BENEFIT FROM ANY PARTICULAR TAX TREATMENT
OR TAX ADVANTAGE OF ANY TYPE AND THE COMPANY SHALL BEAR NO LIABILITY IN CONNECTION WITH THE MANNER IN WHICH ANY AWARD IS EVENTUALLY
TREATED FOR TAX PURPOSES, REGARDLESS OF WHETHER THE AWARD WAS GRANTED OR WAS INTENDED TO QUALIFY UNDER ANY PARTICULAR TAX REGIME
OR TREATMENT. THIS PROVISION SHALL SUPERSEDE ANY DESIGNATION OF AWARDS OR TAX QUALIFICATION INDICATED IN ANY CORPORATE RESOLUTION
OR AWARD AGREEMENT, WHICH SHALL AT ALL TIMES BE SUBJECT TO THE REQUIREMENTS OF APPLICABLE LAW. THE COMPANY DOES NOT UNDERTAKE
AND SHALL NOT BE REQUIRED TO TAKE ANY ACTION IN ORDER TO QUALIFY ANY AWARD WITH THE REQUIREMENTS OF ANY PARTICULAR TAX TREATMENT
AND NO INDICATION IN ANY DOCUMENT TO THE EFFECT THAT ANY AWARD IS INTENDED TO QUALIFY FOR ANY TAX TREATMENT SHALL IMPLY SUCH AN
UNDERTAKING. NO ASSURANCE IS MADE BY THE COMPANY OR THE AFFILIATE THAT ANY PARTICULAR TAX TREATMENT ON THE DATE OF GRANT WILL
CONTINUE TO EXIST OR THAT THE AWARD WILL QUALIFY AT THE TIME OF EXERCISE OR DISPOSITION THEREOF WITH ANY PARTICULAR TAX TREATMENT.
THE COMPANY AND THE AFFILIATE SHALL NOT HAVE ANY LIABILITY OR OBLIGATION OF ANY NATURE IN THE EVENT THAT AN AWARD DOES NOT QUALIFY
FOR ANY PARTICULAR TAX TREATMENT, REGARDLESS WHETHER THE COMPANY COULD HAVE TAKEN ANY ACTION TO CAUSE SUCH QUALIFICATION TO BE
MET AND SUCH QUALIFICATION REMAINS AT ALL TIMES AND UNDER ALL CIRCUMSTANCES AT THE RISK OF THE PARTICIPANT. THE COMPANY DOES NOT
UNDERTAKE OR ASSUME ANY LIABILITY TO CONTEST A DETERMINATION OR INTERPRETATION (WHETHER WRITTEN OR UNWRITTEN) OF ANY TAX AUTHORITY,
INCLUDING IN RESPECT OF THE QUALIFICATION UNDER ANY PARTICULAR TAX REGIME OR RULES APPLYING TO PARTICULAR TAX TREATMENT. IF THE
AWARDS DO NOT QUALIFY UNDER ANY PARTICULAR TAX TREATMENT IT COULD RESULT IN ADVERSE TAX CONSEQUENCES TO THE PARTICIPANT.

 

5.5.
The Company or the Affiliate may take such action as it may deem necessary or appropriate, in its discretion, for the purpose
of or in connection with withholding of any taxes and compulsory payments which the Trustee, the Company or the Affiliate is required
by any Applicable Law to withhold in connection with any Awards (collectively, “Withholding Obligations”).
Such actions may include (i) requiring Participants to remit to the Company in cash an amount sufficient to satisfy such Withholding
Obligations and any other taxes and compulsory payments, payable by the Company in connection with the Award or the exercise or
(if applicable) vesting thereof; (ii) subject to Applicable Law, allowing the Participants to provide shares of Common Stock,
in an amount that at such time, reflects a value that the Committee determines to be sufficient to satisfy such Withholding Obligations;
(iii) withholding shares of Common Stock otherwise issuable upon the exercise of an Award at a value which is determined by the
Committee to be sufficient to satisfy such Withholding Obligations; or (iv) any combination of the foregoing. The Company shall
not be obligated to allow the exercise of any Award by or on behalf of a Participant until all tax consequences arising from the
exercise of such Award are resolved in a manner acceptable to the Company.

 

    D-14

     

    

 

5.6.
Each Participant shall notify the Company in writing promptly and in any event within ten (10) days after the date on which such
Participant first obtains knowledge of any tax bureau inquiry, audit, assertion, determination, investigation, or question relating
in any manner to the Awards granted or received hereunder or shares of Common Stock issued thereunder and shall continuously inform
the Company of any developments, proceedings, discussions and negotiations relating to such matter, and shall allow the Company
and its representatives to participate in any proceedings and discussions concerning such matters. Upon request, a Participant
shall provide to the Company any information or document relating to any matter described in the preceding sentence, which the
Company, in its discretion, requires.

 

5.7.
With respect to 102 Non-Trustee Awards, if the Participant ceases to be employed by the Company or any Affiliate, the Participant
shall extend to the Company and/or the Affiliate with whom the Participant is employed a security or guarantee for the payment
of taxes due at the time of sale of shares of Common Stock, all in accordance with the provisions of Section 102 and the Rules.

 

		6.	RIGHTS
AND OBLIGATIONS AS A STOCKHOLDER

 

6.1.
A Participant shall have no rights as a stockholder of the Company with respect to any shares of Common Stock covered by an Award
until the Participant exercises the Award, pays the exercise price therefor and becomes the record holder of the subject shares
of Common Stock. In the case of 102 Awards or 3(9) Awards (if such Awards are being held by a Trustee), the Trustee shall have
no rights as a stockholder of the Company with respect to the shares of Common Stock covered by such Award until the Trustee becomes
the record holder for such Common Stock for the Participant’s benefit, and the Participant shall not be deemed to be a stockholder
and shall have no rights as a stockholder of the Company with respect to the shares of Common Stock covered by the Award until
the date of the release of such shares of Common Stock from the Trustee to the Participant and the transfer of record ownership
of such shares of Common Stock to the Participant (provided however that the Participant shall be entitled to receive from the
Trustee any cash dividend or distribution made on account of the shares of Common Stock held by the Trustee for such Participant’s
benefit, subject to any tax withholding and compulsory payment). No adjustment shall be made for dividends (ordinary or extraordinary,
whether in cash, securities or other property) or distribution of other rights for which the record date is prior to the date
on which the Participant or Trustee (as applicable) becomes the record holder of the shares of Common Stock covered by an Award,
except as provided in the Plan.

 

6.2.
With respect to shares of Common Stock issued upon the exercise or (if applicable) vesting of Awards hereunder, any and all voting
rights attached to such Common Stock shall be subject to the provisions of the Plan, and the Participant shall be entitled to
receive dividends distributed with respect to such shares of Common Stock, subject to the provisions of the Company’s Certificate
of Incorporation and By-laws, as amended from time to time, and subject to any Applicable Law (after deduction of all applicable
tax payments).

 

		7.	GOVERNING
LAW

 

7.1.
This Appendix shall be governed by, construed and enforced in accordance with the laws of the State of Delaware, without reference
to conflicts of law principles, except that applicable Israeli laws, rules and regulations (as amended) shall apply to any mandatory
tax matters arising hereunder.

 

****

 

 

D-15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}]]